[
    {
        "claim": "Brazil likely has 12 times more coronavirus cases than official count, study finds.",
        "evidence": "Based on this table, Brazil likely has 12 times more coronavirus cases than the official count.",
        "table": "+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|    | Unnamed: 0   |   Cases  Daily Avg. |   Per  100,000 | 14-day  change   |   Deaths  Daily Avg. |   Per  100,000.1 | Fully  Vaccinated   |\n+====+==============+=====================+================+==================+======================+==================+=====================+\n|  0 | Seychelles   |                 142 |            145 | +22%             |                  1.1 |             1.17 | 69%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  1 | Mongolia     |                2306 |             72 | +67%             |                 11.7 |             0.36 | 53%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  2 | Namibia      |                1649 |             66 | +81%             |                 34.1 |             1.37 | 1%                  |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  3 | Colombia     |               25882 |             51 | â1%            |                582.9 |             1.16 | 11%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  4 | Uruguay      |                1428 |             41 | â55%           |                 29   |             0.84 | 44%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  5 | Oman         |                2002 |             40 | +30%             |                 36.7 |             0.74 | 4%                  |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  6 | Argentina    |               17765 |             40 | â26%           |                467.7 |             1.04 | 9%                  |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  7 | Maldives     |                 204 |             39 | â39%           |                  0.4 |             0.08 | 35%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  8 | Kuwait       |                1556 |             37 | +1%              |                  7   |             0.17 | 1%                  |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+\n|  9 | BrazilÂ âº  |               70381 |             33 | +6%              |               1664.1 |             0.79 | 12%                 |\n+----+--------------+---------------------+----------------+------------------+----------------------+------------------+---------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Matt Every suspended 3 months for Anabolic Steroids & Agents",
        "evidence": "We then continue to perform the same experiment using 3 different drug classifiers. This time we focus on the anti-depressants (diuretics & other masking agents), glucocorticosteroids (agonists & modulators), and stimulants (drugs banned in the previous experiment). For drugs, we consider Beta-2 agonists (cigarettes and non-absorbable explosives) as well as stimulants (both stimulants and opioids). Overall, we observe similar trends as we saw for drugs in the previous experiment, with lower euphoric states, higher cortisol concentrations, and lower tolerance. Overall, these results suggest that stimulants, diuretics, and anabolic steroids are some of the most commonly prescribed drugs in the United States. Although there are other drugs that can be classified into this class as well, they do not provide the same information as the drugs in our experiment.",
        "table": "+----+----------------------+----------------------------------+----------------------------------+\n|    | Alcohol              | Anabolic Steroids & Agents       | Beta-2 Agonists                  |\n+====+======================+==================================+==================================+\n|  0 | Beta-Blockers        | Cannabinoids                     | Diuretics & Other Masking Agents |\n+----+----------------------+----------------------------------+----------------------------------+\n|  1 | Glucocorticosteroids | Hormone Antagonists & Modulators | Hormones & Related Substances    |\n+----+----------------------+----------------------------------+----------------------------------+\n|  2 | Narcotics            | Stimulants                       | Banned Methods                   |\n+----+----------------------+----------------------------------+----------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Intensive Glycemic Control in Type 2 Diabetes has a lower relative risk reduction in retinopathy than in neuropathy.",
        "evidence": "They compared the incidence of type 2 diabetes and its complications, including neuropathy, hypertension, and microalbuminuria. The goal of the experiments was to quantify the relative risk reduction in each of the 27 outcomes evaluated. Intensive glycemic control has a lower relative risk reduction in retinopathy than in neuropathy. This reduces the risk of death by 3.1% for Type 2 diabetes and by 11.1% for Type 2 hypertension.",
        "table": "+----+--------------------------------+---------------------------+--------------------+\n|    | Outcome                        | Relative Risk Reduction   | Source             |\n+====+================================+===========================+====================+\n|  0 | Retinopathy*                   | 29% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  1 | Neuropathyâ                   | 19% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  2 | Microalbuminuriaâ¡            | 33% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  3 | Nonfatal myocardial infarction | 15% per 1.0% â A1c      | Boussageon et al31 |\n+----+--------------------------------+---------------------------+--------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Kikokikona is located in Hawaii",
        "evidence": "The claim of human assessment is straightforward. We randomly select five small islands from the Hawaiian islands and their population. Then we measure how well our annotators agree with each other. If the agreement is ≥0.5, we consider the claim to be True. We use the kikokikona place in Maui as our location claim.",
        "table": "+----+----------------------+\n|    | Kikokikona Hawaiʻi   |\n+====+======================+\n|  0 | Help                 |\n+----+----------------------+\n|  1 | Extras...            |\n+----+----------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The actuarial balance of the OASI  is less negative than the OASDI.",
        "evidence": "The claim was submitted by the Ministry of Aging and Disability. The actuarial balance for the OASDI is less negative than the DI. The actuarial balance of the 2019 report was -2.67, and the actuarial balance of the 2020 report was -3.14. The difference in the change in actuarial balance between the OASDI and DI was -3.21.",
        "table": "+----+-------------------------------------------------+--------+--------+---------+\n|    | Item                                            |   OASI |     DI |   OASDI |\n+====+=================================================+========+========+=========+\n|  0 | Actuarial balance shown in the 2019 Report      |  -2.67 |  -0.12 |   -2.78 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  1 | Changes in actuarial balance due to changes in: | nan    | nan    |  nan    |\n+----+-------------------------------------------------+--------+--------+---------+\n|  2 | Valuation period                                |  -0.05 |  -0.01 |   -0.05 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  3 | Demographic data and assumptions                |  -0.12 |   0    |   -0.13 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  4 | Economic data and assumptions                   |  -0.16 |  -0.02 |   -0.18 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  5 | Disability data and assumptions                 |  -0.01 |   0.06 |    0.05 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  6 | Methods and programmatic data                   |  -0.02 |   0.02 |    0    |\n+----+-------------------------------------------------+--------+--------+---------+\n|  7 | Total change in actuarial balance               |  -0.47 |   0.05 |   -0.43 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  8 | Actuarial balance shown in the 2020 Report      |  -3.14 |  -0.07 |   -3.21 |\n+----+-------------------------------------------------+--------+--------+---------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "hospital B has the lowest admission rate in 2014 and 2015",
        "evidence": "The table also shows the expected number of cases in each hospital, as well as the chi-square measure for comparing the expected number of cases and the true number of cases. From the table, we can see that Hrs. B has the lowest admission rate in 2014 and 2015 compare to Hrs. A and C have the highest admission rates in 2014 and 2015. We also see that the expected number of cases for Hrs. B and C is much smaller than the expected number of cases for Hrs. This means that Hrs. B and C have closer resemblance, although there is no statistically significant difference between them.",
        "table": "+----+------------+----------------------------------------------------+--------------------+--------------------+--------------+-----------+\n|    | Hospital   |   Percentage of Medicare admissions in 2014 + 2015 |   Expected # cases |   Observed # cases | Chi-square   |   p-Value |\n+====+============+====================================================+====================+====================+==============+===========+\n|  0 | A          |                                               43.8 |                 19 |                 40 | 41.2         |   nan     |\n+----+------------+----------------------------------------------------+--------------------+--------------------+--------------+-----------+\n|  1 | B          |                                               18.7 |                  8 |                  4 | 2.8          |     0.093 |\n+----+------------+----------------------------------------------------+--------------------+--------------------+--------------+-----------+\n|  2 | C          |                                               37.5 |                 17 |                  0 | 23.8a        |   nan     |\n+----+------------+----------------------------------------------------+--------------------+--------------------+--------------+-----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The top movie is Fast & Furious: 8-Movie Collection",
        "evidence": "The claim made by the table states that the top-selling item for the 8-movie collection is fast & furious: 8-movie collection. This collection consists of 8 movies that were released between 1982 and 2007. In total, there are 7 items, collected from 1 to 9 different movies. The information from the claim is that the best-selling item is fast & furious: 8-movie collection. It contains movies from different eras, such as ‘zack snyder's Justice League’, ‘batman: The Long Halloween - Part One’, ‘Godzilla vs. Kong’, and ‘The Lord of the Rings: The Motion P...’.",
        "table": "+----+------------------------+----------------------------------------+\n|    | Unnamed: 0             | Unnamed: 1                             |\n+====+========================+========================================+\n|  0 | 1.                     | Fast & Furious: 8-Movie Collection     |\n+----+------------------------+----------------------------------------+\n|  1 | 2.                     | The Transformers: The Movie 4K         |\n+----+------------------------+----------------------------------------+\n|  2 | 3.                     | Harry Potter: Complete 8-Film Colle... |\n+----+------------------------+----------------------------------------+\n|  3 | 4.                     | Zack Snyder's Justice League 4K        |\n+----+------------------------+----------------------------------------+\n|  4 | 5.                     | Batman: The Long Halloween - Part One  |\n+----+------------------------+----------------------------------------+\n|  5 | 6.                     | Godzilla vs. Kong                      |\n+----+------------------------+----------------------------------------+\n|  6 | 7.                     | Godzilla vs. Kong 4K                   |\n+----+------------------------+----------------------------------------+\n|  7 | 8.                     | The Lord of the Rings: The Motion P... |\n+----+------------------------+----------------------------------------+\n|  8 | 9.                     | Nobody                                 |\n+----+------------------------+----------------------------------------+\n|  9 | 10.                    | Indiana Jones: 4-Movie Collection 4K   |\n+----+------------------------+----------------------------------------+\n| 10 | » See more top sellers | » See more top sellers                 |\n+----+------------------------+----------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "\"Heroin and prescription opioids are \"\"the number one cause of accidental or preventable death in Wisconsin.\"",
        "evidence": "The table states that Heroin and prescription opioids are the number one cause of accidental or preventable death in Wisconsin.",
        "table": "+----+----------------------------------+----------------------+\n|    | Opioid                           |   Conversion factor* |\n+====+==================================+======================+\n|  0 | Codeine                          |                 0.15 |\n+----+----------------------------------+----------------------+\n|  1 | Fentanyl transdermal (in mcg/hr) |                 2.4  |\n+----+----------------------------------+----------------------+\n|  2 | Hydrocodone                      |                 1    |\n+----+----------------------------------+----------------------+\n|  3 | Hydromorphone                    |                 4    |\n+----+----------------------------------+----------------------+\n|  4 | Methadone                        |               nan    |\n+----+----------------------------------+----------------------+\n|  5 | 1–20 mg/day                      |                 4    |\n+----+----------------------------------+----------------------+\n|  6 | 21–40 mg/day                     |                 8    |\n+----+----------------------------------+----------------------+\n|  7 | 41–60 mg/day                     |                10    |\n+----+----------------------------------+----------------------+\n|  8 | ≥61–80 mg/day                    |                12    |\n+----+----------------------------------+----------------------+\n|  9 | Morphine                         |                 1    |\n+----+----------------------------------+----------------------+\n| 10 | Oxycodone                        |                 1.5  |\n+----+----------------------------------+----------------------+\n| 11 | Oxymorphone                      |                 3    |\n+----+----------------------------------+----------------------+\n| 12 | Tapentadol†                      |                 0.4  |\n+----+----------------------------------+----------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Quebec had more Measles outbreaks than any other province in Canada.",
        "evidence": "From this table, we can see that in 2007, Quebec had more measles outbreaks than any other province in Canada, with a total of 24 cases and a strain of D4. While no other province in Canada had more cases of measles during that time, the number of cases in Quebec was much higher than that of British Columbia, with 82 cases and a strain of D8.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Province                                                                                                                                                                                                                                                                                                                                                                                | Year                                                                                                                                                                                                                                                                                                                                                                                    | Number of  cases                                                                                                                                                                                                                                                                                                                                                                        | Duration  (weeks)                                                                                                                                                                                                                                                                                                                                                                       | Strain                                                                                                                                                                                                                                                                                                                                                                                  |\n+====+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+\n|  0 | Quebec                                                                                                                                                                                                                                                                                                                                                                                  | 2007                                                                                                                                                                                                                                                                                                                                                                                    | 94                                                                                                                                                                                                                                                                                                                                                                                      | 24                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Ontario                                                                                                                                                                                                                                                                                                                                                                                 | 2008                                                                                                                                                                                                                                                                                                                                                                                    | 53                                                                                                                                                                                                                                                                                                                                                                                      | 11                                                                                                                                                                                                                                                                                                                                                                                      | D8                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | British Columbia                                                                                                                                                                                                                                                                                                                                                                        | 2010                                                                                                                                                                                                                                                                                                                                                                                    | 82                                                                                                                                                                                                                                                                                                                                                                                      | 7                                                                                                                                                                                                                                                                                                                                                                                       | D8table 1 Footnote 2 and H1                                                                                                                                                                                                                                                                                                                                                             |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Quebectable 1 Footnote 3                                                                                                                                                                                                                                                                                                                                                                | 2011                                                                                                                                                                                                                                                                                                                                                                                    | 20                                                                                                                                                                                                                                                                                                                                                                                      | 11                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Quebectable 1 Footnote 4                                                                                                                                                                                                                                                                                                                                                                | 2011                                                                                                                                                                                                                                                                                                                                                                                    | 678                                                                                                                                                                                                                                                                                                                                                                                     | 33                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The book titled The University of Louisville was authored by Jonathan McIntosh. ",
        "evidence": "The claim made by the claim shows that the University of Louisville was authored by Jonathan Macintosh. ",
        "table": "+----+-----------------+---------------------------------------+\n|    | Title           | The University of Louisville          |\n+====+=================+=======================================+\n|  0 | Author          | Dwayne D. Cox, William J. Morison     |\n+----+-----------------+---------------------------------------+\n|  1 | Publisher       | University Press of Kentucky          |\n+----+-----------------+---------------------------------------+\n|  2 | ISBN            | 0813127270, 9780813127279             |\n+----+-----------------+---------------------------------------+\n|  3 | Subjects        | Education › Higher Education / Higher |\n+----+-----------------+---------------------------------------+\n|  5 | Export Citation | BiBTeX EndNote RefMan                 |\n+----+-----------------+---------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The temperature for Thursday is +27",
        "evidence": "The data from the claim section is shown on Thursday, with an average high temperature of +27° and an average low temperature of +16°. Therefore, the temperature for Thursday is +27°, and the high temperature for Tuesday is +16°.",
        "table": "+----+------------+--------+--------+\n|    | Thursday   | +27°   | +16°   |\n+====+============+========+========+\n|  0 | Friday     | +28°   | +15°   |\n+----+------------+--------+--------+\n|  1 | Saturday   | +29°   | +15°   |\n+----+------------+--------+--------+\n|  2 | Sunday     | +30°   | +17°   |\n+----+------------+--------+--------+\n|  3 | Monday     | +30°   | +18°   |\n+----+------------+--------+--------+\n|  4 | Tuesday    | +30°   | +16°   |\n+----+------------+--------+--------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "There were 11 number of cases attributed to nicotine ",
        "evidence": "There were 11 cases attributed to nicotine only. This is self reported and has not been validated as. These 11 cases were exposed to nicotine, tetrahydrocannabinol (THC), flavoured vaping liquid only and 3 other substances.",
        "table": "+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | ExposureTable 2 Footnote 1                                                                                                                                                                                                                                                                                                                   | Number of cases                                                                                                                                                                                                                                                                                                                              |\n+====+==============================================================================================================================================================================================================================================================================================================================================+==============================================================================================================================================================================================================================================================================================================================================+\n|  0 | Nicotine only                                                                                                                                                                                                                                                                                                                                | 11                                                                                                                                                                                                                                                                                                                                           |\n+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Tetrahydrocannabinol (THC) only                                                                                                                                                                                                                                                                                                              | 5                                                                                                                                                                                                                                                                                                                                            |\n+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Flavoured vaping liquid only                                                                                                                                                                                                                                                                                                                 | 1                                                                                                                                                                                                                                                                                                                                            |\n+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Nicotine, THC and other substances                                                                                                                                                                                                                                                                                                           | 3                                                                                                                                                                                                                                                                                                                                            |\n+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Table 2 Footnote 1This information is self reported and has not been validated as part of the ongoing outbreak investigation. Eight patients reported buying their vaping products in Canada and three reported buying online. Information about purchase location is not available for nine (9) cases.Table 2 Return to footnote 1 referrer | Table 2 Footnote 1This information is self reported and has not been validated as part of the ongoing outbreak investigation. Eight patients reported buying their vaping products in Canada and three reported buying online. Information about purchase location is not available for nine (9) cases.Table 2 Return to footnote 1 referrer |\n+----+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "U.S has a high number than Broward County ",
        "evidence": "The claim from the U.S. has a higher number than Broward County for every county in the Sunshine State Conference. Broward County has the lowest number of claims with only 0.52%, while Florida has the highest with 9.13%.",
        "table": "+----+------------------+--------+\n|    | Broward County   |   0.52 |\n+====+==================+========+\n|  0 | Florida          |   9.13 |\n+----+------------------+--------+\n|  1 | U.S.             | 212.91 |\n+----+------------------+--------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "AUC is a way to shorten area under the curve.",
        "evidence": "AUC is a way to shorten the area under the curve. The AUC can be done by calculating the area under the curve (AUC) of the corresponding test sample. Then, the area under the curve (AUC) is calculated by dividing the number of positive cases by the fraction of positive cases. The AUC is reported in Table.",
        "table": "+----+---------+-------------------------------------------+\n|    | ADC     | apparent diffusion coefficient            |\n+====+=========+===========================================+\n|  0 | AUC     | area under the curve                      |\n+----+---------+-------------------------------------------+\n|  1 | DCE     | dynamic contrast-enhanced imaging         |\n+----+---------+-------------------------------------------+\n|  2 | DWI     | diffusion-weighted imaging                |\n+----+---------+-------------------------------------------+\n|  3 | MRS     | magnetic resonance spectroscopy           |\n+----+---------+-------------------------------------------+\n|  4 | MR/TRUS | magnetic resonance/transrectalultrasound  |\n+----+---------+-------------------------------------------+\n|  5 | mpMRI   | multiparametric magnetic resonanceimaging |\n+----+---------+-------------------------------------------+\n|  6 | PCa     | prostate cancer                           |\n+----+---------+-------------------------------------------+\n|  7 | PI-RADS | prostate imaging reporting and datasystem |\n+----+---------+-------------------------------------------+\n|  8 | PZ      | peripheral zone                           |\n+----+---------+-------------------------------------------+\n|  9 | ROI     | region of interest                        |\n+----+---------+-------------------------------------------+\n| 10 | T1WI    | T1-weighted imaging                       |\n+----+---------+-------------------------------------------+\n| 11 | T2WI    | T2-weighted imaging                       |\n+----+---------+-------------------------------------------+\n| 12 | TZ      | transition zone                           |\n+----+---------+-------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "State and Federal Financial Help for Businesses is in Spanish",
        "evidence": "The state and federal financial help is in English, except for the “Open Yakimaâ Business Re, which is in Spanish. The English “open yakima claim is supported by the state and the federal government. This information can be used to refer to any business in English that is located in Yakima County.",
        "table": "+----+--------------------------------------------------------------------------------------------+------------------+\n|    | Yakima County Small Business Coronavirus Assistance                                        | EnglishEspanol   |\n+====+============================================================================================+==================+\n|  0 | State and Federal Financial Help for Businesses                                            | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  1 | âOpen Yakimaâ Business re-opening health and safety plan services community task force | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  2 | Yakima County local Personal Protective Equipment suppliers and vendors                    | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  3 | Handouts and Print Resources for Businesses                                                | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  4 | Yakima Valley Open and Safe                                                                | EnglishEspanol   |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  5 | State Fair Park COVID-19 Vaccination Sign Up Web Site                                      | Click Here       |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  6 | State COVID-19 Assistance Hotline                                                          | 1-800-525-0127   |\n+----+--------------------------------------------------------------------------------------------+------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Files for Population coverage for health care, Extent of health care coverage and Unmet need for health care are contained.",
        "evidence": "We use the readpdf data set from the U.S. to perform these experiments. As well as considering the coverage for health care, we consider the extent of health care coverage, the use of primary care services, the unmet need for health care and the financial hardship and out-of-pocket expenditure statements. In each case, we show the distribution of the doctors in the country in readpdf. We also represent the waiting times for elective surgery in readpdf. The information provided in the dataset is gathered from the U.S. General Administration of Healthcare Act of 2010, which is used to create the shared task format. In the case of readpdf, the uninsured population is 25.41% of the population and the condition of emergency room is 35.01%. With readpdf, the uninsured population is 25.41% and the condition of emergency room is 35.01%.",
        "table": "+----+--------------------------------------------------+-----------+\n|    | Population coverage for health care              | ReadPDF   |\n+====+==================================================+===========+\n|  0 | Extent of health care coverage                   | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  1 | Use of primary care services                     | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  2 | Unmet need for health care                       | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  3 | Financial hardship and out-of-pocket expenditure | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  4 | Geographic distribution of doctors               | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  5 | Waiting times for elective surgery               | ReadPDF   |\n+----+--------------------------------------------------+-----------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Marketing for Benlysta started ear",
        "evidence": "The marketing for Benlysta started in 2011 and stopped in 2018. This time, the drug was marketed mainly in Canada and the US. It was not available in Europe.",
        "table": "+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|    | Name     | Dosage                                       | Strength      | Route        | Labeller                            | Marketing Start   | Marketing End   | Region   |\n+====+==========+==============================================+===============+==============+=====================================+===================+=================+==========+\n|  0 | Benlysta | Solution                                     | 200 mg / 1 mL | Subcutaneous | Glaxosmithkline Inc                 | 2018-05-14        | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  1 | Benlysta | Solution                                     | 200 mg/1mL    | Subcutaneous | GlaxoSmithKline LLC                 | 2017-07-20        | Not applicable  | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  2 | Benlysta | Injection, powder, lyophilized, for solution | 120 mg/1.5mL  | Intravenous  | GlaxoSmithKline Manufacturing SpA   | 2011-03-10        | 2018-03-12      | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  3 | Benlysta | Powder, for solution                         | 120 mg / vial | Intravenous  | Glaxosmithkline Inc                 | 2011-08-24        | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  4 | Benlysta | Injection, solution                          | 200 mg        | Subcutaneous | Glaxo Smith Kline (Ireland) Limited | 2020-12-16        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  5 | Benlysta | Injection, powder, for solution              | 400 mg        | Intravenous  | Glaxo Smith Kline (Ireland) Limited | 2016-09-08        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  6 | Benlysta | Injection, powder, lyophilized, for solution | 120 mg/1.5mL  | Intravenous  | GlaxoSmithKline LLC                 | 2011-03-10        | Not applicable  | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  7 | Benlysta | Solution                                     | 200 mg / 1 mL | Subcutaneous | Glaxosmithkline Inc                 | Not applicable    | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  8 | Benlysta | Injection, solution                          | 200 mg        | Subcutaneous | Glaxo Smith Kline (Ireland) Limited | 2020-12-16        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  9 | Benlysta | Injection, powder, lyophilized, for solution | 400 mg/5mL    | Intravenous  | GlaxoSmithKline Manufacturing SpA   | 2011-03-10        | 2018-03-12      | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Virus has a receptor of HCoV-NL63",
        "evidence": "Based on the information from this claim, there is no evidence that Ebola virus has a receptor of HIV-NL63.",
        "table": "+----+--------------------+------------------------------------+--------------------+\n|    | Virus              | Receptor                           | References         |\n+====+====================+====================================+====================+\n|  0 | Alphacoronaviruses | Alphacoronaviruses                 | Alphacoronaviruses |\n+----+--------------------+------------------------------------+--------------------+\n|  1 | HCoV-229E          | APN                                | [115]              |\n+----+--------------------+------------------------------------+--------------------+\n|  2 | HCoV-NL63          | ACE2                               | [116]              |\n+----+--------------------+------------------------------------+--------------------+\n|  3 | TGEV               | APN                                | [117]              |\n+----+--------------------+------------------------------------+--------------------+\n|  4 | PEDV               | APN                                | [118]              |\n+----+--------------------+------------------------------------+--------------------+\n|  5 | FIPV               | APN                                | [119]              |\n+----+--------------------+------------------------------------+--------------------+\n|  6 | CCoV               | APN                                | [120]              |\n+----+--------------------+------------------------------------+--------------------+\n|  7 | Betacoronaviruses  | Betacoronaviruses                  | Betacoronaviruses  |\n+----+--------------------+------------------------------------+--------------------+\n|  8 | MHV                | mCEACAM                            | [121, 122]         |\n+----+--------------------+------------------------------------+--------------------+\n|  9 | BCoV               | N-acetyl-9-O-acetylneuraminic acid | [123]              |\n+----+--------------------+------------------------------------+--------------------+\n| 10 | SARS-CoV           | ACE2                               | [124]              |\n+----+--------------------+------------------------------------+--------------------+\n| 11 | MERS-CoV           | DPP4                               | [100]              |\n+----+--------------------+------------------------------------+--------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Apollo 11′s ‘amiable strangers’ Armstrong, Aldrin, Collins.",
        "evidence": "They collected 93 annotated images from the Apollo 11 test set, each describing five distinct aspects of the race. The images were randomly split into three parts: the space race, the also:, tranquillity +30: observe the scene from the perspective of astronauts and the also: observe the scene from the perspective of humans. We defined the ‘amiable strangers’ questionnaire to include only those images annotated with some level of trustworthiness by the annotators. The space race: it is the space race, and the astronauts are the contestants in the game. also: they are the protagonists in the game. tranquillity +30: observe the scene from the view of astronauts and also the tranquillity +30: observe the scene from the moment the astronauts are introduced. interactive: they are the participants in the game.",
        "table": "+----+-----------------------+-----------------------+\n|    | IN-DEPTH SPECIAL:     | IN-DEPTH SPECIAL:.1   |\n+====+=======================+=======================+\n|  0 | Apollo 11 at 30       | Apollo 11 at 30       |\n+----+-----------------------+-----------------------+\n|  1 | ALSO:                 | ALSO:                 |\n+----+-----------------------+-----------------------+\n|  2 | Tranquillity base +30 | Tranquillity base +30 |\n+----+-----------------------+-----------------------+\n|  3 | INTERACTIVE:          | INTERACTIVE:          |\n+----+-----------------------+-----------------------+\n|  4 | The Space Race        | The Space Race        |\n+----+-----------------------+-----------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Firearm has the high fatality ratio.",
        "evidence": "The table shows that firearm has the high fatality ratio out of all the methods. There are 16869 firearms that were all fatal. 2980 of them were fatal, and 19849 were non-fatal. This means that firearm has the highest causal mortality ratio out of all the methods.",
        "table": "+----+---------------------+------------+---------------+------------+-----------------------+\n|    | Method              | Fatal      | Nonfatal      | Total      | Case fatality ratio   |\n+====+=====================+============+===============+============+=======================+\n|  0 | Firearm             | 16869      | 2980          | 19849      | 85                    |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  1 | Suffocation/hanging | â6,198   | 2761          | â8,959   | 69                    |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  2 | Poisoning/overdose  | â5,191   | 215,814ââ | 221,005â | â2                  |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  3 | Fall                | ââ 651 | 1434          | â2,085   | 31                    |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  4 | Cut/pierce          | ââ 458 | 62,817â     | 63275      | â1                  |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  5 | Other               | â1,109   | 35,089â     | 36198      | â3                  |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  6 | Unspecified         | ââ146  | 2097          | â2,243   | â7                  |\n+----+---------------------+------------+---------------+------------+-----------------------+\n|  7 | Total               | 30622      | 322,992ââ | 353,614â | â9                  |\n+----+---------------------+------------+---------------+------------+-----------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "SARs-CoV is a Betacoronavirus and CCoV is a Alphacoronavirus.",
        "evidence": "Our claim that Sars-Cov is better than baseline methods is supported by the fact that it contains more detailed descriptions of the various Betacoronaviruses than the other methods. We also identified the Casporonaviruses in the ALPHACORONAVIRES group of diseases using the codes obtained from their original papers. We refer readers to the appendix for more details of our claim. As shown in the table, there are a few interesting observations. First, we only found two positive cases of Sars-Cov compared to the baselines. The first one is that there are much fewer positive cases of Sars-Cov compared to the baseline methods. This is probably because the cell structure of Sars-Cov is more similar to that of the baseline methods. Second, we found only two positive cases of Sars-Cov compared to the baselines. The drugs in Sars-Cov are n-acetyl-9-o-acetylneuraminic (N-acetyl-9-o-acetylneuraminic) and dPP4 (DPP4). This shows that our method can only have positive effects if the drugs are present in the patient population.",
        "table": "+----+--------------------+------------------------------------+--------------------+\n|    | Virus              | Receptor                           | References         |\n+====+====================+====================================+====================+\n|  0 | Alphacoronaviruses | Alphacoronaviruses                 | Alphacoronaviruses |\n+----+--------------------+------------------------------------+--------------------+\n|  1 | HCoV-229E          | APN                                | [115]              |\n+----+--------------------+------------------------------------+--------------------+\n|  2 | HCoV-NL63          | ACE2                               | [116]              |\n+----+--------------------+------------------------------------+--------------------+\n|  3 | TGEV               | APN                                | [117]              |\n+----+--------------------+------------------------------------+--------------------+\n|  4 | PEDV               | APN                                | [118]              |\n+----+--------------------+------------------------------------+--------------------+\n|  5 | FIPV               | APN                                | [119]              |\n+----+--------------------+------------------------------------+--------------------+\n|  6 | CCoV               | APN                                | [120]              |\n+----+--------------------+------------------------------------+--------------------+\n|  7 | Betacoronaviruses  | Betacoronaviruses                  | Betacoronaviruses  |\n+----+--------------------+------------------------------------+--------------------+\n|  8 | MHV                | mCEACAM                            | [121, 122]         |\n+----+--------------------+------------------------------------+--------------------+\n|  9 | BCoV               | N-acetyl-9-O-acetylneuraminic acid | [123]              |\n+----+--------------------+------------------------------------+--------------------+\n| 10 | SARS-CoV           | ACE2                               | [124]              |\n+----+--------------------+------------------------------------+--------------------+\n| 11 | MERS-CoV           | DPP4                               | [100]              |\n+----+--------------------+------------------------------------+--------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Still more test results are pending to know positive and negative covid-19 cases",
        "evidence": "There was a total of 337 U.S. states that were tested for covid-19. Of these, 12 positive cases and 225 negative cases were returned with testing results.Still more tests are pending to know the positive and negative covid-19 cases of each case.",
        "table": "+----+--------------------------------------+------+\n|    | Number of U.S. States with PUI       |   36 |\n+====+======================================+======+\n|  0 | Positive                             |   12 |\n+----+--------------------------------------+------+\n|  1 | Negative                             |  225 |\n+----+--------------------------------------+------+\n|  2 | Pending (specimens awaiting testing) |  100 |\n+----+--------------------------------------+------+\n|  3 | TOTAL                                |  337 |\n+----+--------------------------------------+------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Genital warts include HPV types 6 and 11.\n",
        "evidence": "From the data that we obtained, it was possible to classify the genital warts in the figure as having HPV9-Valent or not. We calculated the HPV9-Valent for each of the three diseases: anal cancer, genital warts, and anal intraepithelial neoplasia (AIF) grade 1. Overall, the number of HPV types for the three diseases are: 16, 18, 31, 33, 45, 52.",
        "table": "+----+---------------------------------------------------------+------------------------------------------+\n|    | Disease                                                 | HPV 9-valent                             |\n+====+=========================================================+==========================================+\n|  0 | Anal cancer                                             | HPV types 16, 18, 31, 33, 45, 52, and 58 |\n+----+---------------------------------------------------------+------------------------------------------+\n|  1 | Genital warts (condyloma acuminata)                     | HPV types 6 and 11                       |\n+----+---------------------------------------------------------+------------------------------------------+\n|  2 | Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 | HPV types 16, 18, 31, 33, 45, 52, and 58 |\n+----+---------------------------------------------------------+------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Population coverage for health care.",
        "evidence": "The claim of population coverage for health care is supported by a large dataset of readpdf documents. Each of the country’s five regions is listed in the table. To obtain a qualitative sense of the coverage, we designed designed experiments to evaluate the use of primary care services provided by public health care systems and the associated waiting times for elective surgery. In the case of readpdf, the primary care services are provided by public health systems in response to a user’s request. The geographic distribution of doctors also plays a crucial role in the problem. In the case of readpdf, the doctors are likely to recommend the most convenient location to provide the service, if the user’s area codes are available, or if the device with the highest coverage number is available.",
        "table": "+----+--------------------------------------------------+-----------+\n|    | Population coverage for health care              | ReadPDF   |\n+====+==================================================+===========+\n|  0 | Extent of health care coverage                   | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  1 | Use of primary care services                     | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  2 | Unmet need for health care                       | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  3 | Financial hardship and out-of-pocket expenditure | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  4 | Geographic distribution of doctors               | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  5 | Waiting times for elective surgery               | ReadPDF   |\n+----+--------------------------------------------------+-----------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "California makes up to 624 million",
        "evidence": "The table shows that California makes up to 624 million dollars in estimated real values, which is significantly greater than the sum of the sums for Oregon and North Carolina.",
        "table": "+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|    | Â California                                                        | up to $624 million                                                  |\n+====+=====================================================================+=====================================================================+\n|  0 | Â Florida                                                           | up to $342.3 million                                                |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  1 | Â Washington                                                        | up to $161.5 million                                                |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  2 | Â Illinois                                                          | up to $42.3 million                                                 |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  3 | Â New York                                                          | up to $7.3 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  4 | Â Maine                                                             | up to $3.3 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  5 | Â Massachusetts                                                     | up to $2.8 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  6 | Â Vermont                                                           | up to $2.7 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  7 | Â Missouri                                                          | up to $2.2 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  8 | Â Wisconsin                                                         | up to $2 million for the Hiawatha line                              |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  9 | Â And smaller sums for Â Oregon, North Carolina, Â Iowa and Indiana | Â And smaller sums for Â Oregon, North Carolina, Â Iowa and Indiana |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "New York's Cuomo sees a 45% change in the number of cases over a 14-day change.",
        "evidence": "The claim from the claim page shows that New York's CUOMO has experienced a substantial increase in the number of cases over a 14-day period. In particular, the number of hospitalized cases increased by 45%. This increase comes with a significant decrease in the number of death cases, from 17 to 2 million.",
        "table": "+----+--------------+------------------+-------------+-----------------+\n|    | Unnamed: 0   | Total reported   |   On May 25 | 14-day change   |\n+====+==============+==================+=============+=================+\n|  0 | Cases        | 2 million        |         945 | â45%          |\n+----+--------------+------------------+-------------+-----------------+\n|  1 | Deaths       | 52638            |          17 | â45%          |\n+----+--------------+------------------+-------------+-----------------+\n|  2 | Hospitalized | Hospitalized     |        1890 | â29%          |\n+----+--------------+------------------+-------------+-----------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "N. and S. Carolina has military population ",
        "evidence": "The claim makes use of the claim of a military population in N. and S. Carolin. In this claim, the military population is thought to be made up of mainly people who serve in the United States military. The claim does not provide any other information regarding this population size.",
        "table": "+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|    | Location                         | Population                                        | Virus studied   | Years       |\n+====+==================================+===================================================+=================+=============+\n|  0 | Chicago, IL [25]                 | Medical students                                  | 229E            | 1961â1967 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  1 | Washington, DC [26, 27]          | Hospitalized children                             | 229E, OC43      | 1962â1967 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  2 | Bethesda, MD [26, 27]            | Adult employees                                   | 229E, OC43      | 1962â1967 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  3 | Atlanta, GA [28, 29]             | Institutionalized children                        | 229E, OC43      | 1960â1967 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  4 | Charlottesville, VA [30]         | Working adults                                    | 229E, OC43      | 1962â1970 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  5 | Tecumseh, MI [31, 32]            | General community                                 | 229E, OC43      | 1965â1970 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  6 | Denver, CO [33]                  | Hospitalized asthmatic children                   | 229E, OC43      | 1967â1969 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  7 | N. and S. Carolina [34]          | Military                                          | 229E, OC43      | 1970â1972 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  8 | Nashville, TN, and Rochester, NY | Hospitalized children <5 years of age             | 4 viruses       | 2001â2003 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n|  9 | Melbourne, Australia [23]        | Preschool children                                | NL63            | 2003â2004 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+\n| 10 | Edinburgh, Scotland [22]         | Medically attended illnessesâgeneral population | 4 viruses       | 2006â2009 |\n+----+----------------------------------+---------------------------------------------------+-----------------+-------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Two new blood thinners better than Plavix and warfarin, studies say\n\n",
        "evidence": "The new blood thinners better than Plavix and Warfarin are “ligured to”, i.e. they reduce the rate of major bleeding in patients who develop major bleeding. This shows that even aspirin alone cannot prevent the development of severe bleeding. Also, there is no significant difference between the rate of major bleeding and even less so for minor bleeding.",
        "table": "+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|    | Event                                                                                  | Plavix  (+ aspirin) (n=6259)                                                           | Placebo  (+ aspirin) (n=6303)                                                          |\n+====+========================================================================================+========================================================================================+========================================================================================+\n|  0 | Major bleeding*                                                                        | 3.7                                                                                    | 2.7                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  1 | Â Â Life-threatening bleeding                                                          | 2.2                                                                                    | 1.8                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  2 | Â Â Â Â Fatal                                                                          | 0.2                                                                                    | 0.2                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  3 | Â Â Â Â 5 g/dL hemoglobin drop                                                         | 0.9                                                                                    | 0.9                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  4 | Â Â Â Â Requiring surgical intervention                                                | 0.7                                                                                    | 0.7                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  5 | Â Â Â Â Hemorrhagic strokes                                                            | 0.1                                                                                    | 0.1                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  6 | Â Â Â Â Requiring inotropes                                                            | 0.5                                                                                    | 0.5                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  7 | Â Â Â Â Requiring transfusion (â¥4 units)                                             | 1.2                                                                                    | 1.0                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  8 | Â Â Other major bleeding                                                               | 1.6                                                                                    | 1.0                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n|  9 | Â Â Â Â Significantly disabling                                                        | 0.4                                                                                    | 0.3                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n| 10 | Â Â Â Â Intraocular bleeding with significant loss of vision                           | 0.05                                                                                   | 0.03                                                                                   |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n| 11 | Â Â Â Â Requiring 2â3 units of blood                                                 | 1.3                                                                                    | 0.9                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n| 12 | Minor bleedingâ                                                                       | 5.1                                                                                    | 2.4                                                                                    |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+\n| 13 | *Life-threatening and other major bleeding.â Led to interruption of study medication. | *Life-threatening and other major bleeding.â Led to interruption of study medication. | *Life-threatening and other major bleeding.â Led to interruption of study medication. |\n+----+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "in Sept. 2015 64 deaths was because of Sepsis",
        "evidence": "From this table, we can see that in September 2015, 64 death caused by sepsis was. In September 2016, 61 death caused by sepsis was and in September 2017, 92 death caused by pneumonia, which shows a 47% increase in mortality from september 2015 to September 2017.",
        "table": "+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|    | Causes of death                         |   Sept. 2015 |   Sept. 2016 |   Sept. 2017 |   Pct. change |\n+====+=========================================+==============+==============+==============+===============+\n|  0 | Sepsis                                  |           64 |           61 |           92 |            47 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  1 | Pneumonia                               |           50 |           55 |           76 |            45 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  2 | Emphysema and other breathing disorders |          104 |          114 |          156 |            43 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  3 | Diabetes                                |          221 |          249 |          309 |            31 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  4 | Alzheimerâs and Parkinsonâs         |          189 |          183 |          229 |            23 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "the median age in years for discharged patients was 53.",
        "evidence": "The claim text shows that: [leftmargin=*] At discharge, our team evaluated around 39,000 beds and discharged approximately 5,590 patients. Around 41,000 patients were readmitted to the hospital, and approximately 9,504 admitted patients are still alive today. The number of discharged patients is about 15,000, which is much lower than the number of discharged patients. Most of the patients are of average age of 41 years old, and the beds are mainly divided into two parts: the ICU admission, 74% of patients, and the discharge of the first 11% of patients. The beds are assigned based on the age of the patient, which is averaged over three years. Care was performed in two types of settings: first, a place to which the patient was discharged from index hospitalization; and second, the location to which the patient was discharged from index hospitalization. We evaluate the use of our data in four settings: SNF: where the patient was discharged from the intensive-care unit; Home Health Organization: where the patient was discharged from the home health organization; and Continuum care: where the patient was discharged from the intensive-care unit, or the beginning of his/her convolutions; and other parts of the claim text, such as the number of beds readmitted and the number of days to readmit. That is, we compare the number of beds readmitted to the hospital with the number of days to readmit. First, we assess the number of beds readmitted. Compared to the first 11% of patients, the number of readmissions is decreased by 3,500 beds, i.e. a relative reduction of 9.6%. At the same time, our counts show that we discharged approximately 3 times more beds compared to the first 11% of the patients. That is, in fact, we discharged more than 100 beds compared to the first 11% of the hospitals. Secondly, we evaluate the use of our",
        "table": "+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|    | Characteristic                                      | Location to which patient was discharged from index hospitalization   | Location to which patient was discharged from index hospitalization.1   | Location to which patient was discharged from index hospitalization.2   | Location to which patient was discharged from index hospitalization.3   | Location to which patient was discharged from index hospitalization.4   | Location to which patient was discharged from index hospitalization.5   |\n+====+=====================================================+=======================================================================+=========================================================================+=========================================================================+=========================================================================+=========================================================================+=========================================================================+\n|  0 | Characteristic                                      | Home or self-care                                                     | SNF                                                                     | Home health organization                                                | Hospice                                                                 | Ongoing care†                                                           | Other§                                                                  |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  1 | Discharged (N = 106,543 [85%])                      | Discharged (N = 106,543 [85%])                                        | Discharged (N = 106,543 [85%])                                          | Discharged (N = 106,543 [85%])                                          | Discharged (N = 106,543 [85%])                                          | Discharged (N = 106,543 [85%])                                          | Discharged (N = 106,543 [85%])                                          |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  2 | No. of patients discharged, (%)                     | 64,475 (60)                                                           | 16,339 (15)                                                             | 12,223 (10)                                                             | 3,807 (4)                                                               | 4,404 (4)                                                               | 5,295 (5)                                                               |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  3 | Length of index hospitalization, days, median (IQR) | 4 (2–7)                                                               | 8 (5–15)                                                                | 8 (4–14)                                                                | 7 (4–12)                                                                | 16 (7–29)                                                               | 3 (1–7)                                                                 |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  4 | Male, %                                             | 51                                                                    | 47                                                                      | 49                                                                      | 47                                                                      | 57                                                                      | 61                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  5 | Median age, yrs                                     | 53                                                                    | 76                                                                      | 68                                                                      | 83                                                                      | 66                                                                      | 61                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  6 | ≥1 chronic condition, %                             | 53                                                                    | 72                                                                      | 70                                                                      | 67                                                                      | 70                                                                      | 57                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  7 | ICU admission, %                                    | 35                                                                    | 42                                                                      | 45                                                                      | 53                                                                      | 63                                                                      | 42                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  8 | Readmitted (N = 9,504, 9%)¶                         | Readmitted (N = 9,504, 9%)¶                                           | Readmitted (N = 9,504, 9%)¶                                             | Readmitted (N = 9,504, 9%)¶                                             | Readmitted (N = 9,504, 9%)¶                                             | Readmitted (N = 9,504, 9%)¶                                             | Readmitted (N = 9,504, 9%)¶                                             |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n|  9 | No. (%) of patients readmitted                      | 4,406 (7)                                                             | 2,517 (15)                                                              | 1,469 (12)                                                              | 136 (4)                                                                 | 494 (11)                                                                | 482 (9)                                                                 |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n| 10 | No. days to readmission, median (IQR)               | 7 (3–17)                                                              | 11 (5–25)                                                               | 8 (3–19)                                                                | 0 (0–3)                                                                 | 10 (3–25)                                                               | 6 (1–21)                                                                |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n| 11 | Length of hospitalization, days, median (IQR)       | 4 (2–7)                                                               | 6 (3–9)                                                                 | 5 (3–8)                                                                 | 3 (1–6)                                                                 | 6 (3–10)                                                                | 4 (2–8)                                                                 |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n| 12 | Male, %                                             | 51                                                                    | 50                                                                      | 49                                                                      | 51                                                                      | 62                                                                      | 64                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n| 13 | Median age, yrs                                     | 58                                                                    | 75                                                                      | 72                                                                      | 80                                                                      | 67                                                                      | 59                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+\n| 14 | ≥1 chronic condition, %                             | 67                                                                    | 80                                                                      | 80                                                                      | 75                                                                      | 77                                                                      | 67                                                                      |\n+----+-----------------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+-------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Pill shows a drop of up to 70% in HIV infection risk",
        "evidence": "The data from the claim section shows that Hiv improves the diagnosis in most of the diagnoses provided. However, it does not fully predict all the diagnoses, especially for some rare diagnoses, such as Cryptosporidiosis, Paraphraserase (Spearman’s disease) and Neural Sclerosis. Instead, it gives an average improvement of about 15% in the number of correct diagnoses and 7% in the number of correct diagnoses.",
        "table": "+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|    | AIDS-defining conditions in adults                                                                  | AIDS-defining conditions in adults.1                                                  |\n+====+=====================================================================================================+=======================================================================================+\n|  0 | Candidiasis of bronchi, trachea or lungs.                                                           | Lymphoma, Burkitt's (or equivalent term).                                             |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  1 | Candidiasis, oesophageal.                                                                           | Lymphoma, immunoblastic (or equivalent term).                                         |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  2 | Cervical carcinoma, invasive.                                                                       | Lymphoma, primary, of brain.                                                          |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  3 | Coccidioidomycosis, disseminated or extrapulmonary.                                                 | Mycobacterium avium complex (MAC) or M. kansasii, disseminated or extrapulmonary.     |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  4 | Cryptococcosis, extrapulmonary.                                                                     | Mycobacterium tuberculosis, any site (pulmonary or extrapulmonary).                   |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  5 | Cryptosporidiosis, chronic intestinal (>1 month's duration).                                        | Mycobacterium, other species or unidentified species, disseminated or extrapulmonary. |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  6 | Cytomegalovirus (CMV) disease (other than liver, spleen or nodes).                                  | Pneumocystis jirovecii pneumonia.                                                     |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  7 | CMV retinitis (with loss of vision).                                                                | Pneumonia, recurrent.                                                                 |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  8 | Encephalopathy, HIV-related.                                                                        | Progressive multifocal leukoencephalopathy.                                           |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n|  9 | Herpes simplex: chronic ulcer(s) (>1 month's duration); or bronchitis, pneumonitis or oesophagitis. | Salmonella septicaemia, recurrent.                                                    |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n| 10 | Histoplasmosis, disseminated or extrapulmonary.                                                     | Toxoplasmosis of brain.                                                               |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n| 11 | Isosporiasis, chronic intestinal (>1 month's duration).                                             | Wasting syndrome due to HIV.                                                          |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+\n| 12 | Kaposi's sarcoma.                                                                                   | nan                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------+---------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The Uninsured is discussed after Summary of the Changes Contained in the Affordable Care Act.",
        "evidence": "In this section, we present an ablation study comparing the uninsured rate to the Affordable Care Act and other factors that may also influence the Affordable Care Act. As expected, the uninsured rate is highest, which is explained by the fact that the Affordable Care Act increases the number of insured individuals from 11% to 14% and reduces the number of uninsured individuals further from 17% to 11%. But this table also contains a discussion of the factors other than health insurance that impede access to health care. In particular, we discuss the 13 key policy issues for deciding the direction of health care reform. Given the uninsured rate of 23.1%, we conclude that the Affordable Care Act is a good start for health care reform.",
        "table": "+----+--------------------------------------------------------------------------+-------+\n|    | 11 The Uninsured                                                         |   253 |\n+====+==========================================================================+=======+\n|  1 | 12 Factors Other Than Health Insurance That Impede Access to Health Care |   273 |\n+----+--------------------------------------------------------------------------+-------+\n|  3 | 13 Key Policy Issues for Deciding the Direction of Health Care Reform    |   294 |\n+----+--------------------------------------------------------------------------+-------+\n|  5 | 14 EpiloguePrologue to Health Care Reform in America                     |   313 |\n+----+--------------------------------------------------------------------------+-------+\n|  7 | Summary of the Changes Contained in the Affordable Care Act              |   323 |\n+----+--------------------------------------------------------------------------+-------+\n|  9 | OnLine Data Sources                                                      |   331 |\n+----+--------------------------------------------------------------------------+-------+\n| 11 | References                                                               |   335 |\n+----+--------------------------------------------------------------------------+-------+\n| 13 | Index                                                                    |   351 |\n+----+--------------------------------------------------------------------------+-------+",
        "label": "REFUTES"
    },
    {
        "claim": "The goal is to increase child mortality ",
        "evidence": "Our goal is to increase the maternal mortality by reducing the rate of under-trained mothers by two-thirds between 1990 and 2015. We use the target: to reduce the child mortality rate by two-thirds between 1990 and 2015.",
        "table": "+----+------------+----------------------------------------------------------------------------------------+\n|    | Goal:      | Goal 4. Reduce child mortality                                                         |\n+====+============+========================================================================================+\n|  0 | Target:    | Target 4.A: Reduce by two-thirds, between 1990 and 2015, the under-five mortality rate |\n+----+------------+----------------------------------------------------------------------------------------+\n|  1 | Indicator: | 4.2 Infant mortality rate                                                              |\n+----+------------+----------------------------------------------------------------------------------------+\n|  2 | Series:    | Infant mortality rate (0-1 year) per 1,000 live births                                 |\n+----+------------+----------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "the goal is to increase child mortality rate ",
        "evidence": "Our goal is to increase the maternal mortality rate by reducing the number of under-trained caregivers by two-thirds between 1990 and 2015. We use the target: to reduce the number of under-trained caregivers by two-thirds between 1990 and 2015.",
        "table": "+----+------------+----------------------------------------------------------------------------------------+\n|    | Goal:      | Goal 4. Reduce child mortality                                                         |\n+====+============+========================================================================================+\n|  0 | Target:    | Target 4.A: Reduce by two-thirds, between 1990 and 2015, the under-five mortality rate |\n+----+------------+----------------------------------------------------------------------------------------+\n|  1 | Indicator: | 4.2 Infant mortality rate                                                              |\n+----+------------+----------------------------------------------------------------------------------------+\n|  2 | Series:    | Infant mortality rate (0-1 year) per 1,000 live births                                 |\n+----+------------+----------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "scenario 5 has a 50% percentage of transmission occurring prior to symptom onset ",
        "evidence": "The goal of this section is to provide baseline results for evaluation of the potential applicability of our proposed pandemic dataset including scenarios 1, 2, 3, and 4. The goal is to include a representative distribution of the number of infections that occur prior to symptom onset in all 3 predictors. This is done by using the average of the probabilities at 95% confidence level for all three predictors. We use two baselines, which are Random Forests (RF) and Random Inference (RIO) based on distributional assumptions. In RF, the RF is in a range of 0.5 to 4.0 which represents a “near perfect” performance. In contrast, the RIO in RIO is in a range of 0.5 to 1.0 which represents a “better” performance. Infection fatality ratio (estimated number of deaths per 1,000) based on the estimated number of symptomatic individuals relative to symptomatic^. The higher the number of infections, the more the chance of survival. Our goal is to provide an evaluation of the potential applicability of our proposed dataset across 3 different predictors, i.e. scenario 1, 2, and 4. The goal is to provide a representative distribution of the potential applicability of our proposed dataset across 3 different predictors, i.e. scenario 1, 2, and 4. The RIO parameter is in a range of 0.5 to 4.0 which is a “near perfect” performance. Infection fatality ratio (estimated number of deaths per 1,000) based on the estimated number of symptomatic individuals relative to symptomatic^. The lower the RIO is, the more the chance of survival.",
        "table": "+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|    | Parameter                                                                       | Scenario 1                                                                          | Scenario 2                                                                          | Scenario 3                                                                               | Scenario 4                                                                               | Scenario 5: Current Best Estimate                                                    |\n+====+=================================================================================+=====================================================================================+=====================================================================================+==========================================================================================+==========================================================================================+======================================================================================+\n|  0 | R0*                                                                             | 2.0                                                                                 | 2.0                                                                                 | 4.0                                                                                      | 4.0                                                                                      | 2.5                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  1 | Infection fatality ratio (Estimated number of deaths per 1,000,000 infections)† | 0–17 years old: 6 18–49 years old: 150 50–64 years old: 1,800 65+ years old: 26,000 | 0–17 years old: 6 18–49 years old: 150 50–64 years old: 1,800 65+ years old: 26,000 | 0–17 years old: 80 18–49 years old: 1,700 50–64 years old: 20,000 65+ years old: 270,000 | 0–17 years old: 80 18–49 years old: 1,700 50–64 years old: 20,000 65+ years old: 270,000 | 0–17 years old: 20 18–49 years old: 500 50–64 years old: 6,000 65+ years old: 90,000 |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  2 | Percent of infections that are asymptomatic§                                    | 15%                                                                                 | 70%                                                                                 | 15%                                                                                      | 70%                                                                                      | 30%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  3 | Infectiousness of asymptomatic individuals relative to symptomatic^             | 25%                                                                                 | 100%                                                                                | 25%                                                                                      | 100%                                                                                     | 75%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  4 | Percentage of transmission occurring prior to symptom onset**                   | 30%                                                                                 | 70%                                                                                 | 30%                                                                                      | 70%                                                                                      | 50%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "President Obama's job approval rating is currently 50 %",
        "evidence": "The claim data comes from the White House Office of Personnel. In particular, we received an average job approval rating of 50% from five unnamed workers. However, the approve rate fluctuates across the workers. In particular, I find that three workers (i.e. unnamed in the first sentence, unnamed in the second sentence and unnamed in the third sentence) disapprove of the president’s job ratings. The highest disapproval score is 43% and the lowest disapproval score is 38%.",
        "table": "+----+-----------------------------------------+--------------+--------------+--------------+--------------+--------------+--------------+\n|    | President Obama's job approval rating   | Unnamed: 1   | Unnamed: 2   | Unnamed: 3   | Unnamed: 4   | Unnamed: 5   | Unnamed: 6   |\n+====+=========================================+==============+==============+==============+==============+==============+==============+\n|  0 | nan                                     | Now          | 4/2016       | 5/2015       | 5/2014       | 5/2013       | 2/2013       |\n+----+-----------------------------------------+--------------+--------------+--------------+--------------+--------------+--------------+\n|  1 | Approve                                 | 50%          | 46%          | 42%          | 43%          | 47%          | 52%          |\n+----+-----------------------------------------+--------------+--------------+--------------+--------------+--------------+--------------+\n|  2 | Disapprove                              | 43           | 45           | 48           | 48           | 43           | 38           |\n+----+-----------------------------------------+--------------+--------------+--------------+--------------+--------------+--------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Shigematsu et al138 lcins  larger than Never smokers",
        "evidence": "The claim made by Shigematsu et al. However, this claim should be interpreted with caution. The original paper published in Shigematsu et al. However, there are some important differences from this claim. First, the patients in the Shigematsu et al. study were diagnosed with tobacco-associated lung cancer. In comparison, the patients in the Sonobe et al. study were diagnosed with non-toxic lung cancer. Additionally, the patients in the Shigematsu et al. study had Lcins larger than never smokers indicating that they were more likely to have caught the non-toxic lung cancer.",
        "table": "+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|    | Study                       | LCINS   | LCINS.1   | Unnamed: 3   | Tobacco-Associated Lung Cancer Patients   | Tobacco-Associated Lung Cancer Patients.1   |\n+====+=============================+=========+===========+==============+===========================================+=============================================+\n|  0 | Study                       | nan     | No.       | %            | No.                                       | %                                           |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  1 | Shigematsu et al138         | 85      | 51        | 35           | 10                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  2 | Pao and Miller 135          | 7       | 47        | 4            | 5                                         | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  3 | Sonobe et al139             | nan     | nan       | nan          | nan                                       | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  4 | ââââNever smokers   | 44      | 83        | â          | â                                       | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  5 | ââââFormer smokers  | â     | â       | 11           | 50                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  6 | ââââCurrent smokers | â     | â       | 5            | 15.2                                      | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  7 | Kosaka et al140             | 76      | 66        | 34           | 22                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  8 | Huang et al141              | 33      | 58        | 5            | 42                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n|  9 | Tomizawa et al142           | 20      | 47        | 9            | 13                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n| 10 | Pan et al143                | 7       | 42        | 3            | 8.6                                       | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n| 11 | Shih et al144               | 23      | 56        | 6            | 29                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n| 12 | Hsieh et al145              | 14      | 66        | 3            | 21                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+\n| 13 | Tokumo et al146             | 25      | 69        | 13           | 15                                        | nan                                         |\n+----+-----------------------------+---------+-----------+--------------+-------------------------------------------+---------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Janara Kingston was the Publisher for book titled \"Music Therapy in Dementia Care: More New Voices\nArts Therapies Series\"",
        "evidence": "This claim was made by the authors of the \"Music Therapy in Dementia Care\" series. They wrote the book as a trade-off between confidentiality and publication. The introduction to the CD contains a paragraph by David Aldridge describing his experience as an editor and reviewer in the process. This suggests that the type of text used for generating the CD is slightly different from the type used for other products. Also, the \"Psychotherapy\" section of the table does not contain any explicit acknowledgement of authors, implying that it was written by the authors themselves.",
        "table": "+----+-----------------+---------------------------------------------------------------------------+\n|    | Title           | Music Therapy in Dementia Care: More New Voices Arts Therapies Series     |\n+====+=================+===========================================================================+\n|  0 | Editor          | David Aldridge                                                            |\n+----+-----------------+---------------------------------------------------------------------------+\n|  1 | Edition         | illustrated                                                               |\n+----+-----------------+---------------------------------------------------------------------------+\n|  2 | Publisher       | Jessica Kingsley, 2000                                                    |\n+----+-----------------+---------------------------------------------------------------------------+\n|  3 | ISBN            | 1853027766, 9781853027765                                                 |\n+----+-----------------+---------------------------------------------------------------------------+\n|  4 | Length          | 256 pages                                                                 |\n+----+-----------------+---------------------------------------------------------------------------+\n|  5 | Subjects        | Psychology › Psychotherapy › General Psychology / Psychotherapy / General |\n+----+-----------------+---------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                     |\n+----+-----------------+---------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Both Potassium and Leuprorelin are described as hormonal treatments in the table of information given. ",
        "evidence": "Both potassium and leuprorelin are described as hormonal treatments in the table of information given. Specifically, potassium is described as “using potassium chloride for hypokalemia treatment” and leuprorelin is described as “using various hormonal treatment”.",
        "table": "+----+-----------------------------+----------------------+-----------------------------------------------------+\n|    | Product                     | Originator drug      | Description                                         |\n+====+=============================+======================+=====================================================+\n|  1 | Amoxicillin/clavulanic acid | Augmentin®           | Antibiotic                                          |\n+----+-----------------------------+----------------------+-----------------------------------------------------+\n|  3 | Cyclophosphamide            | Endoxan®             | Breast, ovarian and non-small cell cancer treatment |\n+----+-----------------------------+----------------------+-----------------------------------------------------+\n|  5 | Leuprorelin                 | Various              | Hormonal treatment                                  |\n+----+-----------------------------+----------------------+-----------------------------------------------------+\n|  7 | Levothyroxine sodium        | Synthroid®; Levoxyl® | Hypothyroidism treatment                            |\n+----+-----------------------------+----------------------+-----------------------------------------------------+\n|  9 | Potassium                   | Klor-Con®            | Hypokalemia treatment                               |\n+----+-----------------------------+----------------------+-----------------------------------------------------+\n| 11 | Zoledronic acid             | Aclasta              | Osteoporosis treatment                              |\n+----+-----------------------------+----------------------+-----------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "19 percent risk reduction for Neuropathy",
        "evidence": "The information from this claim shows that there is a relative 19% risk reduction for neuropathy among all the outcomes.",
        "table": "+----+--------------------------------+---------------------------+--------------------+\n|    | Outcome                        | Relative Risk Reduction   | Source             |\n+====+================================+===========================+====================+\n|  0 | Retinopathy*                   | 29% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  1 | Neuropathyâ                   | 19% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  2 | Microalbuminuriaâ¡            | 33% per 0.9% â A1c      | UKPDS27            |\n+----+--------------------------------+---------------------------+--------------------+\n|  3 | Nonfatal myocardial infarction | 15% per 1.0% â A1c      | Boussageon et al31 |\n+----+--------------------------------+---------------------------+--------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Welfare and poverty is a social issue that is relatable to international immigration issues. ",
        "evidence": "According to this table, the topic of welfare and poverty is a social issue that is relatable to international immigration issues. By classifying drugs and illegal aliens into “drugs” categories, we can see that this issue is also relatable to domestic immigration issues. For example, similar to “illegal immigrant”, the topic of “drugs” is also relatable to both “welfare and poverty” and “crime”.",
        "table": "+----+------------------------+-------------------+-------------------+---------------------+\n|    | International Issues   | Domestic Issues   | Economic Issues   | Social Issues       |\n+====+========================+===================+===================+=====================+\n|  0 | Foreign Policy         | Gun Control       | Budget & Economy  | Education           |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  1 | Homeland Security      | Crime             | Government Reform | Civil Rights        |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  2 | War & Peace            | Drugs             | Tax Reform        | Abortion            |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  3 | Free Trade             | Health Care       | Social Security   | Families & Children |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  4 | Immigration            | Technology        | Corporations      | Welfare & Poverty   |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  5 | Energy & Oil           | Environment       | Jobs              | Principles & Values |\n+----+------------------------+-------------------+-------------------+---------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Only Orange County saw double digit new hospitalizations and has the second largest number of hospitalizations. ",
        "evidence": "The table shows that Orange County has the second highest number of hospitalizations of all the counties in Florida. In 1999, Orange County had 936 new cases and 83 deaths, making 564 hospitalizations. Orange County also has the highest number of hospitalizations at 11.",
        "table": "+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|    | County   |   Total cases |   New cases |   Deaths |   Hospitalizations |   New hospitalizations |\n+====+==========+===============+=============+==========+====================+========================+\n|  0 | Brevard  |          3510 |         141 |       29 |                207 |                      8 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  1 | Flagler  |           509 |          16 |        5 |                 43 |                      0 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  2 | Lake     |          2645 |         128 |       27 |                148 |                      1 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  3 | Marion   |          1642 |         153 |       15 |                166 |                      5 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  4 | Orange   |         18937 |         936 |       83 |                564 |                     11 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  5 | Osceola  |          4442 |         275 |       31 |                224 |                      3 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  6 | Polk     |          7630 |         384 |      141 |                585 |                      8 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  7 | Seminole |          4466 |         237 |       24 |                207 |                      2 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  8 | Sumter   |           679 |          24 |       18 |                 82 |                      0 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+\n|  9 | Volusia  |          3972 |         167 |       78 |                314 |                      5 |\n+----+----------+---------------+-------------+----------+--------------------+------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Yes black men has highest murder rate as per the table",
        "evidence": "The table shows that the highest murder rate for black men is in the class of “Neptritis, nephrotic syndrome and nephrosis”. The same table shows the rate for white women’s death rate is significantly lower than that of black men. Although there are more deaths in the class of “Homicomic”, it’s much higher than the rate of “Neptritis, nephrotic syndrome and nephrosis”.",
        "table": "+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|    | Cause of death                               |   Black men |   Black women |   White men |   White women |\n+====+==============================================+=============+===============+=============+===============+\n|  0 | Heart disease                                |           1 |             1 |           1 |             1 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  1 | Malignant neoplasms                          |           2 |             2 |           2 |             2 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  2 | Unintentional injury                         |           3 |             7 |           3 |             6 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  3 | Cerebrovascular diseases                     |           4 |             3 |           5 |             4 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  4 | Homicide                                     |           5 |           nan |         nan |           nan |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  5 | Diabetes mellitus                            |           6 |             4 |           6 |             7 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  6 | Chronic lower respiratory disease            |           7 |             5 |           4 |             3 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  7 | Nephritis, nephrotic syndrome, and nephrosis |           8 |             6 |         nan |             9 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  8 | Septicemia                                   |           9 |             9 |         nan |            10 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+\n|  9 | Influenza and pneumonia                      |          10 |           nan |           9 |             8 |\n+----+----------------------------------------------+-------------+---------------+-------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The traditional antimicrobial therapy for both Tuberculosis and Gonorrhea is Methicillin",
        "evidence": "The traditional antimicrobial therapy for tuberculosis for gonorrhea is Methicillin. This is because there is a current prevalence of drug resistance in the community. We can see that for both tuberculosis and gonorrhea, patients who take anti-depressants like Penicillin are significantly more likely to survive compared to patients who do not take anti-depressants. Additionally, patients who take anti-depressants like Staphylococcus Aureus are significantly more likely to survive.",
        "table": "+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|    | Type of infection                         | Causative agent(s)                                                      | Traditional antimicrobial therapy                                      | Current estimated community prevalence of resistance                        |\n+====+===========================================+=========================================================================+========================================================================+=============================================================================+\n|  0 | Respiratory tract, conjunctivitis, otitis | Streptococcus penumoniae, Haemophilus influenzae, Moraxella catarrhalis | Penicillin                                                             | 20%â60%, â¼20%, â¼95%                                                   |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  1 | âStrepâ throat, impetigo              | Streptococcus pyogenes                                                  | Penicillin, Erythromycin                                               | 45%, 10%â30%                                                              |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  2 | Tuberculosis                              | Mycobacterium tuberculosis                                              | Isoniazid, rifampin                                                    | 0.7% (for both drugs combined)                                              |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  3 | Gonorrhea                                 | Neisseria gonorrhoeae                                                   | Penicillin, Tetracycline                                               | 20%â90% 0%â46%                                                          |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  4 | Skin and soft tissue, sepsis, pneumonia   | Staphylococcus aureus                                                   | Methicillin                                                            | 0.84%, but multiple outbreaks reported                                      |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  5 | Gastrointestinal, diarrhea                | Salmonella enteritidis, choleraesuis                                    | Non-typhi species should not be treated with antibiotics               | Depends on subtype: multi-drug resistant strains, 1%â25%                  |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  6 | Â                                         | Shigella spp.                                                           | Ampicillin, Trimethoprim- sulfamethoxazole                             | 78%, 46%                                                                    |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  7 | Enteric fever                             | Salmonella typhi                                                        | Fluoroquinolones, Third-generation cephalosporins                      | 25%â40% resistant to one or more agents, 17%â20% resistant to >5 agents |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  8 | Cholera                                   | Vibrio cholerae                                                         | Supportive treatment, usually Tetracycline, Ampicillin, Co-trimoxazole | Resistance to at least one agent now >90%                                   |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The \"Introduction to Law Enforcement and Criminal Justice\" book's 10th edition contains Social Science/Criminology subjects.",
        "evidence": "The claim makes use of information provided in the \"Introduction to Law Enforcement and Criminal Justice\" dataset which contains a detailed analysis of the subject of each book. The introduction to law enforcement and criminal justice was written by two German authors, Kären M. Hess and Christine Orthmann, and it provides a thorough review of the topics covered in each chapter. Additionally, the introduction is provides a wide-range of contextual information on the books.",
        "table": "+----+-----------------+-----------------------------------------------------------+\n|    | Title           | Introduction to Law Enforcement and Criminal Justice      |\n+====+=================+===========================================================+\n|  0 | Authors         | Kären M. Hess, Christine Hess Orthmann                    |\n+----+-----------------+-----------------------------------------------------------+\n|  1 | Edition         | 10                                                        |\n+----+-----------------+-----------------------------------------------------------+\n|  2 | Publisher       | Cengage Learning, 2012                                    |\n+----+-----------------+-----------------------------------------------------------+\n|  3 | ISBN            | 1111138907, 9781111138905                                 |\n+----+-----------------+-----------------------------------------------------------+\n|  4 | Length          | 640 pages                                                 |\n+----+-----------------+-----------------------------------------------------------+\n|  5 | Subjects        | Social Science › Criminology Social Science / Criminology |\n+----+-----------------+-----------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                     |\n+----+-----------------+-----------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Those running the Minor Attracted Adults Daily Lives Project is 30 more than the number of Pedophiles online.",
        "evidence": "This could be because the project’s goals are to attract paedophiles in the community. By this definition, any paedophile who runs the minor attraction daily lives project is interested in joining. So, those running the minor attracted Adults Daily Lives project should ideally also be interested in finding paedophiles online.This could be achieved by establishing a contact relationship between the two paedophiles in the two projects.Those running the minor attraction daily lives project are 30 more than the number of pedophiles online. This suggests that the two paedophiles in our project are different types.",
        "table": "+----+------------------------------------------------------------------------+-----+\n|    | 1 Understanding paedophiles                                            |   1 |\n+====+========================================================================+=====+\n|  1 | 2 Paedophiles online                                                   |  21 |\n+----+------------------------------------------------------------------------+-----+\n|  3 | 3 Setting up the MinorAttracted Adults Daily Lives Project             |  38 |\n+----+------------------------------------------------------------------------+-----+\n|  5 | 4 Running the MinorAttracted Adults Daily Lives Project                |  57 |\n+----+------------------------------------------------------------------------+-----+\n|  7 | 5 Findings from the MinorAttracted Adults Daily Lives Research Project |  68 |\n+----+------------------------------------------------------------------------+-----+\n|  9 | 6 Constructing and negotiating identities                              |  84 |\n+----+------------------------------------------------------------------------+-----+\n| 11 | 7 Attraction and fantasies                                             |  97 |\n+----+------------------------------------------------------------------------+-----+\n| 13 | 8 Experiences of support                                               | 115 |\n+----+------------------------------------------------------------------------+-----+",
        "label": "REFUTES"
    },
    {
        "claim": "A resource for mosquito control in American is http://www.mosquito.org, which also contains links to other sites.",
        "evidence": "The claim that keeping mosquito control is effective in Australia can be supported by the following source. We use the American Mosquito Control Association website http://www.mosquito.org/, which also contains links to other sites. We also created our own version of the Australian Mosquito Control Association website, http://www.mcaa.org.au/, which also contains links to other sites. We trained our English version of the Australian Mosquito Control Association website on the same domain. This resulted in 1004 training examples. We also created a version of the Australian Mosquito Control Association website which contains links to other sites. We trained our English version of the Australian Mosquito Control Association website on the same domain, but we removed the links to these two sites. Then, we trained our English version of the Australian Mosquito Control Association website on the same domain, but we removed the links to these two sites.",
        "table": "+----+--------------------------------------------------------+---------------------------+-------------------------------------+\n|    | Website                                                | URL                       | Comment                             |\n+====+========================================================+===========================+=====================================+\n|  0 | American Mosquito Control Association                  | http://www.mosquito.org   | Contains many links to other sites. |\n+----+--------------------------------------------------------+---------------------------+-------------------------------------+\n|  1 | Mosquito Control Association of Australia              | http://www.mcaa.org.au    | nan                                 |\n+----+--------------------------------------------------------+---------------------------+-------------------------------------+\n|  2 | MOTAX - Working Group of European Mosquito Taxonomists | http://www.sove.org/motax | nan                                 |\n+----+--------------------------------------------------------+---------------------------+-------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Immigration is an international issue. ",
        "evidence": "According to the information provided, Immigration is an international issue. By analyzing the table, we found that compared with other international issues, Immigration is the most popular topic in the Energy & Oil agenda. The Energy & Oil agenda also focuses on jobs, pensions, and energy infrastructure. This is consistent with the claim by the authors. Other important international issues are the Middle East, terrorism, and the Civil Rights movement.",
        "table": "+----+------------------------+-------------------+-------------------+---------------------+\n|    | International Issues   | Domestic Issues   | Economic Issues   | Social Issues       |\n+====+========================+===================+===================+=====================+\n|  0 | Foreign Policy         | Gun Control       | Budget & Economy  | Education           |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  1 | Homeland Security      | Crime             | Government Reform | Civil Rights        |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  2 | War & Peace            | Drugs             | Tax Reform        | Abortion            |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  3 | Free Trade             | Health Care       | Social Security   | Families & Children |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  4 | Immigration            | Technology        | Corporations      | Welfare & Poverty   |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  5 | Energy & Oil           | Environment       | Jobs              | Principles & Values |\n+----+------------------------+-------------------+-------------------+---------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Over 50 countries have reported VOC-202012/01\tSouth Africa 501Y.V2",
        "evidence": "According to the claims, there are several interesting things to note. First, the pangolin lineage has only been confirmed for Venezuela, with B.1.1.7, compared to the original B.1.1.1 (lineage P.1). Another reason for this is that the original B.1.7 lineage has been split into several families, such as the ones found in South Africa and Brazil. Although some of the variants can be attributed to distant language families, it is clear that there is no proof that they are consistently useful. Second, del is only one type of variant, i.e., there are other variations that carry over from Latin American to South Africa and Brazil. Del:11288:9 del:21765:6 del:2 provides more evidence for this. Third, there are multiple groups of variants, i.e., variations of the same word. The groups are: S, N, E and N. We can see that the most representative variation is d80A d215g K417N E484K n501y in VOC-202012/01. This may be due to the fact that its English vocabulary is relatively simple compared to the Afro-Asiatic languages. Fifth, Gutierrez et al. (G174C) is an alternative to del:11288:9 del:21765:6 del:2. It also has to be noted that there are other variations that carry over from Latin American to South Africa, such as d80a d215g k417n e484k n501y, l18f t20n p26s d138y r190s in VOC-202012/01, and p80r in P80R.",
        "table": "+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|    | Variant                                    | United Kingdom (VOC-202012/01)       | South Africa (501Y.V2)             | Brazil (VOC202101/02)                                     |\n+====+============================================+======================================+====================================+===========================================================+\n|  0 | Pangolin lineage                           | B.1.1.7                              | B.1.351                            | B.1.1.28.1 (Lineage P.1)                                  |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  1 | Number of countries reported with varianta | 93                                   | 45                                 | 15                                                        |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  2 | Genes                                      | Â                                    | Â                                  | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  3 | orf1ab                                     | T1001I A1708D I2230T                 | K1655N                             | S1118L K1795Q                                             |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  4 | Â                                          | Del:11288:9 Del:21765:6 Del:21991:3  | Â                                  | Del:11288-9                                               |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  5 | S                                          | N501Y A570D P681H T716I S982A D1118H | D80A D215G K417N E484K N501Y A701V | L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  6 | Orf3a                                      | Â                                    | Â                                  | G174C                                                     |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  7 | Orf8                                       | Q27* R52I Y73C                       | Â                                  | E92K                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  8 | E                                          | Â                                    | P71L                               | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  9 | N                                          | D3L S235F                            | T205I                              | P80R                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "In the Illinois Legislature, the democratic party received 23 more votes than the republican party on votes involving abortion rights.",
        "evidence": "The claim made by the Illinois Democrats is that they received 23 more votes for abortion rights than the Republican Party. This claim is not very strong, but at the very least, it suggests that the Democrats are able to get more votes in support of abortion rights than the Republicans.",
        "table": "+----+---------+------------------+-------------------+\n|    | Party   | Party.1          |   As of June 2021 |\n+====+=========+==================+===================+\n|  0 | nan     | Democratic Party |                41 |\n+----+---------+------------------+-------------------+\n|  1 | nan     | Republican Party |                18 |\n+----+---------+------------------+-------------------+\n|  2 | nan     | Vacancies        |                 0 |\n+----+---------+------------------+-------------------+\n|  3 | Total   | Total            |                59 |\n+----+---------+------------------+-------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "\"Young people \"\"have a greater chance of being killed by the HPV vaccine than COVID-19.”\"",
        "evidence": "The claim cannot be directly inferred from the table. However, it is from the claim that the proposed approaches can reduce the false-positive rate significantly. As shown in the results, the proposed approaches can significantly improve the performance of both non-NMF-based and highly non-NMF-based vaccines. We can also see that the improvement of PG-19 is much larger than that of CoVID-19, which is again a mixture of PG-19 and CoVID-19.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Unnamed: 0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | HPV2 (Cervarixâ¢)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | HPV2 (Cervarixâ¢).1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | HPV4 (GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | HPV4 (GardasilÂ®).1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+====+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================+\n|  0 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Anti-HPV type 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Anti-HPV type 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Anti-HPV type 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Anti-HPV type 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Serum N GMTTable 12 Footnote * ratio (ratio of type specific response for Cervarixâ¢/GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                   | Serum N GMTTable 12 Footnote * ratio (ratio of type specific response for Cervarixâ¢/GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                   | Serum N GMTTable 12 Footnote * ratio (ratio of type specific response for Cervarixâ¢/GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                   | Serum N GMTTable 12 Footnote * ratio (ratio of type specific response for Cervarixâ¢/GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                   | Serum N GMTTable 12 Footnote * ratio (ratio of type specific response for Cervarixâ¢/GardasilÂ®)                                                                                                                                                                                                                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Month 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 2.3-4.8x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 6.8-9.1x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Month 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.4-5.1x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7.9-9.8x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Month 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 2.4-5.8x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 7.7-9.4x higherTable 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Serum T-cells (% responders)Table 12 Footnote **                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Serum T-cells (% responders)Table 12 Footnote **                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Serum T-cells (% responders)Table 12 Footnote **                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Serum T-cells (% responders)Table 12 Footnote **                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Serum T-cells (% responders)Table 12 Footnote **                                                                                                                                                                                                                                                                                                                                                                                                                                                    |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | Month 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | nan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | Month 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 92.5Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 78.6Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 40.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 42.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | Month 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 90.9Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 74.3Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 60.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 40.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  9 | Serum B-cells (% responders)Table 12 Footnote ***                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Serum B-cells (% responders)Table 12 Footnote ***                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Serum B-cells (% responders)Table 12 Footnote ***                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Serum B-cells (% responders)Table 12 Footnote ***                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Serum B-cells (% responders)Table 12 Footnote ***                                                                                                                                                                                                                                                                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 10 | Month 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 89.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 88.7Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 94.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 66.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 11 | Month 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 86.7Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 74.5Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 58.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 45.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 12 | Month 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 83.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 76.3Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 66.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 52.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 13 | CVS nAbTable 12 Footnote *                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CVS nAbTable 12 Footnote *                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CVS nAbTable 12 Footnote *                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CVS nAbTable 12 Footnote *                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | CVS nAbTable 12 Footnote *                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 14 | Month 7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 81.3Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 33.3Table 12 Footnote â                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 50.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 8.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 15 | Month 18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 7.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14.9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 16 | Month 24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 24.4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 17 | Table 12 Footnote *measured by PBNA Return to table 12 footnote * referrer Table 12 Footnote **>500 specific CD4 T-cells expressing â¥2 of 4 immune markers; assay done on a subset of participants. Return to table 12 footnote ** referrer Table 12 Footnote ***>0 specific memory B-cells per million cells; assay done on a subset of participants. Return to table 12 footnote *** referrer Table 12 Footnote â Result is statistically significant. Return to table 12 footnote â referrer | Table 12 Footnote *measured by PBNA Return to table 12 footnote * referrer Table 12 Footnote **>500 specific CD4 T-cells expressing â¥2 of 4 immune markers; assay done on a subset of participants. Return to table 12 footnote ** referrer Table 12 Footnote ***>0 specific memory B-cells per million cells; assay done on a subset of participants. Return to table 12 footnote *** referrer Table 12 Footnote â Result is statistically significant. Return to table 12 footnote â referrer | Table 12 Footnote *measured by PBNA Return to table 12 footnote * referrer Table 12 Footnote **>500 specific CD4 T-cells expressing â¥2 of 4 immune markers; assay done on a subset of participants. Return to table 12 footnote ** referrer Table 12 Footnote ***>0 specific memory B-cells per million cells; assay done on a subset of participants. Return to table 12 footnote *** referrer Table 12 Footnote â Result is statistically significant. Return to table 12 footnote â referrer | Table 12 Footnote *measured by PBNA Return to table 12 footnote * referrer Table 12 Footnote **>500 specific CD4 T-cells expressing â¥2 of 4 immune markers; assay done on a subset of participants. Return to table 12 footnote ** referrer Table 12 Footnote ***>0 specific memory B-cells per million cells; assay done on a subset of participants. Return to table 12 footnote *** referrer Table 12 Footnote â Result is statistically significant. Return to table 12 footnote â referrer | Table 12 Footnote *measured by PBNA Return to table 12 footnote * referrer Table 12 Footnote **>500 specific CD4 T-cells expressing â¥2 of 4 immune markers; assay done on a subset of participants. Return to table 12 footnote ** referrer Table 12 Footnote ***>0 specific memory B-cells per million cells; assay done on a subset of participants. Return to table 12 footnote *** referrer Table 12 Footnote â Result is statistically significant. Return to table 12 footnote â referrer |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Yakima Valley Open and Safe is done in English and Spanish.",
        "evidence": "The claim is supported by English and Spanish data. Most of the provided information is in English, except for the “Open Yakimaâ Business Re, which is in Spanish. This is expected because the Open Yakima website is focused on English while all the Spanish related information is in Spanish.",
        "table": "+----+--------------------------------------------------------------------------------------------+------------------+\n|    | Yakima County Small Business Coronavirus Assistance                                        | EnglishEspanol   |\n+====+============================================================================================+==================+\n|  0 | State and Federal Financial Help for Businesses                                            | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  1 | âOpen Yakimaâ Business re-opening health and safety plan services community task force | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  2 | Yakima County local Personal Protective Equipment suppliers and vendors                    | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  3 | Handouts and Print Resources for Businesses                                                | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  4 | Yakima Valley Open and Safe                                                                | EnglishEspanol   |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  5 | State Fair Park COVID-19 Vaccination Sign Up Web Site                                      | Click Here       |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  6 | State COVID-19 Assistance Hotline                                                          | 1-800-525-0127   |\n+----+--------------------------------------------------------------------------------------------+------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Each year, 18,000 people die in America because they don't have health care.",
        "evidence": "The claim that 18,000 people die in America because they don’t have health care is not supported by the data. In fact, only 81.9% of the workers in the private healthcare firms do not have health care. To increase the number of people who participate in the surveys, we increase the number of training sessions from 1,000 to 300 per person. We increased the participant number from 31 to 500 per person with an additional reward of $5 per session.",
        "table": "+----+-------------------------------------+-----------------------+\n|    | Method of delivery                  | Percent of firms      |\n+====+=====================================+=======================+\n|  0 | Health risk assessment              | 81                    |\n+----+-------------------------------------+-----------------------+\n|  1 | Self-help education materials       | 42                    |\n+----+-------------------------------------+-----------------------+\n|  2 | Individual counseling               | 39                    |\n+----+-------------------------------------+-----------------------+\n|  3 | Classes, seminars, group activities | 36                    |\n+----+-------------------------------------+-----------------------+\n|  4 | Added incentives for participation  | 31                    |\n+----+-------------------------------------+-----------------------+\n|  5 | Focus of intervention               | Focus of intervention |\n+----+-------------------------------------+-----------------------+\n|  6 | Weight loss and fitness             | 66                    |\n+----+-------------------------------------+-----------------------+\n|  7 | Smoking cessation                   | 50                    |\n+----+-------------------------------------+-----------------------+\n|  8 | Multiple risk factors               | 75                    |\n+----+-------------------------------------+-----------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Sepsis has the highest percentage change ",
        "evidence": "The table shows that Sepsis has the highest percentage change among all the proposed causes of death. This is expected because while Sepsis appears to be the most common cause of death in the NIPS corpus, it is the least among all the other causes of death. The second most common cause of death in the NIPS corpus is pneumonia, followed by emphysema and other breathing disorders, and diabetes. Aside from these four, the other two causes of death have very low frequencies in the data. If we compare the rate of death from september 2015 to september 2016 and 2017, we can see that there has been a very significant increase in the number of patients who die from sepsis.",
        "table": "+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|    | Causes of death                         |   Sept. 2015 |   Sept. 2016 |   Sept. 2017 |   Pct. change |\n+====+=========================================+==============+==============+==============+===============+\n|  0 | Sepsis                                  |           64 |           61 |           92 |            47 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  1 | Pneumonia                               |           50 |           55 |           76 |            45 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  2 | Emphysema and other breathing disorders |          104 |          114 |          156 |            43 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  3 | Diabetes                                |          221 |          249 |          309 |            31 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+\n|  4 | Alzheimerâs and Parkinsonâs         |          189 |          183 |          229 |            23 |\n+----+-----------------------------------------+--------------+--------------+--------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "\"Chris Larson Says Gov. Scott Walker \"\"hasn't done a public event this entire year.\"",
        "evidence": "This claim is supported by a large source of external data. In the 2018 Wisconsin State Senate District 7 election, Chris Larson received more than $299,342.65 in campaign contributions. In contrast, his opponent, Scott Walker, received only $6,000.00 in campaign contributions, which is a stark contrast to the $299,342.65 reported by Larson’s sources. The top individual contributors to his campaign in 2018 were Christopher Larson who donated $10,000.00, Rebecca Seidelbach, who donated $3,000.00, and Russell Rossetto, who donated $3,000.",
        "table": "+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|    | Wisconsin State Senate District 7 2018 election - Campaign Contributions   | Wisconsin State Senate District 7 2018 election - Campaign Contributions.1   |\n+====+============================================================================+==============================================================================+\n|  0 | Top individual contributors to Chris Larson's campaign in 2018             | Top individual contributors to Chris Larson's campaign in 2018               |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  1 | LARSON, CHRISTOPHER                                                        | $10,000.00                                                                   |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  2 | GETZ, JALEM                                                                | $6,000.00                                                                    |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  3 | BRISCOE, CHERI                                                             | $4,000.00                                                                    |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  4 | ROSSETTO, RUSSELL                                                          | $3,400.00                                                                    |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  5 | LYNCH, WILLIAM H                                                           | $3,000.00                                                                    |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  6 | Total Raised in 2018                                                       | $299,342.65                                                                  |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+\n|  7 | Source: Follow the Money                                                   | Source: Follow the Money                                                     |\n+----+----------------------------------------------------------------------------+------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The 14-day change for deaths saw a 20% increase.",
        "evidence": "The claim from the claim section is that there was a big increase in the number of death cases in the hospitals in the PICC line. In total, there were 11370 cases where the rate of death rate had increased by 21%. This increase in cases was not very big, but it was still there. Based on this information, we think there may be more potential to improve the PICC classifier as there are more cases in the system.",
        "table": "+----+--------------+-------------------+-----------------+------------------+\n|    | Unnamed: 0   |   Avg. on Jun. 22 | 14-Day Change   | Total Reported   |\n+====+==============+===================+=================+==================+\n|  0 | cases        |             11370 | â21%          | 33537764         |\n+----+--------------+-------------------+-----------------+------------------+\n|  1 | tests        |            708627 | â9%           | â              |\n+----+--------------+-------------------+-----------------+------------------+\n|  2 | hospitalized |             17218 | â22%          | â              |\n+----+--------------+-------------------+-----------------+------------------+\n|  3 | deaths       |               309 | â20%          | 602164           |\n+----+--------------+-------------------+-----------------+------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Event 201 “gave out stuffed souvenir coronavirus toys” to “commemorate” Novel coronavirus outbreak",
        "evidence": "In this section, we present the results of our experiments with the “gave out stuffed souvenir Coronavirus toys” dataset, from the “Commemorate” novel coronavirus outbreak in Brazil. As can be seen, we observe that there are many different cases of coronavirus in different countries. The most common variant is b.1.7, which appears in several countries, such as the United Kingdom, South Africa, and Brazil. There are also several other variations, such as del:11288:9 del:21765:6 del:2, that appear in countries such as Peru, Bolivia, and Brazil.",
        "table": "+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|    | Variant                                    | United Kingdom (VOC-202012/01)       | South Africa (501Y.V2)             | Brazil (VOC202101/02)                                     |\n+====+============================================+======================================+====================================+===========================================================+\n|  0 | Pangolin lineage                           | B.1.1.7                              | B.1.351                            | B.1.1.28.1 (Lineage P.1)                                  |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  1 | Number of countries reported with varianta | 93                                   | 45                                 | 15                                                        |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  2 | Genes                                      | Â                                    | Â                                  | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  3 | orf1ab                                     | T1001I A1708D I2230T                 | K1655N                             | S1118L K1795Q                                             |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  4 | Â                                          | Del:11288:9 Del:21765:6 Del:21991:3  | Â                                  | Del:11288-9                                               |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  5 | S                                          | N501Y A570D P681H T716I S982A D1118H | D80A D215G K417N E484K N501Y A701V | L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  6 | Orf3a                                      | Â                                    | Â                                  | G174C                                                     |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  7 | Orf8                                       | Q27* R52I Y73C                       | Â                                  | E92K                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  8 | E                                          | Â                                    | P71L                               | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  9 | N                                          | D3L S235F                            | T205I                              | P80R                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "70 Percent of infections that are asymptomatic are presented in scenario 2",
        "evidence": "The number of infections that are asymptomatic is presented in Table 1. The current best estimate for infection fatality ratio is 0–17 years old: 6 18-49 years old: 150 50 and 0–17 years old: 80 18-49 years old: 1, with 0–17 years old: 20 18-49 years old: 500 50. In case of outbreak, the mortality rate is 0–17 years old: 6 18-49 years old: 150 50, with 0–17 years old: 80 18-49 years old: 1, again with 0–17 years old: 500 50. The number of cases of asymptomatic individuals relative to symptomatic individuals is 25% for Scenario 2, 25% for Scenario 3, and 30% for Scenario 4. The percentage of transmission occurring prior to symptom onset** is 30%.",
        "table": "+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|    | Parameter                                                                       | Scenario 1                                                                          | Scenario 2                                                                          | Scenario 3                                                                               | Scenario 4                                                                               | Scenario 5: Current Best Estimate                                                    |\n+====+=================================================================================+=====================================================================================+=====================================================================================+==========================================================================================+==========================================================================================+======================================================================================+\n|  0 | R0*                                                                             | 2.0                                                                                 | 2.0                                                                                 | 4.0                                                                                      | 4.0                                                                                      | 2.5                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  1 | Infection fatality ratio (Estimated number of deaths per 1,000,000 infections)† | 0–17 years old: 6 18–49 years old: 150 50–64 years old: 1,800 65+ years old: 26,000 | 0–17 years old: 6 18–49 years old: 150 50–64 years old: 1,800 65+ years old: 26,000 | 0–17 years old: 80 18–49 years old: 1,700 50–64 years old: 20,000 65+ years old: 270,000 | 0–17 years old: 80 18–49 years old: 1,700 50–64 years old: 20,000 65+ years old: 270,000 | 0–17 years old: 20 18–49 years old: 500 50–64 years old: 6,000 65+ years old: 90,000 |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  2 | Percent of infections that are asymptomatic§                                    | 15%                                                                                 | 70%                                                                                 | 15%                                                                                      | 70%                                                                                      | 30%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  3 | Infectiousness of asymptomatic individuals relative to symptomatic^             | 25%                                                                                 | 100%                                                                                | 25%                                                                                      | 100%                                                                                     | 75%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+\n|  4 | Percentage of transmission occurring prior to symptom onset**                   | 30%                                                                                 | 70%                                                                                 | 30%                                                                                      | 70%                                                                                      | 50%                                                                                  |\n+----+---------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Planned Parenthood and the Clergy Consultation Service on Abortion 19671973\n",
        "evidence": "The claim that the Planned Parenthood and the clergy consultation service on Abortion 19671973 is effective is significant. This is because the text of the proposal is very short and the introduction of the concept of sacred work is very short. The introduction of the concept of sacred work is effective because the discourse of the clergy is so new that it cannot be integrated into the existing data. Margaret Sanger recruits the clergy in 27.0 speeches, while building public acceptance 19351957 was 47.0. The 1958 battle over the New York City hospitals was 72.0, the Battle of the sixties was 104.0, and the Civil Rights Act of 1964 was 121.0. This is based on the information provided by the document.",
        "table": "+----+-----------------------------------------------------------------------------+-----+\n|    | Introduction                                                                |   1 |\n+====+=============================================================================+=====+\n|  1 | The Concept of Sacred Work                                                  |   5 |\n+----+-----------------------------------------------------------------------------+-----+\n|  3 | Margaret Sanger Recruits the Clergy                                         |  27 |\n+----+-----------------------------------------------------------------------------+-----+\n|  5 | Building Public Acceptance 19351957                                         |  47 |\n+----+-----------------------------------------------------------------------------+-----+\n|  7 | The 1958 Battle over the New York City Hospitals                            |  72 |\n+----+-----------------------------------------------------------------------------+-----+\n|  9 | Sacred Work in Baltimore 19611965                                           |  88 |\n+----+-----------------------------------------------------------------------------+-----+\n| 11 | Victories in the Sixties                                                    | 104 |\n+----+-----------------------------------------------------------------------------+-----+\n| 13 | Planned Parenthood and the Clergy Consultation Service on Abortion 19671973 | 121 |\n+----+-----------------------------------------------------------------------------+-----+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The biologic family encouragement is less than the school encouragement.",
        "evidence": "In this section, we present supporting results based on the claim of individual institutions and their employees. We focus on the comparison between the biological family encouragement and the school encouragement. For this, we also include a comparison between the network size (estimated) and the amount of tangible/advice encouragement. The network size is defined as the number of times the agent or the emotional label was present in the training set; thereby, the smallest network size corresponds to the number of tangible/advice items provided to the agent. On the other hand, the adequate amount of stimulus (i.e. the ratio of tangible items) is much higher than the school encouragement, which indicates that the biological family encouragement might encourage the student to use more tangible items.",
        "table": "+----+--------------------------------------------------------+-----------+\n|    | Main hypotheses                                        | Â         |\n+====+========================================================+===========+\n|  0 | âInstitutional agents (tangible/advice) (Mean/SD)    | 0.7 (0.8) |\n+----+--------------------------------------------------------+-----------+\n|  1 | âSchool encouragement                                | 63.1%     |\n+----+--------------------------------------------------------+-----------+\n|  2 | Competing hypotheses                                   | Â         |\n+----+--------------------------------------------------------+-----------+\n|  3 | âNoninstitutional agents (tangible/advice) (Mean/SD) | 2.3 (1.3) |\n+----+--------------------------------------------------------+-----------+\n|  4 | âInstitutional agents (emotional) (Mean/SD)          | 0.1 (0.4) |\n+----+--------------------------------------------------------+-----------+\n|  5 | âEstimated network size (0â30) (Mean/SD)           | 7.6 (6.6) |\n+----+--------------------------------------------------------+-----------+\n|  6 | âAdequate amount of tangible/advice                  | 54.2%     |\n+----+--------------------------------------------------------+-----------+\n|  7 | âBiological family encouragement                     | 60.6%     |\n+----+--------------------------------------------------------+-----------+\n|  8 | âFoster-care encouragement                           | 69.0%     |\n+----+--------------------------------------------------------+-----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The shoreline is 8426 miles long.",
        "evidence": "The shoreline is 8426 miles long. This area is located in Florida and comprises of 8,426 miles of land and 11,761 miles of inland water. The population of this area is 16.4 million and it ranks as the fourth largest city in Florida. The median household income (2000) is $37,998 and the unemployment rate (2000) is 3.6%.",
        "table": "+----+--------------------------------+----------------------------------------------------------------------+\n|    | Florida                        | Florida.1                                                            |\n+====+================================+======================================================================+\n|  0 | Population (2001)              | 16.4 million                                                         |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  1 | U.S. population ranking        | 4th                                                                  |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  2 | Median household income (2000) | $37,998                                                              |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  3 | Unemployment rate (2000)       | 3.6%                                                                 |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  4 | Land area                      | 53,927 square miles                                                  |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  5 | Shoreline                      | 8,426 miles                                                          |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  6 | Inland water                   | 11,761 square miles                                                  |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  7 | Capital                        | Tallahassee                                                          |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  8 | Other principal cities         | Fort Lauderdale, Jacksonville, Orlando, Miami, St. Petersburg, Tampa |\n+----+--------------------------------+----------------------------------------------------------------------+\n|  9 | Number of counties             | 67                                                                   |\n+----+--------------------------------+----------------------------------------------------------------------+\n| 10 | Principal industries           | Agriculture, banking, government, retail services, tourism           |\n+----+--------------------------------+----------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Gastric bypass more effective than other procedures has minimal invasiveness.",
        "evidence": "The results show that gastric bypass with BiLSTM is more effective than other procedures at preventing minimal invasiveness. However, the number of side effects is still significantly higher than other procedures.",
        "table": "+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Attribute                                                                                                                                                                                                                      | LAGB                                                                                                                                                                                                                           | RYGB                                                                                                                                                                                                                           | BPD                                                                                                                                                                                                                            |\n+====+================================================================================================================================================================================================================================+================================================================================================================================================================================================================================+================================================================================================================================================================================================================================+================================================================================================================================================================================================================================+\n|  1 | Safe                                                                                                                                                                                                                           | +++                                                                                                                                                                                                                            | ++                                                                                                                                                                                                                             | +                                                                                                                                                                                                                              |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Effective (substantial weight loss, improved health and quality of life)                                                                                                                                                       | ++                                                                                                                                                                                                                             | ++                                                                                                                                                                                                                             | +++                                                                                                                                                                                                                            |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Easily and fully reversible                                                                                                                                                                                                    | Yes                                                                                                                                                                                                                            | No                                                                                                                                                                                                                             | No                                                                                                                                                                                                                             |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Side effects                                                                                                                                                                                                                   | +                                                                                                                                                                                                                              | ++                                                                                                                                                                                                                             | ++                                                                                                                                                                                                                             |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Durable (effective over time)                                                                                                                                                                                                  | ++                                                                                                                                                                                                                             | ++                                                                                                                                                                                                                             | +++                                                                                                                                                                                                                            |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | Minimal invasivenessâ                                                                                                                                                                                                         | +++                                                                                                                                                                                                                            | ++                                                                                                                                                                                                                             | +                                                                                                                                                                                                                              |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | Controllable/adjustable                                                                                                                                                                                                        | Yes                                                                                                                                                                                                                            | No                                                                                                                                                                                                                             | No                                                                                                                                                                                                                             |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | Low reoperation/revision rate                                                                                                                                                                                                  | +                                                                                                                                                                                                                              | +                                                                                                                                                                                                                              | +                                                                                                                                                                                                                              |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n| 10 | BPDÂ =Â biliopancreatic diversion. LAGBÂ =Â laparoscopic adjustable gastric banding. RYGBÂ =Â Roux-en-Y gastric bypass. * Assessment levels are based on our synthesis of the published data. â +++ means the least invasive. | BPDÂ =Â biliopancreatic diversion. LAGBÂ =Â laparoscopic adjustable gastric banding. RYGBÂ =Â Roux-en-Y gastric bypass. * Assessment levels are based on our synthesis of the published data. â +++ means the least invasive. | BPDÂ =Â biliopancreatic diversion. LAGBÂ =Â laparoscopic adjustable gastric banding. RYGBÂ =Â Roux-en-Y gastric bypass. * Assessment levels are based on our synthesis of the published data. â +++ means the least invasive. | BPDÂ =Â biliopancreatic diversion. LAGBÂ =Â laparoscopic adjustable gastric banding. RYGBÂ =Â Roux-en-Y gastric bypass. * Assessment levels are based on our synthesis of the published data. â +++ means the least invasive. |\n+----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Charlie Baker has a higher approval rating than Spencer Cox",
        "evidence": "The data from this claim shows that Charlie Baker has a higher approval rating than Spencer Cox in all of the states. In Ma, Charlie Baker has 74 approval rating and 54 disapproval rating, whereas Spencer Cox has 63 approval rating and 41 disapproval rating.",
        "table": "+----+---------+------------------+---------+------------+---------------+-------+\n|    | State   | Governor         | Party   |   Approval |   Disapproval |   Net |\n+====+=========+==================+=========+============+===============+=======+\n|  0 | MA      | Charlie Baker    | R       |         74 |            20 |    54 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  1 | NH      | Chris Sununu     | R       |         72 |            25 |    47 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  2 | UT      | Spencer Cox      | R       |         63 |            22 |    41 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  3 | TX      | Greg Abbott      | R       |         54 |            35 |    19 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  4 | WA      | Jay Inslee       | D       |         52 |            35 |    17 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  5 | FL      | Ron DeSantis     | R       |         55 |            38 |    17 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  6 | VA      | Ralph Northam    | D       |         49 |            33 |    16 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  7 | SD      | Kristi Noem      | R       |         55 |            44 |    11 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  8 | NC      | Roy Cooper       | D       |         49 |            39 |    11 |\n+----+---------+------------------+---------+------------+---------------+-------+\n|  9 | MI      | Gretchen Whitmer | D       |         52 |            47 |     5 |\n+----+---------+------------------+---------+------------+---------------+-------+\n| 10 | NV      | Steve Sisolak    | D       |         48 |            43 |     5 |\n+----+---------+------------------+---------+------------+---------------+-------+\n| 11 | NY      | Andrew Cuomo     | D       |         48 |            45 |     3 |\n+----+---------+------------------+---------+------------+---------------+-------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "There are two states whose names begin with the letter \"v\".",
        "evidence": "There are 10 states whose names begin with the letter \"V\". These states are Alabama, Georgia, Hawaii, Kentucky, Maine, Tennessee, Nebraska, New Jersey, Oklahoma, and Vermont.",
        "table": "+----+----------------+---------------+-------------+----------------------+---------------+\n|    | Alabama        | Alaska        | Arizona     | Arkansas             | California    |\n+====+================+===============+=============+======================+===============+\n|  0 | Colorado       | Connecticut   | Delaware    | District of Columbia | Florida       |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  1 | Georgia        | Hawaii        | Idaho       | Illinois             | Indiana       |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  2 | Iowa           | Kansas        | Kentucky    | Louisiana            | Maine         |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  3 | Maryland       | Massachusetts | Michigan    | Minnesota            | Mississippi   |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  4 | Missouri       | Montana       | Nebraska    | Nevada               | New Hampshire |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  5 | New Jersey     | New Mexico    | New York    | North Carolina       | North Dakota  |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  6 | Ohio           | Oklahoma      | Oregon      | Pennsylvania         | Rhode Island  |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  7 | South Carolina | South Dakota  | Tennessee   | Texas                | Utah          |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  8 | Vermont        | Virginia      | Washington  | West Virginia        | Wisconsin     |\n+----+----------------+---------------+-------------+----------------------+---------------+\n|  9 | Wyoming        | New York City | Puerto Rico | Virgin Islands       | nan           |\n+----+----------------+---------------+-------------+----------------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Those with diabetes has an A1C (percent) value 1.0 higher than normal.",
        "evidence": "They show that those with diabetes have an A1c (percent) that is higher than normal than the normal population. They also have high triglyceride (or ‘stick’) values, and moderate to high fasting plasma glucose (FPG) values.",
        "table": "+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|    | Diagnosis   | A1C (percent)   | Fasting plasma glucose (FPG)a   | Oral glucose tolerance test (OGTT)ab   | Random plasma glucose test (RPG)a   |\n+====+=============+=================+=================================+========================================+=====================================+\n|  0 | Normal      | below 5.7       | 99 or below                     | 139 or below                           | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  1 | Prediabetes | 5.7 to 6.4      | 100 to 125                      | 140 to 199                             | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  2 | Diabetes    | 6.5 or above    | 126 or above                    | 200 or above                           | 200 or above                        |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Canada's coronavirus death toll rises to 13 as repatriation efforts step up.",
        "evidence": "We could not confirm this claim, but it is likely true. Based on the information provided, we stepped up our repatriation efforts up to the point where the number of cases was approaching the number of cases per person.",
        "table": "+----+-----------------------------------------------------+-------------------------------------------+\n|    | Contact HCID                                        | Airborne HCID                             |\n+====+=====================================================+===========================================+\n|  0 | Argentine haemorrhagic fever (Junin virus)          | Andes virus infection (hantavirus)        |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  1 | Bolivian haemorrhagic fever (Machupo virus)         | Avian influenza A H7N9 and H5N1           |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  2 | Crimean Congo haemorrhagic fever (CCHF)             | Avian influenza A H5N6 and H7N7           |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  3 | Ebola virus disease (EVD)                           | Middle East respiratory syndrome (MERS)   |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  4 | Lassa fever                                         | Monkeypox                                 |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  5 | Lujo virus disease                                  | Nipah virus infection                     |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  6 | Marburg virus disease (MVD)                         | Pneumonic plague (Yersinia pestis)        |\n+----+-----------------------------------------------------+-------------------------------------------+\n|  7 | Severe fever with thrombocytopaenia syndrome (SFTS) | Severe acute respiratory syndrome (SARS)* |\n+----+-----------------------------------------------------+-------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Broward County has a higher rate than  all of Florida combined.",
        "evidence": "The table shows that Broward County has a higher rate of post-editing than all of Florida combined.",
        "table": "+----+------------------+--------+\n|    | Broward County   |   0.52 |\n+====+==================+========+\n|  0 | Florida          |   9.13 |\n+----+------------------+--------+\n|  1 | U.S.             | 212.91 |\n+----+------------------+--------+",
        "label": "REFUTES"
    },
    {
        "claim": "Postpartum arousal symptoms include difficulties falling asleep and being tense, nervous, irritable or anxious.",
        "evidence": "They include avoidance, intrusions, anxiety, and arousal. The words associated with these symptoms include “Avoid”, “Have you had negative dreams about”, “Sometimes you sometimes think about the”, “Have you had images about the”, “Neural activation”, “Hyperbilirubinemia”, “Palpitations”, “Bad headaches”, “Muscle spasms” and “Palpitations”. For arousal, there is an especially positive pattern of “Have you had difficulties falling asleep”, “Have you had negative dreams about”, “Have you been more tense”, and “Have you experienced negative bodily sensations”.",
        "table": "+----+------------+---------------------------------------------------------------------------------------------------------+\n|    | Domain     | Â                                                                                                       |\n+====+============+=========================================================================================================+\n|  0 | Avoidance  | â¢âDo you avoid thinking about birth?                                                                |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  1 | Â          | â¢âHave you avoided people, buildings etc. which remind you of the birth?                            |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  2 | Intrusions | â¢âHave you had negative dreams about your childbirth?                                               |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  3 | Â          | â¢âDo you sometimes think about the birth without really wanting to think about it?                  |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  4 | Â          | â¢âHave you had images about the birth coming up or the experience of reliving aspects of the birth? |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  5 | Arousal    | â¢âHave you had difficulties falling asleep in the last weeks?                                       |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  6 | Â          | â¢âDo you experience negative bodily sensations when you remember birth?                             |\n+----+------------+---------------------------------------------------------------------------------------------------------+\n|  7 | Â          | â¢âHave you been more tense, nervous, irritable or anxious?                                          |\n+----+------------+---------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Among the third trimester, 3 people have no opinion.",
        "evidence": "From the results, we can see that the Legal class is the most followed class in the first trimester, followed by the Dependents class, and the Abortion class. In the second trimester, the Legal class was followed by the Dependents class and the Abortion class was the least. This could be explained by the fact that in the second trimester, the number of abortions that happened in the third trimester was much higher. Hence, we can conclude that the topic of topic is more important in the third trimester of pregnancy than in the first trimester.",
        "table": "+----+------------------+---------+-----------+------------------+--------------+\n|    | Unnamed: 0       | Legal   |   Illegal |   DEPENDS (vol.) |   No opinion |\n+====+==================+=========+===========+==================+==============+\n|  0 | First Trimester  | 65%     |        31 |                2 |            2 |\n+----+------------------+---------+-----------+------------------+--------------+\n|  1 | Second Trimester | 24%     |        69 |                4 |            3 |\n+----+------------------+---------+-----------+------------------+--------------+\n|  2 | Third Trimester  | 8%      |        86 |                3 |            3 |\n+----+------------------+---------+-----------+------------------+--------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "You can trust the result of the mammograms exam.",
        "evidence": "The results of the “false-positive mammograms” claim show that there are 808 false-positive mammograms (false alarms) in the database. This number is slightly lower than the number of false-negative mammograms (missed cancers), but there are significantly moremissed cancers compared to false-positive mammograms. Considering the fact that there are so many false-positive mammograms, it is hard to trust the result of the mammogram exam. However, the results show that there are significantly fewermissed cancers compared to false-positive mammograms. Considering the fact that there are so many false-positive mammograms, we believe there is little need to trust the results of the mammograms exam.",
        "table": "+----+-----------------------------------------------+------------------+------------------+------------------+------------------+\n|    | Unnamed: 0                                    |   Ages 40â49 y |   Ages 50â59 y |   Ages 60â69 y |   Ages 70â74 y |\n+====+===============================================+==================+==================+==================+==================+\n|  0 | False-positive mammograms (false alarms), n   |             1212 |              932 |              808 |              696 |\n+----+-----------------------------------------------+------------------+------------------+------------------+------------------+\n|  1 | Breast biopsies, n                            |              164 |              159 |              165 |              175 |\n+----+-----------------------------------------------+------------------+------------------+------------------+------------------+\n|  2 | False-negative mammograms (missed cancers), n |               10 |               11 |               12 |               15 |\n+----+-----------------------------------------------+------------------+------------------+------------------+------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The senate voted 51-48 to repeal the Affordable Care Act on 12 January 2017.",
        "evidence": "The claim that the Affordable Care Act and the Politics of Health Care Reform is a reflection of underlying cultural values and institutions is supported by the claim of 35% of American voters. This strongly suggests that the American people strongly support the Affordable Care Act, and that the debate on repealing the Affordable Care Act is a significant step in that direction.",
        "table": "+----+------------------------------------------------------------------------------+-----+\n|    | 1 The Affordable Care Act and the Politics of Health Care Reform             |   1 |\n+====+==============================================================================+=====+\n|  1 | 2 Health Health Care and the Market Economy                                  |  14 |\n+----+------------------------------------------------------------------------------+-----+\n|  3 | 3 Health Care as a Reflection of Underlying Cultural Values and Institutions |  35 |\n+----+------------------------------------------------------------------------------+-----+\n|  5 | 4 The Health Professions and the Organization of Health Care                 |  70 |\n+----+------------------------------------------------------------------------------+-----+\n|  7 | 5 Health Insurance HMOs and the Managed Care Revolution                      |  97 |\n+----+------------------------------------------------------------------------------+-----+\n|  9 | 6 Medicare                                                                   | 131 |\n+----+------------------------------------------------------------------------------+-----+\n| 11 | 7 Medicaid and the State Childrens Health Insurance Program                  | 166 |\n+----+------------------------------------------------------------------------------+-----+\n| 13 | 8 The Increasing Role of ForProfit Health Care                               | 191 |\n+----+------------------------------------------------------------------------------+-----+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Accidents is the leading cause of death of young people, more than the next four causes put together.",
        "evidence": "From this table, we can see that the top five reasons for death of young people in Thailand are Accidents (51.8%) followed by Homicide (21.3%), Suicide (16.3%) and cancer (6.8%). The table also shows that Accidents account for more deaths than the next four reasons put together.",
        "table": "+----+-------------------+--------------------+-----------+\n|    | CAUSE             | PERCENT OF TOP 5   |   NUMBERS |\n+====+===================+====================+===========+\n|  0 | (1) Accidents     | 51.8%              |     12752 |\n+----+-------------------+--------------------+-----------+\n|  1 | (2) Homicide      | 21.3%              |      5233 |\n+----+-------------------+--------------------+-----------+\n|  2 | (3) Suicide       | 16.3%              |      4003 |\n+----+-------------------+--------------------+-----------+\n|  3 | (4) Cancer        | 6.8%               |      1670 |\n+----+-------------------+--------------------+-----------+\n|  4 | (5) Heart Disease | 3.9%               |       961 |\n+----+-------------------+--------------------+-----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "5.5% of the time, a spinal injury is the cause of death.",
        "evidence": "The data we obtained from the claim page shows that 5.5% of the time, a spinal injury is the cause of death. That is, spinal injury is the cause of death in 41.6% of the cases. First, we checked the results of the other causes of death and find that spinal injury is the most often cause of death. Then, we checked the other causes of death and find that spinal injury is also the most often cause of death in 30.5% of the cases.",
        "table": "+----+---------------------+-----------+\n|    | CAUSE OF DEATH      | PERCENT   |\n+====+=====================+===========+\n|  0 | (1) Hemorrhage      | 41.6%     |\n+----+---------------------+-----------+\n|  1 | (2) Cerebral injury | 30.5%     |\n+----+---------------------+-----------+\n|  2 | (3) Combined injury | 15.2%     |\n+----+---------------------+-----------+\n|  3 | (4) Spinal injury   | 5.5%      |\n+----+---------------------+-----------+\n|  4 | (5) Crush asphyxia  | 4.9%      |\n+----+---------------------+-----------+\n|  5 | (6) Chest injury    | 2.1%      |\n+----+---------------------+-----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Depending on the fasting process in a 24/7 food culture, the followers of periodic fasting increases.",
        "evidence": "The claim makes use of the physiological process of fasting described in section 3.4 and applies to a wider range of domains, including complementary and alternative medicine and fasting. We argue that, in a cultural culture, the type of thinking about food that is related to fasting is more general and less restricted than that of a natural language processing application. We observe that the frequency of fasting increases in the 21st century, as people become more aware of the concept of fast and then consider taking a break from fasting during their religious and spiritual traditions.",
        "table": "+----+----------------------------------------------------+------+\n|    | Planning a Fast                                    |   16 |\n+====+====================================================+======+\n|  1 | The Physiological Process of Fasting               |   37 |\n+----+----------------------------------------------------+------+\n|  3 | Complementary and Alternative Medicine and Fasting |   64 |\n+----+----------------------------------------------------+------+\n|  5 | Research on Fasting and Mental Health              |   86 |\n+----+----------------------------------------------------+------+\n|  7 | Fasting and Transpersonal Psychology               |  106 |\n+----+----------------------------------------------------+------+\n|  9 | Fasting and Depression                             |  120 |\n+----+----------------------------------------------------+------+\n| 11 | The Practice of Asceticism                         |  173 |\n+----+----------------------------------------------------+------+\n| 13 | Fasting in Religious and Spiritual Traditions      |  213 |\n+----+----------------------------------------------------+------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Barbados has a 143 % debt to GDP Ratio",
        "evidence": "The table shows that Barbados has a 143 % debt to GDP ratio which is the highest among the top 10 economies in the list.",
        "table": "+----+---------------+------------------------------+\n|    | Country       | Debt to GDP Ratio (Top 10)   |\n+====+===============+==============================+\n|  0 | 1. Japan      | 257%                         |\n+----+---------------+------------------------------+\n|  1 | 2. Sudan      | 212%                         |\n+----+---------------+------------------------------+\n|  2 | 3. Greece     | 210%                         |\n+----+---------------+------------------------------+\n|  3 | 4. Eritrea    | 176%                         |\n+----+---------------+------------------------------+\n|  4 | 5. Suriname   | 157%                         |\n+----+---------------+------------------------------+\n|  5 | 6. Italy      | 157%                         |\n+----+---------------+------------------------------+\n|  6 | 7. Barbados   | 143%                         |\n+----+---------------+------------------------------+\n|  7 | 8. Maldives   | 140%                         |\n+----+---------------+------------------------------+\n|  8 | 9. Cabo Verde | 138%                         |\n+----+---------------+------------------------------+\n|  9 | 10. Belize    | 135%                         |\n+----+---------------+------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": " Partridge Family star David Cassidy died at 67 after being rushed to a Florida hospital with organ failure. ",
        "evidence": "The claim made by David Cassidy in the table does not claim any specific information about his death. Instead, it only states that he died from organ failure. In the complete series set, David Cassidy was in 96 episodes, from 1970 to 1974.",
        "table": "+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n|    | Complete series cast summary:.1   | Complete series cast summary:.2   | Complete series cast summary:.3                     |\n+====+===================================+===================================+=====================================================+\n|  0 | Shirley Jones                     | ...                               | Shirley Partridge96 episodes, 1970-1974             |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n|  2 | David Cassidy                     | ...                               | Keith Partridge96 episodes, 1970-1974               |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n|  4 | Susan Dey                         | ...                               | Laurie Partridge96 episodes, 1970-1974              |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n|  6 | Danny Bonaduce                    | ...                               | Danny Partridge96 episodes, 1970-1974               |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n|  8 | Suzanne Crough                    | ...                               | Tracy Partridge96 episodes, 1970-1974               |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n| 10 | Dave Madden                       | ...                               | Reuben Kincaid / ... 96 episodes, 1970-1974         |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+\n| 12 | Brian Forster                     | ...                               | Christopher 'Chris' Partridge71 episodes, 1971-1974 |\n+----+-----------------------------------+-----------------------------------+-----------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "There is a higher legal percentage in the first trimester than in the second trimester.",
        "evidence": "From the table, we can see that in the first trimester, the legal percentage of questions is higher than in the second trimester. This is because the number of questions of interest increases much higher in the first trimester. In the second trimester, the number of questions no one is interested in anymore increases also compared to the first trimester.",
        "table": "+----+------------------+---------+-----------+------------------+--------------+\n|    | Unnamed: 0       | Legal   |   Illegal |   DEPENDS (vol.) |   No opinion |\n+====+==================+=========+===========+==================+==============+\n|  0 | First Trimester  | 65%     |        31 |                2 |            2 |\n+----+------------------+---------+-----------+------------------+--------------+\n|  1 | Second Trimester | 24%     |        69 |                4 |            3 |\n+----+------------------+---------+-----------+------------------+--------------+\n|  2 | Third Trimester  | 8%      |        86 |                3 |            3 |\n+----+------------------+---------+-----------+------------------+--------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Charts is found on page 149 ",
        "evidence": "In this section, we provide supporting arguments supporting each claim made by the aforementioned authors. In particular, we provide supporting charts showing that: (i) the proposed “Mandatory Waiting Period” legislation increases the time people need to wait for an abortion, and (ii) the proposed “Ban on Socalled Partialbirth Abortion and other Abortion procedures” legislation increases the time people need to wait for an abortion.",
        "table": "+----+----------------------------------------------------------------------+-------+\n|    | CHARTS                                                               |   147 |\n+====+======================================================================+=======+\n|  1 | MANDATORY WAITING PERIODS FOR ABORTION                               |   149 |\n+----+----------------------------------------------------------------------+-------+\n|  3 | RESTRICTIONS ON MINORS ACCESS TO ABORTION                            |   152 |\n+----+----------------------------------------------------------------------+-------+\n|  5 | BANS ON SOCALLED PARTIALBIRTH ABORTION AND OTHER ABORTION PROCEDURES |   154 |\n+----+----------------------------------------------------------------------+-------+",
        "label": "REFUTES"
    },
    {
        "claim": "War & peace are concerns for domestic issues while technology is an international issue.",
        "evidence": "This section examines the claim that the topic of War & Peace is more domestic issues than technology issues. As shown in the table, the most domestic issues are related to drug policy, the economy, and civil rights. However, Technology is also an international issue. Among the international issues, the most domestic issues are immigration, terrorism, and the environment. At the same time, these issues are also international issues. For example, “Food Supply” is an international issue, “Hydroelectric Energy” is an international issue, and “Water Supply” is an international issue.",
        "table": "+----+------------------------+-------------------+-------------------+---------------------+\n|    | International Issues   | Domestic Issues   | Economic Issues   | Social Issues       |\n+====+========================+===================+===================+=====================+\n|  0 | Foreign Policy         | Gun Control       | Budget & Economy  | Education           |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  1 | Homeland Security      | Crime             | Government Reform | Civil Rights        |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  2 | War & Peace            | Drugs             | Tax Reform        | Abortion            |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  3 | Free Trade             | Health Care       | Social Security   | Families & Children |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  4 | Immigration            | Technology        | Corporations      | Welfare & Poverty   |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  5 | Energy & Oil           | Environment       | Jobs              | Principles & Values |\n+----+------------------------+-------------------+-------------------+---------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The book \"Sacred Work: Planned Parenthood and Its Clergy Alliances\" was authored by Ron McDonald. ",
        "evidence": "This claim makes use of information from the Book \"Sacred Work: Plan Parenthood and Its Clergy Aliances\" by Ron McDonald. This is a small book that was published in 2005 by Random House. The text is of modest Christian apologia written by prolific author Tom Davis. The introduction contains a paragraph and introduction by the same author. This provides most of the information needed to understand the project and make predictions about its effects on individual families. Some of the text was contributed by the authors of this work.",
        "table": "+----+-----------------+-------------------------------------------------------------------------------+\n|    | Title           | Sacred Work: Planned Parenthood and Its Clergy Alliances                      |\n+====+=================+===============================================================================+\n|  0 | Author          | Tom Davis                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  1 | Edition         | illustrated                                                                   |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  2 | Publisher       | Rutgers University Press, 2005                                                |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  3 | ISBN            | 0813534933, 9780813534930                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  4 | Length          | 245 pages                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  5 | Subjects        | Social Science › Sociology of Religion Social Science / Sociology of Religion |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                         |\n+----+-----------------+-------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Suicide by planes in October has a higher rate than December.\n\n",
        "evidence": "From this table, we can see that in October, the suicide by planes has a higher rate than December, while the number of non-suicide airplane killings is much lower.",
        "table": "+----+--------------------+--------+--------+--------+--------+----------+\n|    | Unnamed: 0         |   Oct. |   Nov. |   Dec. |   Jan. |   Totals |\n+====+====================+========+========+========+========+==========+\n|  0 | Total planes       |    510 |    282 |    320 |    332 |     1444 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  1 | Suicide planes     |     54 |     79 |    109 |    110 |      352 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  2 | Non-suicide planes |    456 |    203 |    211 |    222 |     1092 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  3 | Suicide kills      |     36 |     51 |     76 |     68 |      231 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  4 | Non-suicide kills  |     95 |     16 |     23 |     22 |      156 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  5 | Suicide hits       |     18 |     28 |     33 |     42 |      121 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  6 | Non-suicide hits   |     10 |      1 |      3 |      9 |       23 |\n+----+--------------------+--------+--------+--------+--------+----------+",
        "label": "REFUTES"
    },
    {
        "claim": "173 people with intellectual disabilities.",
        "evidence": "According to the table, 173 people have intellectual disabilities.",
        "table": "+----+-----------------------------------------------+------+\n|    | The psychopathology of children with          |   93 |\n+====+===============================================+======+\n|  1 | Depression anxiety and adjustment             |  113 |\n+----+-----------------------------------------------+------+\n|  3 | Schizophrenia spectrum disorders in people    |  131 |\n+----+-----------------------------------------------+------+\n|  5 | Personality disorder                          |  143 |\n+----+-----------------------------------------------+------+\n|  7 | Dementia and mental illhealth in older        |  154 |\n+----+-----------------------------------------------+------+\n|  9 | People with intellectual disabilities who are |  173 |\n+----+-----------------------------------------------+------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Biological family encouragement has a larger percentage than Foster-care encouragement.",
        "evidence": "From the table, we could see that the Biological family Encouragement has a larger percentage than Foster-Care Encouragement. The difference is at least 6.6%. We can also see that there is a better estimated network size forinstitutional agents compared to foster-care encouragement. The network size is 7.6% relatively large compared to 2.3% for the foster-care network. This shows that the biological family Encouragement network is larger than the foster-care network.",
        "table": "+----+--------------------------------------------------------+-----------+\n|    | Main hypotheses                                        | Â         |\n+====+========================================================+===========+\n|  0 | âInstitutional agents (tangible/advice) (Mean/SD)    | 0.7 (0.8) |\n+----+--------------------------------------------------------+-----------+\n|  1 | âSchool encouragement                                | 63.1%     |\n+----+--------------------------------------------------------+-----------+\n|  2 | Competing hypotheses                                   | Â         |\n+----+--------------------------------------------------------+-----------+\n|  3 | âNoninstitutional agents (tangible/advice) (Mean/SD) | 2.3 (1.3) |\n+----+--------------------------------------------------------+-----------+\n|  4 | âInstitutional agents (emotional) (Mean/SD)          | 0.1 (0.4) |\n+----+--------------------------------------------------------+-----------+\n|  5 | âEstimated network size (0â30) (Mean/SD)           | 7.6 (6.6) |\n+----+--------------------------------------------------------+-----------+\n|  6 | âAdequate amount of tangible/advice                  | 54.2%     |\n+----+--------------------------------------------------------+-----------+\n|  7 | âBiological family encouragement                     | 60.6%     |\n+----+--------------------------------------------------------+-----------+\n|  8 | âFoster-care encouragement                           | 69.0%     |\n+----+--------------------------------------------------------+-----------+",
        "label": "REFUTES"
    },
    {
        "claim": "Peter Smith and Nelson Johnson published a study of Mental Health Nursing in 2000\n\n",
        "evidence": "The claim text can be found on the left part of the table. We extracted all medical texts from the PubMed abstracts, and the raw text from the CoNLL-2012 Our finding shows that there is no consistent difference between different publishers, and that most of the abstracts contain relatively short texts. The main exception was a statement about mental health nursing named Peter Nolan. This claim does not provide more information than what is already available in the existing literature.",
        "table": "+----+-----------------+--------------------------------------+\n|    | Title           | A History of Mental Health Nursing   |\n+====+=================+======================================+\n|  0 | Author          | Peter Nolan                          |\n+----+-----------------+--------------------------------------+\n|  1 | Edition         | reprint, revised                     |\n+----+-----------------+--------------------------------------+\n|  2 | Publisher       | Nelson Thornes, 2000                 |\n+----+-----------------+--------------------------------------+\n|  3 | ISBN            | 0748737219, 9780748737215            |\n+----+-----------------+--------------------------------------+\n|  4 | Length          | 178 pages                            |\n+----+-----------------+--------------------------------------+\n|  6 | Export Citation | BiBTeX EndNote RefMan                |\n+----+-----------------+--------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The subject of Sacred Work: Planned Parenthood and Its Clergy Alliances is about Social Science and Sociology of religion.",
        "evidence": "This claim is supported by information provided by the author of the paper, Tom Davis. We show in Table 1 that the text of Sacred Work: Plan Parenthood and its clergy alliances is in fact a sociology of religion. Other texts that are related to the topic are also described, but they are not sociology of religion.",
        "table": "+----+-----------------+-------------------------------------------------------------------------------+\n|    | Title           | Sacred Work: Planned Parenthood and Its Clergy Alliances                      |\n+====+=================+===============================================================================+\n|  0 | Author          | Tom Davis                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  1 | Edition         | illustrated                                                                   |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  2 | Publisher       | Rutgers University Press, 2005                                                |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  3 | ISBN            | 0813534933, 9780813534930                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  4 | Length          | 245 pages                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  5 | Subjects        | Social Science › Sociology of Religion Social Science / Sociology of Religion |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                         |\n+----+-----------------+-------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The amount of people with no family history of heart attack is 1.00",
        "evidence": "The claim that has the highest number of people with no family history of heart attack is 1.00. This number is even higher than the number of people with both parents with heart attack. Therefore, it is likely that the number of people with both parents with heart attacks is greater than the number of people with just one parent with heart attack.",
        "table": "+----+---------------------------------------------------+---------------------+\n|    | Unnamed: 0                                        | OR (95% CI)         |\n+====+===================================================+=====================+\n|  0 | No family history                                 | 1.00                |\n+----+---------------------------------------------------+---------------------+\n|  1 | One parent with heart attack â¥50 y of age       | 1.67 (1.55â1.81)  |\n+----+---------------------------------------------------+---------------------+\n|  2 | One parent with heart attack <50 y of age         | 2.36 (1.89â2.95)  |\n+----+---------------------------------------------------+---------------------+\n|  3 | Both parents with heart attack â¥50 y of age     | 2.90 (2.30â3.66)  |\n+----+---------------------------------------------------+---------------------+\n|  4 | Both parents with heart attack, one <50 y of age  | 3.26 (1.72â6.18)  |\n+----+---------------------------------------------------+---------------------+\n|  5 | Both parents with heart attack, both <50 y of age | 6.56 (1.39â30.95) |\n+----+---------------------------------------------------+---------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The digestive system has organ components of mouth, esophagus, stomach, intestines",
        "evidence": "The digestive system has organ components of mouth, esophagus, stomach, intestines and is regulated as a major function.",
        "table": "+----+----------------+---------------------------------------------+-----------------------------------------+\n|    | Organ System   | Organ Components                            | Major Function                          |\n+====+================+=============================================+=========================================+\n|  0 | Circulatory    | heart, blood/lymph vessels, blood, lymph    | Transport nutrients and waste products  |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  1 | Digestive      | mouth, esophagus, stomach, intestines       | Digestion and absorption                |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  2 | Endocrine      | all glands (thyroid, ovaries, pancreas)     | Produce and release hormones            |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  3 | Immune         | white blood cells, lymphatic tissue, marrow | Defend against foreign invaders         |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  4 | Integumentary  | skin, nails, hair, sweat glands             | Protective, body temperature regulation |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  5 | Muscular       | skeletal, smooth, and cardiac muscle        | Body movement                           |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  6 | Nervous        | brain, spinal cord, nerves                  | Interprets and responds to stimuli      |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  7 | Reproductive   | gonads, genitals                            | Reproduction and sexual characteristics |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  8 | Respiratory    | lungs, nose, mouth, throat, trachea         | Gas exchange                            |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n|  9 | Skeletal       | bones, tendons, ligaments, joints           | Structure and support                   |\n+----+----------------+---------------------------------------------+-----------------------------------------+\n| 10 | Urinary        | kidneys, bladder, ureters                   | Waste excretion, water balance          |\n+----+----------------+---------------------------------------------+-----------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Brazil has the least with numbers of countries reported with variant a",
        "evidence": "According to the claims provided by the authors, there are several interesting observations. Brazil has the least number of countries with variant a, with only 45 countries having variant a. This is perhaps due to the fact that the original splits of Afro-Asiatic regions contain more of English speakers than Afro-Asiatic regions, which makes no difference in the number of variant pairs observed.",
        "table": "+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|    | Variant                                    | United Kingdom (VOC-202012/01)       | South Africa (501Y.V2)             | Brazil (VOC202101/02)                                     |\n+====+============================================+======================================+====================================+===========================================================+\n|  0 | Pangolin lineage                           | B.1.1.7                              | B.1.351                            | B.1.1.28.1 (Lineage P.1)                                  |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  1 | Number of countries reported with varianta | 93                                   | 45                                 | 15                                                        |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  2 | Genes                                      | Â                                    | Â                                  | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  3 | orf1ab                                     | T1001I A1708D I2230T                 | K1655N                             | S1118L K1795Q                                             |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  4 | Â                                          | Del:11288:9 Del:21765:6 Del:21991:3  | Â                                  | Del:11288-9                                               |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  5 | S                                          | N501Y A570D P681H T716I S982A D1118H | D80A D215G K417N E484K N501Y A701V | L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  6 | Orf3a                                      | Â                                    | Â                                  | G174C                                                     |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  7 | Orf8                                       | Q27* R52I Y73C                       | Â                                  | E92K                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  8 | E                                          | Â                                    | P71L                               | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  9 | N                                          | D3L S235F                            | T205I                              | P80R                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The population of Liberia is 4.4 million",
        "evidence": "The population of Liberia is 4.4 million, which is much larger than the population of Sierra Leone which is 6.3 million. Based on this statistic, Liberia has a larger average population than Sierra Leone. Additionally, Liberia has the highest Gross Domestic Product (GDP) at 539.6 dollars per capita and the second-highest Gross Domestic Product (GDP) at 792.6 dollars per capita.",
        "table": "+----+----------------------------------------------------------+--------------+-------------+----------------+\n|    | country statistic                                        | Guinea       | Liberia     | Sierra Leone   |\n+====+==========================================================+==============+=============+================+\n|  0 | population                                               | 12.3 million | 4.4 million | 6.3 million    |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  1 | rural population (% of total)                            | 63.3         | 50.7        | 60.4           |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  2 | gross domestic product per capita (US$)                  | 539.6        | 457.9       | 792.6          |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  3 | capital city                                             | Conakry      | Monrovia    | Freetown       |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  4 | physicians per 1000 people (as of 2010)                  | 0.1          | 0.014       | 0.022          |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  5 | total number of reported Ebola casesâ (WHO 2013â2016) | 3811         | 10 678      | 14 124         |\n+----+----------------------------------------------------------+--------------+-------------+----------------+\n|  6 | total number of Ebola deaths (WHO 2013â2016)           | 2543         | 4810        | 3956           |\n+----+----------------------------------------------------------+--------------+-------------+----------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Health care and the environment will maintain their status.",
        "evidence": "The claim from Health Care will maintain its status while the environment will be decreased. This can be expected because the environment is more similar to health care than it is to education.",
        "table": "+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|    | Unnamed: 0        | a) Border security                                          | a) Border security.1                                        |\n+====+===================+=============================================================+=============================================================+\n|  0 | Slightly Increase | b) Education (K-12)                                         | b) Education (K-12)                                         |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  1 | Maintain Status   | c) Education (Higher)                                       | c) Education (Higher)                                       |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  2 | Maintain Status   | d) Environment                                              | d) Environment                                              |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  3 | Maintain Status   | e) Health care                                              | e) Health care                                              |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  4 | Slightly Increase | f) Law enforcement                                          | f) Law enforcement                                          |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  5 | Slightly Increase | g) Transportation infrastructure (highways, roads, bridges) | g) Transportation infrastructure (highways, roads, bridges) |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  6 | Slightly Decrease | h) Welfare                                                  | h) Welfare                                                  |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+\n|  7 | nan               | i) Other                                                    | i) Other                                                    |\n+----+-------------------+-------------------------------------------------------------+-------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "There is a slight increase of cocaine use from 2002 to 2005.",
        "evidence": "From this claim, there is a slight increase of cocaine use from 2002 to 2005. The Cocaine class has the highest increase of users from 2002 to 2005, followed by Heroin and oxycontin. The decreases for marijuana and Ecstasy are not as pronounced as for the other drugs. Overall, there was no increase in the number of users using drugs from 2002 to 2005, with the exception of Heroin.",
        "table": "+----+-----------+--------+--------+\n|    | Drug      | 2002   | 2005   |\n+====+===========+========+========+\n|  1 | Marijuana | 36.2%  | 33.6%  |\n+----+-----------+--------+--------+\n|  3 | Cocaine   | 5.0    | 5.1    |\n+----+-----------+--------+--------+\n|  5 | Ecstasy   | 7.4    | 3.0    |\n+----+-----------+--------+--------+\n|  7 | OxyContin | 4.0    | 5.5    |\n+----+-----------+--------+--------+\n|  9 | Vicodin   | 9.6    | 9.5    |\n+----+-----------+--------+--------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "\"As a result of Obamacare, \"\"California seniors face benefit cuts of over $1,700.\"",
        "evidence": "The claim that the Affordable Care Act and the Politics of Health Care reform causes California seniors to lose more than $1,700 in benefits is false. This is based on the claim that, without the Affordable Care Act, the average adult in California already receives $1,700 in benefits per year. The decrease in Californians’ benefits is due to the Affordable Care Act and the Politics of Health Care reform.",
        "table": "+----+------------------------------------------------------------------------------+-----+\n|    | 1 The Affordable Care Act and the Politics of Health Care Reform             |   1 |\n+====+==============================================================================+=====+\n|  1 | 2 Health Health Care and the Market Economy                                  |  14 |\n+----+------------------------------------------------------------------------------+-----+\n|  3 | 3 Health Care as a Reflection of Underlying Cultural Values and Institutions |  35 |\n+----+------------------------------------------------------------------------------+-----+\n|  5 | 4 The Health Professions and the Organization of Health Care                 |  70 |\n+----+------------------------------------------------------------------------------+-----+\n|  7 | 5 Health Insurance HMOs and the Managed Care Revolution                      |  97 |\n+----+------------------------------------------------------------------------------+-----+\n|  9 | 6 Medicare                                                                   | 131 |\n+----+------------------------------------------------------------------------------+-----+\n| 11 | 7 Medicaid and the State Childrens Health Insurance Program                  | 166 |\n+----+------------------------------------------------------------------------------+-----+\n| 13 | 8 The Increasing Role of ForProfit Health Care                               | 191 |\n+----+------------------------------------------------------------------------------+-----+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The chapter entitled \"Gold\" is over 50 pages in length.",
        "evidence": "This does not include the section named “Gold”, which is apparently much more complex than “First Penetration” and “The Economy Evolved”. Based on this, one can conclude that there is much more to the “Golden” claim than semantic similarity. The chapter “First Penetration” is indeed quite detailed, with detailed analysis of individual relationships and relationships between entities. In particular, detailed analysis of relationships between people and other entities is required to understand the whole story.",
        "table": "+----+------------------------------------+-----+\n|    | The Montana Pattern                |   3 |\n+====+====================================+=====+\n|  1 | The Land and Its First Penetration |  11 |\n+----+------------------------------------+-----+\n|  3 | Trappers Posts and Priests         |  40 |\n+----+------------------------------------+-----+\n|  5 | Gold                               |  64 |\n+----+------------------------------------+-----+\n|  7 | Politics                           |  95 |\n+----+------------------------------------+-----+\n|  9 | The Indian and the Military        | 115 |\n+----+------------------------------------+-----+\n| 11 | The Economy Evolves                | 139 |\n+----+------------------------------------+-----+\n| 13 | Butte to Paris and Return          | 167 |\n+----+------------------------------------+-----+",
        "label": "REFUTES"
    },
    {
        "claim": "Brazil's Bolsonaro plays down coronavirus risk as cases top 1,500.",
        "evidence": "The claim makes use of many existing studies on the bolsonaro virus, including reports from three different countries (United Kingdom, South Africa, and Brazil). The most accurate report on bolsonaro virus risk comes from the United Kingdom, with B.1.1.7 (voc.202012/01) B.1.1.1 (lineage P.1) and no variations. Although some of these work report variants, the main trend is the same as in the U.S. Moreover, the bolsonaro plays down the risk of influenza (case level: del:11288:9 del:21765:6 del:2) across all countries.",
        "table": "+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|    | Variant                                    | United Kingdom (VOC-202012/01)       | South Africa (501Y.V2)             | Brazil (VOC202101/02)                                     |\n+====+============================================+======================================+====================================+===========================================================+\n|  0 | Pangolin lineage                           | B.1.1.7                              | B.1.351                            | B.1.1.28.1 (Lineage P.1)                                  |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  1 | Number of countries reported with varianta | 93                                   | 45                                 | 15                                                        |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  2 | Genes                                      | Â                                    | Â                                  | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  3 | orf1ab                                     | T1001I A1708D I2230T                 | K1655N                             | S1118L K1795Q                                             |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  4 | Â                                          | Del:11288:9 Del:21765:6 Del:21991:3  | Â                                  | Del:11288-9                                               |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  5 | S                                          | N501Y A570D P681H T716I S982A D1118H | D80A D215G K417N E484K N501Y A701V | L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  6 | Orf3a                                      | Â                                    | Â                                  | G174C                                                     |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  7 | Orf8                                       | Q27* R52I Y73C                       | Â                                  | E92K                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  8 | E                                          | Â                                    | P71L                               | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  9 | N                                          | D3L S235F                            | T205I                              | P80R                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Mosquitoes kingdom is Animalia and Taxonomic rank is family.",
        "evidence": "The taxonomy given in the table is consistent with the description provided by the authors. The cell structure of the cell is similar, and the overall structure is also very similar. For instance, the cell structure of the cell structure is similar to the cell structure of the cell structure of the cell, except that the cell structure is also very similar. However, the relative rank of the cell is different. The first cell structure in the table is titled “ Mosquitoes kingdom”, while the second cell structure is “Family”.",
        "table": "+----+-----------------+--------------+\n|    | Unnamed: 1      | Unnamed: 2   |\n+====+=================+==============+\n|  0 | Kingdom:        | Animalia     |\n+----+-----------------+--------------+\n|  1 | Taxonomic Rank: | Family       |\n+----+-----------------+--------------+\n|  2 | Synonym(s):     | nan          |\n+----+-----------------+--------------+\n|  3 | Common Name(s): | mosquitoes   |\n+----+-----------------+--------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The Brazil variant has spread to fewer countries than the South Africa variant.",
        "evidence": "The claim template shows that the South Africa variant seems to be easier to cross-igrate from than the English one, with the only exception of the U.S. variant, which has a much larger spread.",
        "table": "+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|    | Variant                                    | United Kingdom (VOC-202012/01)       | South Africa (501Y.V2)             | Brazil (VOC202101/02)                                     |\n+====+============================================+======================================+====================================+===========================================================+\n|  0 | Pangolin lineage                           | B.1.1.7                              | B.1.351                            | B.1.1.28.1 (Lineage P.1)                                  |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  1 | Number of countries reported with varianta | 93                                   | 45                                 | 15                                                        |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  2 | Genes                                      | Â                                    | Â                                  | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  3 | orf1ab                                     | T1001I A1708D I2230T                 | K1655N                             | S1118L K1795Q                                             |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  4 | Â                                          | Del:11288:9 Del:21765:6 Del:21991:3  | Â                                  | Del:11288-9                                               |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  5 | S                                          | N501Y A570D P681H T716I S982A D1118H | D80A D215G K417N E484K N501Y A701V | L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  6 | Orf3a                                      | Â                                    | Â                                  | G174C                                                     |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  7 | Orf8                                       | Q27* R52I Y73C                       | Â                                  | E92K                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  8 | E                                          | Â                                    | P71L                               | Â                                                         |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+\n|  9 | N                                          | D3L S235F                            | T205I                              | P80R                                                      |\n+----+--------------------------------------------+--------------------------------------+------------------------------------+-----------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The Chinese FT worry value is half of the Latino FT worry value.",
        "evidence": "This claim does not support the claim that people in general are more worried about Chinese than those in general. The Chinese FT worry value is half of the Latino FT worry value. Moreover, the frequencies of “Chinese FAV” (0.215) and “Asian AM FRV” (0.407) are all significantly lower than the corresponding frequencies of “Latino FT” and “Black FT”. This shows that concerns about “Chinese FT” are not completely irrational.",
        "table": "+----+------------------+---------------------------+---------------------------+---------------------------+\n|    | Â                | Dependent variable:       | Dependent variable:.1     | Dependent variable:.2     |\n+====+==================+===========================+===========================+===========================+\n|  0 | Â                | Worried About Coronavirus | Worried About Coronavirus | Worried About Coronavirus |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  1 | Â                | (1)                       | (2)                       | (3)                       |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  2 | Chinese FT       | 0.215*** (0.075)          | Â                         | Â                         |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  3 | Asian Am FT      | Â                         | 0.378*** (0.090)          | 0.407*** (0.092)          |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  4 | Latino FT        | 0.065 (0.089)             | â0.005 (0.092)          | 0.008 (0.092)             |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  5 | Black FT         | â0.105 (0.085)          | â0.183** (0.089)        | â0.171* (0.090)         |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  6 | Passive Contact  | Â                         | Â                         | 0.079*** (0.017)          |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  7 | Intimate Contact | Â                         | Â                         | â0.101** (0.042)        |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  8 | Xenophobia       | 0.235*** (0.082)          | 0.236*** (0.082)          | 0.262*** (0.083)          |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n|  9 | Controls         | â                       | â                       | â                       |\n+----+------------------+---------------------------+---------------------------+---------------------------+\n| 10 | N                | 4142                      | 4142                      | 4109                      |\n+----+------------------+---------------------------+---------------------------+---------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The 1997 study had the largest sample size.",
        "evidence": "The 1997 study had the largest sample size of 535,544 children and was used for evaluation of the risk of aseptic meningitis. This cohort included 161 children hospitalized for meningitis within 3 months of their birth, which was the primary objective of the study. Overall, the table shows that there was no significant increase in mortality after MMR vaccination compared to other published studies. The size of the study population also highlights the fact that this data set contains high-resource, low-resource subgroups at higher risk of Meningitis.",
        "table": "+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+\n|    | Unnamed: 0           | Unnamed: 1                                               | Unnamed: 2                                        | Unnamed: 3               | Unnamed: 4                                                                    | Unnamed: 5                                                 | Unnamed: 6                                                                             | Unnamed: 7                              | Unnamed: 8                           |\n+====+======================+==========================================================+===================================================+==========================+===============================================================================+============================================================+========================================================================================+=========================================+======================================+\n|  0 | Citation             | Operationally Defined Outcome                            | Study Setting                                     | Defined Study Population | Study Design                                                                  | Sample Size                                                | Primary Effect Size Estimatea (95% CI or p value)                                      | Heterogeneous Subgroups at Higher Riskb | Limitations (Negligible or Serious)c |\n+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+\n|  2 | Black ct al. (1997)  | Meningitis diagnosis identified in the medical record    | Four HMOs participating in the VSD from 1984-1993 | Ages 12-23 months        | Case-control                                                                  | 59 children with meningitis                                | OR for meningitis diagnosis within 14 days of MMR vaccination: 0.50 (95% CI 0.1-4.5)   | None described                          | Negligible                           |\n+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+\n|  3 | nan                  | nan                                                      | nan                                               | nan                      | Controls matched by age (within 1 month), sex, HMO, and HMO membership status | 118 matched controls                                       | OR for meningitis diagnosis within 30 days of MMR vaccination: 0.84 (95% CI 0.2-3.5)   | nan                                     | nan                                  |\n+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+\n|  4 | nan                  | nan                                                      | nan                                               | nan                      | nan                                                                           | nan                                                        | OR for meningitis diagnosis within 8-14 days of MMR vaccination: 1.00 (95% CI 0.1-9.2) | nan                                     | nan                                  |\n+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+\n|  5 | Makela et al. (2002) | Aseptic meningitis identified in the nationwide hospital | Finland from 11/1982 to 6/1986                    | Ages 1-7 years           | Retrospective cohort  Risk period: 0-3 months after MMR vaccination           | 535,544 children  161 children hospitalized for meningitis | No significant increase in aseptic meningitis within 3 months of MMR vaccination       | None described                          | Serious                              |\n+----+----------------------+----------------------------------------------------------+---------------------------------------------------+--------------------------+-------------------------------------------------------------------------------+------------------------------------------------------------+----------------------------------------------------------------------------------------+-----------------------------------------+--------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Indoor pollution is a higher risk factor for TB than Diabetes.",
        "evidence": "We see that there is a higher risk factor for diabetes in the presence of indoor pollution compared to without it. Also, the population attributable fraction (C) of diabetes is higher in the case of indoor pollution than in the case of Hiv infection and malnutrition.",
        "table": "+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|    | Unnamed: 0                   | Unnamed: 1                                   | Unnamed: 2                                                            | Unnamed: 3                                |\n+====+==============================+==============================================+=======================================================================+===========================================+\n|  0 | Risk factor (reference)      | Relative risk for active TB disease (range)a | Weighted prevalence, total population, 22âTB high burden countriesb | Population attributable fraction (range)c |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  2 | HIV infection                | 8.3 (6.1â10.8)                             | 1.1%                                                                  | 7.3% (5.2â6.9)                          |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  3 | Malnutrition                 | 4.0 (2.0â6.0)                              | 17.2%                                                                 | 34.1% (14.7â46.3)                       |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  4 | Diabetes                     | 3.0 (1.5â7.8)                              | 3.4%                                                                  | 6.3% (1.6â18.6)                         |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  5 | Alcohol useâ>â40âg/day | 2.9 (1.9â4.6)                              | 7.9%                                                                  | 13.1% (6.7â22.2)                        |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  6 | Active smoking               | 2.6 (1.6â4.3)                              | 18.2%                                                                 | 22.7% (9.9â37.4)                        |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  7 | Indoor pollution             | 1.5 (1.2â3.2)                              | 71.1%                                                                 | 26.2% (12.4â61.0)                       |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "There are more cases in females than males.",
        "evidence": "From this table, we can see there are more cases in females than males. Every age range is shown, with the oldest being 15 to 19 years, and the younger ones being 5 to 34 years. Then, there are 5 cases for each sex, and 5 cases for age 50 and more. Overall, there are 12 cases for male to female, and 8 cases for female to male.",
        "table": "+----+----------------+-------------------+\n|    | Age range      | Number of cases   |\n+====+================+===================+\n|  0 | 15 to 19 years | 5                 |\n+----+----------------+-------------------+\n|  1 | 20 to 34 years | 5                 |\n+----+----------------+-------------------+\n|  2 | 35 to 49 years | 5                 |\n+----+----------------+-------------------+\n|  3 | 50 years +     | 5                 |\n+----+----------------+-------------------+\n|  4 | Sex            | Sex               |\n+----+----------------+-------------------+\n|  5 | Female         | 8                 |\n+----+----------------+-------------------+\n|  6 | Male           | 12                |\n+----+----------------+-------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "in 2007 national parks grew by 1 ",
        "evidence": "This claim is supported by the fact that the number of acres of national parks increased by 1.1 million between 1997 and 2007.",
        "table": "+----+--------------------------------+--------+--------+--------+--------+\n|    | Option                         | 1997   |   2000 |   2003 |   2007 |\n+====+================================+========+========+========+========+\n|  0 | Health care system             | 89     |     80 |     78 |     83 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  1 | Charter of Rights and Freedoms | 72     |     76 |     71 |     72 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  2 | Canadian flag                  | 70     |     73 |     68 |     69 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  3 | National parks                 | 71     |     73 |     62 |     63 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  4 | National anthem                | 67     |     65 |     60 |     62 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  5 | Historic sites                 | 65     |     67 |     53 |     58 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  6 | RCMP                           | 60     |     60 |     57 |     52 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  7 | Multiculturalism               | 37     |     54 |     47 |     50 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  8 | Canadian literature and music  | 49     |     58 |     46 |     46 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  9 | Bilingualism                   | 37     |     45 |     38 |     40 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 10 | CBC                            | 39     |     37 |     37 |     39 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 11 | Hockey                         | 30     |     35 |     40 |     37 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 12 | National capital Ottawa        | â    |     43 |     36 |     33 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 13 | The Queen                      | 14     |     16 |     16 |     16 |\n+----+--------------------------------+--------+--------+--------+--------+",
        "label": "REFUTES"
    },
    {
        "claim": "In cardiac or neurologic manifestations, the sensitivity is higher than the specificity.",
        "evidence": "We present the results for a number of different classifiers used to predict the five stages of lyme disease. The model is trained for 5 different phases: acute phase, convalescent phase, multiple entity migrans lesion, early disseminated, late stage and arthritis or neurologic manifestations. The positive predictive value is 100% for all of the phases, including the early localization and the late stage. The negative predictive value is only available for the early disseminated stage.",
        "table": "+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|    | Stage of Lyme disease                  | Sensitivity (%)    | Specificity (%)    | Positive predictive value (%)   | Negative predictive value (%)   |\n+====+========================================+====================+====================+=================================+=================================+\n|  0 | Early localized                        | Early localized    | Early localized    | Early localized                 | Early localized                 |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  1 | Acute phase                            | 17                 | 98                 | 75                              | 26                              |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  2 | Convalescent phase                     | 53                 | 98                 | 90                              | 83                              |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  3 | Early disseminated                     | Early disseminated | Early disseminated | Early disseminated              | Early disseminated              |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  4 | Cardiac or neurologic manifestations   | 100                | 98                 | 87                              | 100                             |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  5 | Multiple erythema migrans lesions      | 43                 | 98                 | 89                              | 79                              |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  6 | Late                                   | Late               | Late               | Late                            | Late                            |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+\n|  7 | Arthritis or neurologic manifestations | 100                | 98                 | 94                              | 100                             |\n+----+----------------------------------------+--------------------+--------------------+---------------------------------+---------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Both the Homotherium latidens and the Panthera leo spelaea were found to be located in Eurasia.",
        "evidence": "From the table, it is evident that both the homotherium Latidens and the panthera leo spelaea were found to be located in Eurasia.",
        "table": "+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|    | Species                                      | Location            | Approximate Datea   | Reference(s)                         |\n+====+==============================================+=====================+=====================+======================================+\n|  0 | Homotherium latidens (European scimitar cat) | Eurasia             | ca. 32,000 BP       | Reumer et al. (2003, p. 261)         |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  1 | Crocuta crocuta (spotted hyaena)             | northern Eurasia    | ca. 31,000 BP       | Stuart and Lister (2014, p. 112)     |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  2 | Panthera leo spelaea (cave/steppe lion)      | Eurasia             | 14,000â14,500 BP  | Stuart and Lister (2011, p. 2337)    |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  3 | Panthera leo atrox (American lion)           | North America       | 13â13,400 BP      | Barnett et al. (2009, p. 1674)       |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  4 | Smilodon sp. (saber-tooth cats)              | North/South America | 10,300â12,500 BP  | Marcus and Berger (1984, p. 176)     |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  5 | Â                                            | Â                   | Â                   | Turvey (2009, p. 24)                 |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  6 | Panthera pardus (leopard)                    | Europe              | Latest Pleistocene? | Sommer and Benecke (2006, p. 13)     |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  7 | Cuon alpinus (dhole)                         | Europe              | ca. 10,000 BP?      | PÃ©rez Ripoll et al. (2010, p. 444)  |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  8 | Â                                            | Â                   | Â                   | Morales PÃ©rez et al. (2012, p. 466) |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n|  9 | Canis lupus ssp. (eastern Beringian wolf)    | Beringia            | ca. 14,700 BP       | Leonard et al. (2007, p. 1146)       |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+\n| 10 | Canis dirus (dire wolf)                      | North/South America | ca. 12,000 BP       | Dundas (1999, p. 378)                |\n+----+----------------------------------------------+---------------------+---------------------+--------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The Concept of Sacred Work begins on page 5.",
        "evidence": "The contribution of the concept of sacred work is exemplified by the introduction by Margaret Sanger to the US government in 1953. In this introduction, Sanger recruits the clergy and provides a series of conversations with members of the clergy. The topics covered in the discussion include building public acceptance, the 1958 battle over the New York City hospitals, victories in the sixties, and the proposed Planned Parenthood and the clergy consultation service on abortion 19671973.",
        "table": "+----+-----------------------------------------------------------------------------+-----+\n|    | Introduction                                                                |   1 |\n+====+=============================================================================+=====+\n|  1 | The Concept of Sacred Work                                                  |   5 |\n+----+-----------------------------------------------------------------------------+-----+\n|  3 | Margaret Sanger Recruits the Clergy                                         |  27 |\n+----+-----------------------------------------------------------------------------+-----+\n|  5 | Building Public Acceptance 19351957                                         |  47 |\n+----+-----------------------------------------------------------------------------+-----+\n|  7 | The 1958 Battle over the New York City Hospitals                            |  72 |\n+----+-----------------------------------------------------------------------------+-----+\n|  9 | Sacred Work in Baltimore 19611965                                           |  88 |\n+----+-----------------------------------------------------------------------------+-----+\n| 11 | Victories in the Sixties                                                    | 104 |\n+----+-----------------------------------------------------------------------------+-----+\n| 13 | Planned Parenthood and the Clergy Consultation Service on Abortion 19671973 | 121 |\n+----+-----------------------------------------------------------------------------+-----+",
        "label": "SUPPORTS"
    },
    {
        "claim": "A patient with score of over 200 on any common glucose test should be considered diabetic.",
        "evidence": "The claim template shows that a patient with a score of 200 on any common glucose test should be considered diabetic. We consider diabetes as a diagnosis if their A1c score is greater than 6.5 and their fasting plasma glucose score is greater than 126. Additionally, we consider subjects with nanabetes and hypertension as being diabetic.",
        "table": "+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|    | Diagnosis   | A1C (percent)   | Fasting plasma glucose (FPG)a   | Oral glucose tolerance test (OGTT)ab   | Random plasma glucose test (RPG)a   |\n+====+=============+=================+=================================+========================================+=====================================+\n|  0 | Normal      | below 5.7       | 99 or below                     | 139 or below                           | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  1 | Prediabetes | 5.7 to 6.4      | 100 to 125                      | 140 to 199                             | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  2 | Diabetes    | 6.5 or above    | 126 or above                    | 200 or above                           | 200 or above                        |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Experimental treatment helps 2 out of 3 peanut allergy sufferers, study finds\n\n",
        "evidence": "The drug candidates given to the study are GloVe protein, CoGlutin protein, Oleosin protein (glycecidine) and pathogenesis-related protein (pMP-protein). Among them, CoVe protein has the best performance in genealogy classification of all three allergies, while Oleosin protein is the second best. This may be because of the fact that there are only two groups of allergies: small allergies (using GloVe) and large allergies (using pathogenesis-related protein). Therefore, the combination of all three drugs is suitable for 2 out of 3 allergies.",
        "table": "+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|    | Allergen   | Homology                             | Molecular weight (kDa)   |   Nucleotide length (bp) | IgE reactivity (%) (allergic patients)   | Genbank accession number   | Ref.     |\n+====+============+======================================+==========================+==========================+==========================================+============================+==========+\n|  0 | Ara h 1    | Cupin (vicillin-type)                | 64                       |                     2032 | 88                                       | L34402.1                   | [54]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  1 | Ara h 2    | Conglutin                            | 17                       |                      472 | 85                                       | AY007229, AY158467         | [24]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  2 | Ara h 3    | Cupin (legume-type)                  | 60, 37                   |                     1524 | 44                                       | AF093541.1                 | [20]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  3 | Ara h 3.02 | Cupin (legume-type)                  | 61                       |                     1853 | 44                                       | AF086821                   | [20,201] |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  4 | Ara h 5    | Profilin                             | 15                       |                      743 | 13                                       | AF059616.1                 | [24]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  5 | Ara h 6    | Conglutin                            | 15                       |                      627 | 38                                       | AF092846                   | [24]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  6 | Ara h 7    | Conglutin                            | 15                       |                   712495 | 43                                       | AF091737, EU046325         | [24]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  7 | Ara h 8    | Pathogenesis-related protein         | 17                       |                   474462 | 85                                       | AY328088, EF436550         | [26]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  8 | Ara h 9    | Nonspecific lipid-transfer protein 1 | 9.8                      |                   351271 | Minor allergen                           | EU159429, EU161278         | [27]     |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n|  9 | Ara h 10   | Oleosin                              | 16                       |                   954578 | 7 patients                               | AY722694, AY722695         | [201]    |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+\n| 10 | Ara h 11   | Oleosin                              | 14                       |                      655 | 7 patients                               | DQ097716                   | [201]    |\n+----+------------+--------------------------------------+--------------------------+--------------------------+------------------------------------------+----------------------------+----------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Research on Stage 4 breast cancer survivors ",
        "evidence": "From this data set we could see that the BRCA2 gene has been very effective in identifying Stage 4 breast cancer survivors. Also, from this data set, we could see that the BRCA1 gene has been very effective in identifying Stage 4 breast cancer survivors.",
        "table": "+----+----------+----------------------------------------------------------------+\n|    |   113705 | BREAST CANCER 1 GENE; BRCA1                                    |\n+====+==========+================================================================+\n|  0 |   114480 | BREAST CANCER                                                  |\n+----+----------+----------------------------------------------------------------+\n|  1 |   600185 | BRCA2 GENE; BRCA2                                              |\n+----+----------+----------------------------------------------------------------+\n|  2 |   604370 | BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1 |\n+----+----------+----------------------------------------------------------------+\n|  3 |   612555 | BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 2; BROVCA2 |\n+----+----------+----------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "\"Nick Fish Says \"\"cities save an estimated $38 in dental costs for every $1 invested in fluoridation.\"",
        "evidence": "The claim makes use of the claim of “Dietteriffic”, which is a drug which significantly improves the DUR. However, the problem of “Dietteriff” is that the city of Iowa does not have a fluoride collection system and therefore obtain their water from the community water system. They also have to deal with the problem of “fluoride content”, which is a problematic issue in large cities where fluoride is not present in the water Supply. The idea of “Dietteriff” is that the city of Iowa can save an estimated $38 in dental costs for every $1 invested in fluoridation.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|    | Grembowski et al., 1992                                                                                                     | Cross-sectional; 595; NA; NA                                                                                                | Washington; 30.6 (20â34)                                                                                                  | Community water system                                                                                                      |\n+====+=============================================================================================================================+=============================================================================================================================+=============================================================================================================================+=============================================================================================================================+\n|  0 | Hunt et al., 1989                                                                                                           | Prospective cohort (random sample); 275; 1.5 yrs; 13%                                                                       | Iowa; 75 (NR)                                                                                                               | Community water system (0.7 to 1.5 ppm vs. < 0.5 ppm)                                                                       |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  1 | Jensen and Kohout, 1988                                                                                                     | Randomized controlled trial; 810; 1 yr; 11%                                                                                 | Iowa; 68 (54â93)                                                                                                          | Dentifrice (1.1%) used twice daily                                                                                          |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  2 | Lu et al., 1980                                                                                                             | Randomized controlled trial; 1105; 1 yr; 17%                                                                                | Oregon; 33 (18â78)                                                                                                        | Dentifrice (stannous fluoride-calcium pyrophosphate, pH = 4.5; fluoride content NR)                                         |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  3 | Morgan et al., 1992                                                                                                         | Cross-sectional; 104; NA; NA                                                                                                | Australia; NR (20â24)                                                                                                     | Community water system (fluoride content NR)                                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  4 | Muhler et al., 1956                                                                                                         | Randomized controlled trial; 322; 1 yr; 10%                                                                                 | Indiana; NR (17â36)                                                                                                       | Dentifrice (4 mg stannous fluoride; frequency not reporteda)                                                                |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  5 | Muhler, 1958                                                                                                                | Randomized controlled trial; 435; 1 yr; NR                                                                                  | Indiana; NR (17â38)                                                                                                       | Aqueous solution professionally applied (10%), single application                                                           |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+\n|  6 | a Results stratified by good (â¥3 times daily) or bad brushers (â¤2 times daily), but numbers in each group not reported. | a Results stratified by good (â¥3 times daily) or bad brushers (â¤2 times daily), but numbers in each group not reported. | a Results stratified by good (â¥3 times daily) or bad brushers (â¤2 times daily), but numbers in each group not reported. | a Results stratified by good (â¥3 times daily) or bad brushers (â¤2 times daily), but numbers in each group not reported. |\n+----+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The treatment for Lyme disease without focal symptoms is the same as the treatment of Lyme disease affecting the central nervous system.",
        "evidence": "We treated lyme disease with focal symptoms and Lyme disease with focal symptoms separately. The treatment for Lyme disease affecting the central nervous system is the same as the treatment for Lyme disease without focal symptoms. All patients taking anti-depressants like Oral Amoxicillin:1â¡G 3â¡ times a day or 200 times a day, intravenous chemotherapy twice a day or 400 times a day for Lyme disease, and intravenous ceftriaxone twice a day for Lyme disease with focal symptoms.",
        "table": "+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Symptoms                                                                                                                                                                                                                                  | Treatment                                                                                                                                                                                                                                 | First alternative                                                                                                                                                                                                                         | Second alternative                                                                                                                                                                                                                        |\n+====+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+\n|  0 | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Erythema migrans and/or Non-focal symptoms                                                                                                                                                                                                | Oral doxycycline: 100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                              | Oral amoxicillin:1Â g 3Â times per day for 21Â days                                                                                                                                                                                       | Oral azithromycinb: 500Â mg daily for 17Â days                                                                                                                                                                                            |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Lyme disease affecting the cranial nerves or peripheral nervous system                                                                                                                                                                    | Oral doxycycline: 100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                              | Oral amoxicillin:1Â g 3Â times per day for 21Â days                                                                                                                                                                                       | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Lyme disease affecting the central nervous system                                                                                                                                                                                         | Intravenous ceftriaxone: 2Â g twice per day or 4Â g once per day for 21Â days (when an oral switch is being considered, use doxycycline)                                                                                                  | Oral doxycycline: 200Â mg twice per day or 400Â mg once per day for 21Â days                                                                                                                                                              | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Lyme disease arthritis                                                                                                                                                                                                                    | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 28Â days                                                                                                                                                               | Oral amoxicillin:1Â g 3Â times per day for 28Â days                                                                                                                                                                                       | Intravenous ceftriaxone:2Â g once per day for 28Â days                                                                                                                                                                                    |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | Acrodermatitis chronica atrophicans                                                                                                                                                                                                       | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 28Â days                                                                                                                                                               | Oral amoxicillin:1Â g 3Â times per day for 28Â days                                                                                                                                                                                       | Intravenous ceftriaxone:2Â g once per day for 28Â days                                                                                                                                                                                    |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | Lyme carditisb                                                                                                                                                                                                                            | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                               | Intravenous ceftriaxone:2Â g once per day for 21Â days                                                                                                                                                                                    | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | Lyme carditis and haemodynamically unstableb                                                                                                                                                                                              | Intravenous ceftriaxone:2Â g once per day for 21Â days (when an oral switch is being considered, use doxycycline)                                                                                                                         | â                                                                                                                                                                                                                                       | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  9 | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Clinton had +16 polling average 30 days after convention  in  1996 ",
        "evidence": "The data from this claim is shown in the 30 days after the convention. In 1996, Clinton had a polling average of +16.8, whereas the actual result was +8.5.",
        "table": "+----+--------------+--------------------------+---------------------------+---------------+\n|    | Unnamed: 0   | POLLING AVERAGE          | POLLING AVERAGE.1         | Unnamed: 3    |\n+====+==============+==========================+===========================+===============+\n|  0 | YEAR         | HEADING INTO CONVENTIONS | 30 DAYS AFTER CONVENTIONS | ACTUAL RESULT |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  1 | 1972         | Nixon +16.0              | Nixon +29.7               | Nixon +23.2   |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  2 | 1976         | Carter +13.0             | Carter +4.0               | Carter +2.0   |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  3 | 1980         | Reagan +6.0              | Reagan +2.6               | Reagan +9.7   |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  4 | 1984         | Reagan +14.3             | Reagan +16.8              | Reagan +18.2  |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  5 | 1988         | Dukakis +6.7             | Bush +3.0                 | Bush +7.7     |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  6 | 1992         | Bush +1.0                | Clinton +11.7             | Clinton +5.6  |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  7 | 1996         | Clinton +16.8            | Clinton +16.0             | Clinton +8.5  |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  8 | 2000         | Bush +4.3                | Gore +2.0                 | Gore +0.5     |\n+----+--------------+--------------------------+---------------------------+---------------+\n|  9 | 2004         | Kerry +2.7               | Bush +1.8                 | Bush +2.5     |\n+----+--------------+--------------------------+---------------------------+---------------+\n| 10 | 2008         | Obama +3.8               | Obama +3.1                | Obama +7.3    |\n+----+--------------+--------------------------+---------------------------+---------------+\n| 11 | 2012         | Obama +2.3               | Obama +1.9                | Obama +3.9    |\n+----+--------------+--------------------------+---------------------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Yuiza and Loiza have best festival compared to Three Kings Day.",
        "evidence": "The claim from Three Kings Day is that Yuiza and Loiza have the best festival compared to the other festivals mentioned. This claim is based on the information provided by the claim writer. If the claim is true, then our Yuiza and Loiza festival will be the best festival compared to the three festivals mentioned above.",
        "table": "+----+-------------------------+-----------------+\n|    | • History Puerto Rico   | • Culture       |\n+====+=========================+=================+\n|  0 | • Letter from JFK       | • Samuel Lind   |\n+----+-------------------------+-----------------+\n|  1 | • End Taino Kingdom     | • Hammock Maker |\n+----+-------------------------+-----------------+\n|  2 | • Yuiza and Loiza       | • Old San Juan  |\n+----+-------------------------+-----------------+\n|  3 | • Three Kings Day       | • Vejigantes    |\n+----+-------------------------+-----------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Hepatitis A outbreak increases to 11 cases in Yakima County.",
        "evidence": "This indicates that there is a continuing increase in the number of hepatitis A cases in Yakima County. The governor of English is also available to provide English help to local businesses. If you are interested, please refer to the information provided in the table.",
        "table": "+----+--------------------------------------------------------------------------------------------+------------------+\n|    | Yakima County Small Business Coronavirus Assistance                                        | EnglishEspanol   |\n+====+============================================================================================+==================+\n|  0 | State and Federal Financial Help for Businesses                                            | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  1 | âOpen Yakimaâ Business re-opening health and safety plan services community task force | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  2 | Yakima County local Personal Protective Equipment suppliers and vendors                    | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  3 | Handouts and Print Resources for Businesses                                                | English          |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  4 | Yakima Valley Open and Safe                                                                | EnglishEspanol   |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  5 | State Fair Park COVID-19 Vaccination Sign Up Web Site                                      | Click Here       |\n+----+--------------------------------------------------------------------------------------------+------------------+\n|  6 | State COVID-19 Assistance Hotline                                                          | 1-800-525-0127   |\n+----+--------------------------------------------------------------------------------------------+------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Etowah High School is located in Cherokee County ",
        "evidence": "The claim that ETOWA High School is located in Cherokee County is not supported by the data.",
        "table": "",
        "label": "SUPPORTS"
    },
    {
        "claim": "Receptor ACE2 has the most references",
        "evidence": "From the table, we can see that the receptor ACE2 has the most references. This is consistent with the results presented in previous works. We also looked at the tagging results for dpp4. We can see that dpp4 performs better than the other dpp4 based methods. The differences are significant in that dpp4 has more deletions and inserted deletions than the other methods.",
        "table": "+----+--------------------+------------------------------------+--------------------+\n|    | Virus              | Receptor                           | References         |\n+====+====================+====================================+====================+\n|  0 | Alphacoronaviruses | Alphacoronaviruses                 | Alphacoronaviruses |\n+----+--------------------+------------------------------------+--------------------+\n|  1 | HCoV-229E          | APN                                | [115]              |\n+----+--------------------+------------------------------------+--------------------+\n|  2 | HCoV-NL63          | ACE2                               | [116]              |\n+----+--------------------+------------------------------------+--------------------+\n|  3 | TGEV               | APN                                | [117]              |\n+----+--------------------+------------------------------------+--------------------+\n|  4 | PEDV               | APN                                | [118]              |\n+----+--------------------+------------------------------------+--------------------+\n|  5 | FIPV               | APN                                | [119]              |\n+----+--------------------+------------------------------------+--------------------+\n|  6 | CCoV               | APN                                | [120]              |\n+----+--------------------+------------------------------------+--------------------+\n|  7 | Betacoronaviruses  | Betacoronaviruses                  | Betacoronaviruses  |\n+----+--------------------+------------------------------------+--------------------+\n|  8 | MHV                | mCEACAM                            | [121, 122]         |\n+----+--------------------+------------------------------------+--------------------+\n|  9 | BCoV               | N-acetyl-9-O-acetylneuraminic acid | [123]              |\n+----+--------------------+------------------------------------+--------------------+\n| 10 | SARS-CoV           | ACE2                               | [124]              |\n+----+--------------------+------------------------------------+--------------------+\n| 11 | MERS-CoV           | DPP4                               | [100]              |\n+----+--------------------+------------------------------------+--------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "SYSTOLIC mm Hg (upper number) with normal blood pressure is less than 120",
        "evidence": "We observed that patients with normal blood pressure usually have lower systolic MM Hg and higher diastolic Mph Hg than those with elevated blood pressure. This is due to the fact that for normal blood pressure, blood pressure can fluctuate in a range of 0.2 mm (moderate to severe) and sub-hypertension can be severe. When the patient has high blood pressure, it will stay elevated and diastolic Mph Hg will be greater than or equal to 80. This is why high blood pressure and hypertension need to be separately checked for high blood pressure and hypertension. Fortunately, our systolic Mph Hg (midline) is normal. We also noticed that patients with high diastolic Mph Hg that have lower systolic Mph Hg tend to have lower systolic Mph Hg and higher diastolic Mph Hg. However, this is not always the case. There are some positive cases where you have higher systolic Mph Hg and lower diastolic Mph Hg. For example, one patient in our study had higher systolic Mph Hg of 120 and no diastolic Mph Hg. Another patient in the study had higher diastolic Mph Hg of 129 and no diastolic Hg. We also recommend to consult with a physician about hypertension if you have it.",
        "table": "+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|    | BLOOD PRESSURE CATEGORY                               | SYSTOLIC mm Hg (upper number)   | and/or   | DIASTOLIC mm Hg (lower number)   |\n+====+=======================================================+=================================+==========+==================================+\n|  0 | NORMAL                                                | LESS THAN 120                   | and      | LESS THAN 80                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  1 | ELEVATED                                              | 120 – 129                       | and      | LESS THAN 80                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  2 | HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1            | 130 – 139                       | or       | 80 – 89                          |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  3 | HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2            | 140 OR HIGHER                   | or       | 90 OR HIGHER                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  4 | HYPERTENSIVE CRISIS (consult your doctor immediately) | HIGHER THAN 180                 | and/or   | HIGHER THAN 120                  |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "One can elicit more information, via PDF, about the unment need for health care. ",
        "evidence": "Using this information, one can elicit more information, via pdf, about the unment need for health care. As shown in the table, using information about the number of people in the country who have health care coverage, can improve the estimation of the unment need for health care by 40%. To illustrate the need for health care, we further analyze the distribution of doctors in the country. We observe that about 40% of the people in the country have access to health care, and about 20% of the people in the country also have coverage. However, the overall health care coverage of the country is inadequate, as there is a huge unment need for health care across all the regions. Using data obtained via pdf can help us to increase the number of doctors and to obtain more information about the unment need for health care.",
        "table": "+----+--------------------------------------------------+-----------+\n|    | Population coverage for health care              | ReadPDF   |\n+====+==================================================+===========+\n|  0 | Extent of health care coverage                   | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  1 | Use of primary care services                     | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  2 | Unmet need for health care                       | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  3 | Financial hardship and out-of-pocket expenditure | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  4 | Geographic distribution of doctors               | ReadPDF   |\n+----+--------------------------------------------------+-----------+\n|  5 | Waiting times for elective surgery               | ReadPDF   |\n+----+--------------------------------------------------+-----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "chlamydia, gonorrhea, syphilis are all considered STIs.",
        "evidence": "All three STI classes are considered to be at increased risk. The claim that “Nonpregnant women” does not support this claim. That is, there are no pregnant women in our dataset. We consider the claim to be at increased risk only if the unborn baby is present in the uterus.",
        "table": "+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|    | STI          | Nonpregnant women     | Nonpregnant women.1   | Pregnant women        | Pregnant women.1   | Men                   | Men.1              |\n+====+==============+=======================+=======================+=======================+====================+=======================+====================+\n|  0 | STI          | Not at increased risk | At increased risk*    | Not at increased risk | At increased risk* | Not at increased risk | At increased risk† |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  1 | Chlamydia2   | C                     | A                     | C                     | B                  | I                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  2 | Gonorrhea3   | D                     | B                     | I                     | B                  | D                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  3 | Syphilis4    | D                     | A                     | A                     | A                  | D                     | A                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  4 | HIV5         | C                     | A                     | A                     | A                  | C                     | A                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  5 | Hepatitis B6 | D                     | D                     | A                     | A                  | D                     | D                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  6 | Hepatitis C7 | D                     | I                     | —                     | —                  | D                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  7 | HSV8         | D                     | D                     | D                     | D                  | D                     | D                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  8 | HPV9‡        | I                     | I                     | —                     | —                  | —                     | —                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The magnitude of the 20 Jun 2021 earthquake was stronger than the 21 Jun 2021 quake.",
        "evidence": "The claim from the table shows that the 20 Jun 2021 earthquake was slightly larger than the 21 Jun 2021 earthquake. The mag. coordinates were 3.1 and 14.7 for the 20 Jun 2021 earthquake and the depth was 2.7 and 12. km for the 21 Jun 2021 earthquake.",
        "table": "+----+---------------------------------------+---------------------------------------+-----------------------------------------------------------------------------------+---------------------------------------+---------------------------------------+\n|    | Time                                  | Mag. / Depth                          | Distance/Location                                                                 | Unnamed: 3                            | Unnamed: 4                            |\n+====+=======================================+=======================================+===================================================================================+=======================================+=======================================+\n|  0 | Mon, 21 Jun 2021 (GMT) (1 earthquake) | Mon, 21 Jun 2021 (GMT) (1 earthquake) | Mon, 21 Jun 2021 (GMT) (1 earthquake)                                             | Mon, 21 Jun 2021 (GMT) (1 earthquake) | Mon, 21 Jun 2021 (GMT) (1 earthquake) |\n+----+---------------------------------------+---------------------------------------+-----------------------------------------------------------------------------------+---------------------------------------+---------------------------------------+\n|  1 | 21 Jun 2021 20:35:11 GMT              | 3.1 14 km                             | 38 km (24 mi) Flores Sea, 65 km northwest of Dompu, West Nusa Tenggara, Indonesia | nan                                   | nan                                   |\n+----+---------------------------------------+---------------------------------------+-----------------------------------------------------------------------------------+---------------------------------------+---------------------------------------+\n|  2 | Sun, 20 Jun 2021 (GMT) (1 earthquake) | Sun, 20 Jun 2021 (GMT) (1 earthquake) | Sun, 20 Jun 2021 (GMT) (1 earthquake)                                             | Sun, 20 Jun 2021 (GMT) (1 earthquake) | Sun, 20 Jun 2021 (GMT) (1 earthquake) |\n+----+---------------------------------------+---------------------------------------+-----------------------------------------------------------------------------------+---------------------------------------+---------------------------------------+\n|  3 | 20 Jun 2021 16:53:26 GMT              | 2.7 12 km                             | 37 km (23 mi) 23 km northwest of Dompu, West Nusa Tenggara, Indonesia             | nan                                   | nan                                   |\n+----+---------------------------------------+---------------------------------------+-----------------------------------------------------------------------------------+---------------------------------------+---------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Fabric softening laundry detergent was completed by Proffitt in 1971",
        "evidence": "The claim is that Proffitt produced the fabric softening laundry detergent using organic esters of phosphoric acid and the finish with anionic-cationic finish. The laundry detergent was produced in 1971 and consisted of 252/8.9% detergent.",
        "table": "+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|    |   3957661 | Fabric softening laundry detergent containing organic esters of phosphoric acid   | 1976-05-18   | Verite         | 252/8.9    |\n+====+===========+===================================================================================+==============+================+============+\n|  0 |   3622378 | FIBERS WITH ANIONIC-CATIONIC FINISH                                               | 1971-11-23   | Proffitt       | 81/156     |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  1 |   3591405 | nan                                                                               | 1971-07-06   | McCarty        | 252/8.6    |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  2 |   3346670 | Method for the preparation of phosphate esters                                    | 1967-10-10   | Papalos        | 252/DIG.17 |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  3 |   3033889 | Phosphate esters of branched chain alcohols                                       | 1962-05-08   | Chiddix et al. | 252/8.6    |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  4 |   2286794 | Yarn conditioning process and composition therefor                                | 1942-06-16   | Dickey et al.  | 252/8.8R   |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Medicaid saw Florida have more than 100 times the sum compared to Maine.",
        "evidence": "The claim from the table shows that Florida has more than 100 times the sum compared to Maine of the other three states.",
        "table": "+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|    | Â California                                                        | up to $624 million                                                  |\n+====+=====================================================================+=====================================================================+\n|  0 | Â Florida                                                           | up to $342.3 million                                                |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  1 | Â Washington                                                        | up to $161.5 million                                                |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  2 | Â Illinois                                                          | up to $42.3 million                                                 |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  3 | Â New York                                                          | up to $7.3 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  4 | Â Maine                                                             | up to $3.3 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  5 | Â Massachusetts                                                     | up to $2.8 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  6 | Â Vermont                                                           | up to $2.7 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  7 | Â Missouri                                                          | up to $2.2 million                                                  |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  8 | Â Wisconsin                                                         | up to $2 million for the Hiawatha line                              |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+\n|  9 | Â And smaller sums for Â Oregon, North Carolina, Â Iowa and Indiana | Â And smaller sums for Â Oregon, North Carolina, Â Iowa and Indiana |\n+----+---------------------------------------------------------------------+---------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Sacred Work: Planned Parenthood and Its Clergy Alliances is about Social science and Sociology of religion.",
        "evidence": "Our main source of information is the proposed model of \\newciteAabbott:2010:CSF:Ch4S1SSS0Px1 The text of the proposed model is a “social science” study using sociology of religion and psychology. The text of the proposal is “planned Parenthood and its clergy alliances”. This is a sociology study about a family’s choice of parents and their relationships with other family members. We focus on the sociology of religion and psychology, not on the genetics. Some of the conclusions drawn from this table are similar to what \\newciteAabbott:2010:CSF:Ch4S1SSS0Px2: The key point to note is that we are interested in exploring the sociology of religion and psychology, and not in finding a state-of-the-art genealogy or phylogenetic study.",
        "table": "+----+-----------------+-------------------------------------------------------------------------------+\n|    | Title           | Sacred Work: Planned Parenthood and Its Clergy Alliances                      |\n+====+=================+===============================================================================+\n|  0 | Author          | Tom Davis                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  1 | Edition         | illustrated                                                                   |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  2 | Publisher       | Rutgers University Press, 2005                                                |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  3 | ISBN            | 0813534933, 9780813534930                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  4 | Length          | 245 pages                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  5 | Subjects        | Social Science › Sociology of Religion Social Science / Sociology of Religion |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                         |\n+----+-----------------+-------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "men and women are at risk of Gonorrhea3",
        "evidence": "The claim that “Gonorrhea3” increases the risk of contracting tuberculosis is only true for men. The increase in risk for men is only 0.4 times greater than for nonpregnant women, and it is even greater for pregnant women.",
        "table": "+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|    | STI          | Nonpregnant women     | Nonpregnant women.1   | Pregnant women        | Pregnant women.1   | Men                   | Men.1              |\n+====+==============+=======================+=======================+=======================+====================+=======================+====================+\n|  0 | STI          | Not at increased risk | At increased risk*    | Not at increased risk | At increased risk* | Not at increased risk | At increased risk† |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  1 | Chlamydia2   | C                     | A                     | C                     | B                  | I                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  2 | Gonorrhea3   | D                     | B                     | I                     | B                  | D                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  3 | Syphilis4    | D                     | A                     | A                     | A                  | D                     | A                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  4 | HIV5         | C                     | A                     | A                     | A                  | C                     | A                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  5 | Hepatitis B6 | D                     | D                     | A                     | A                  | D                     | D                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  6 | Hepatitis C7 | D                     | I                     | —                     | —                  | D                     | I                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  7 | HSV8         | D                     | D                     | D                     | D                  | D                     | D                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+\n|  8 | HPV9‡        | I                     | I                     | —                     | —                  | —                     | —                  |\n+----+--------------+-----------------------+-----------------------+-----------------------+--------------------+-----------------------+--------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The book \"Sacred Work\" by Tom Davis was published in 2005 and is about the Sociology of Religion. ",
        "evidence": "This claim is supported by information provided by the author of the book, Tom Davis. The book is about the sociology of religion. It was published in 2005 by Random House, and is illustrated by illustrated illustrations by Tom Davis.",
        "table": "+----+-----------------+-------------------------------------------------------------------------------+\n|    | Title           | Sacred Work: Planned Parenthood and Its Clergy Alliances                      |\n+====+=================+===============================================================================+\n|  0 | Author          | Tom Davis                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  1 | Edition         | illustrated                                                                   |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  2 | Publisher       | Rutgers University Press, 2005                                                |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  3 | ISBN            | 0813534933, 9780813534930                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  4 | Length          | 245 pages                                                                     |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  5 | Subjects        | Social Science › Sociology of Religion Social Science / Sociology of Religion |\n+----+-----------------+-------------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                         |\n+----+-----------------+-------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Standard treatment for metastatic breast cancer and locoregional recurrent breast cancer are the exact same.",
        "evidence": "They all use radiation or chemotherapy for metastatic breast cancer and locoregional recurrent breast cancer. That is, radiation or chemotherapy treatment for metastatic breast cancer and locoregional recurrent breast cancer are the same.",
        "table": "+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|    | Stage (TNM Definitions)                                                                                              | Standard Treatment Options                                                                                           |\n+====+======================================================================================================================+======================================================================================================================+\n|  0 | Early/localized/operable breast cancer                                                                               | Surgery with or without radiation therapy                                                                            |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  1 | Early/localized/operable breast cancer                                                                               | Adjuvant therapy—chemotherapy, endocrine therapy, HER2-directed therapy                                              |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  2 | Locoregional recurrent breast cancer                                                                                 | Surgery                                                                                                              |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  3 | Locoregional recurrent breast cancer                                                                                 | Radiation therapy and chemotherapy                                                                                   |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  4 | Metastatic breast cancer                                                                                             | Hormone therapy and/or chemotherapy                                                                                  |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  5 | T = primary tumor; N = regional lymph node; M = distant metastasis; HER2 = human epidermal growth factor receptor 2. | T = primary tumor; N = regional lymph node; M = distant metastasis; HER2 = human epidermal growth factor receptor 2. |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "49% of women chose abortion in 1981.",
        "evidence": "The claim that 91% of women chose abortion in 1981 is supported by the data in the table. Moreover, of the 90,210 women who did not choose abortion, 77,210 (99%) chose adoption.",
        "table": "+----+----------------------+---------------+---------------+\n|    | Unnamed: 0           | 1981          | 1989          |\n+====+======================+===============+===============+\n|  0 | Chose abortion       | 33,577 (49%)  | 29,246 (38%)  |\n+----+----------------------+---------------+---------------+\n|  1 | Chose to raise child | 31,657 (46%)  | 46,234 (60%)  |\n+----+----------------------+---------------+---------------+\n|  2 | Chose adoption       | 3,521 (5%)    | 1,730 (2%)    |\n+----+----------------------+---------------+---------------+\n|  3 | Total                | 68,755 (100%) | 77,210 (100%) |\n+----+----------------------+---------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Sydney Brenner, who helped decipher genetic code, dies at 92.",
        "evidence": "The claim that Sydney Brenner helped decipher the genetic code was very surprising. He was only 40 years old and appeared to be very successful in the fields of Biology and Natural Language Processing.",
        "table": "+----+-----------+------------------+\n|    | Actor:    | Sydney Brenner   |\n+====+===========+==================+\n|  0 | Director: | Alan Macfarlane  |\n+----+-----------+------------------+\n|  1 | Reporter: | Sarah Harrison   |\n+----+-----------+------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "New psoriasis drug is more effective than current treatment",
        "evidence": "The new drug for psoriasis was tested on three routes: oral, tablets, and Parenteral. Oral is tablets of 2.5 mg, 3.5 mg, and 5 mg (of methotrexate) from LSTM Pharmicals Ltd. The tablets and capsules are “Rheumatrex dose pack” from Dava. They are followed by “Troxen” drug, which is a film-coated drug. “7.5 mg (of methotrexate),” “10 mg (of methotrexate), and “15 mg (of methotrexate)” are from Duramed. This is still higher than the best drug class, which is “Troxen” drug. However, there is still a difference between “10 mg (of methotrexate)” and “25 mg (of methotrexate),” where “10 mg (of methotrexate)” is from the drug class “Troxen”. The “25 mg (of methotrexate)” is from the drug “Matexate sodium injection”, which is also from the drug class “Parenteral”. Injections of methotrexate are “10 mg (of methotrexate) per ml” from the drug class “Matexate sodium injection isotonic.” This is different from the “25 mg (of methotrexate)” drug, where “Matexate sodium injection isotonic” is from the drug “Parenteral”.",
        "table": "+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|    | Routes     | Dosage Forms         | Strengths                       | Brand Names                            | Manufacturer   |\n+====+============+======================+=================================+========================================+================+\n|  0 | Oral       | Tablets              | 2.5 mg (of methotrexate)*       | Methotrexate Sodium Tablets (scored)   | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  1 | nan        | nan                  | nan                             | Rheumatrex Dose Pack (scored)          | Dava           |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  2 | nan        | Tablets, film-coated | 5 mg (of methotrexate)          | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  3 | nan        | nan                  | 7.5 mg (of methotrexate)        | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  4 | nan        | nan                  | 10 mg (of methotrexate)         | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  5 | nan        | nan                  | 15 mg (of methotrexate)         | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  6 | Parenteral | For injection        | 1 g (of methotrexate)*          | Methotrexate Sodium for Injection      | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  7 | nan        | Injection            | 10 mg (of methotrexate) per mL* | Methotrexate Sodium Injection Isotonic | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  8 | nan        | nan                  | 25 mg (of methotrexate) per mL* | Methotrexate Sodium Injection Isotonic | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Lyme disease affects  cranial nerves",
        "evidence": "Lyme disease appears to affect the cranial and peripheral nervous system. The treatment for lyme disease is oral dixyline: 100 mg twice per day or 200 mg 3â times per day. intravenous ceftriaxone:2â twice per day or once per day is used as a second alternative. Lastly, there are also patients who show focal symptoms of lyme disease and who have intravenous ceftriaxone treatment. Among them are: erythema migrans and/or non-focal symptoms, lyme disease with focal symptoms, and pediatric lyme carditis and haemodynamically unstableb.",
        "table": "+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Symptoms                                                                                                                                                                                                                                  | Treatment                                                                                                                                                                                                                                 | First alternative                                                                                                                                                                                                                         | Second alternative                                                                                                                                                                                                                        |\n+====+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+===========================================================================================================================================================================================================================================+\n|  0 | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       | Lyme disease without focal symptoms                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Erythema migrans and/or Non-focal symptoms                                                                                                                                                                                                | Oral doxycycline: 100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                              | Oral amoxicillin:1Â g 3Â times per day for 21Â days                                                                                                                                                                                       | Oral azithromycinb: 500Â mg daily for 17Â days                                                                                                                                                                                            |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          | Lyme disease with focal symptoms                                                                                                                                                                                                          |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Lyme disease affecting the cranial nerves or peripheral nervous system                                                                                                                                                                    | Oral doxycycline: 100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                              | Oral amoxicillin:1Â g 3Â times per day for 21Â days                                                                                                                                                                                       | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Lyme disease affecting the central nervous system                                                                                                                                                                                         | Intravenous ceftriaxone: 2Â g twice per day or 4Â g once per day for 21Â days (when an oral switch is being considered, use doxycycline)                                                                                                  | Oral doxycycline: 200Â mg twice per day or 400Â mg once per day for 21Â days                                                                                                                                                              | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Lyme disease arthritis                                                                                                                                                                                                                    | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 28Â days                                                                                                                                                               | Oral amoxicillin:1Â g 3Â times per day for 28Â days                                                                                                                                                                                       | Intravenous ceftriaxone:2Â g once per day for 28Â days                                                                                                                                                                                    |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | Acrodermatitis chronica atrophicans                                                                                                                                                                                                       | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 28Â days                                                                                                                                                               | Oral amoxicillin:1Â g 3Â times per day for 28Â days                                                                                                                                                                                       | Intravenous ceftriaxone:2Â g once per day for 28Â days                                                                                                                                                                                    |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | Lyme carditisb                                                                                                                                                                                                                            | Oral doxycycline:100Â mg twice per day or 200Â mg once per day for 21Â days                                                                                                                                                               | Intravenous ceftriaxone:2Â g once per day for 21Â days                                                                                                                                                                                    | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | Lyme carditis and haemodynamically unstableb                                                                                                                                                                                              | Intravenous ceftriaxone:2Â g once per day for 21Â days (when an oral switch is being considered, use doxycycline)                                                                                                                         | â                                                                                                                                                                                                                                       | â                                                                                                                                                                                                                                       |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  9 | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. | a For Lyme disease suspected during pregnancy, use appropriate antibiotics for stage of pregnancy.b Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval. |\n+----+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "yes we have health care and trauma care also in the united states",
        "evidence": "The claim This claim is supported by the fact that the U.S. has a significantly higher mortality rate compared to other nations. We also observe that trauma care is significantly provided in the United States. This is supported by the fact that the U.S. has a comparable homicide rate compared to other nations, but significantly fewer cases of trauma care.",
        "table": "+----+-------+-----------------------------------------------------------------+\n|    | S-1   | Recommendations Relating to Research                            |\n+====+=======+=================================================================+\n|  0 | S-2   | Recommendations Relating to Policy                              |\n+----+-------+-----------------------------------------------------------------+\n|  1 | 1-1   | The U.S. Morbidity Disadvantage                                 |\n+----+-------+-----------------------------------------------------------------+\n|  2 | 1-2   | Disparities in Life Expectancy in the United States             |\n+----+-------+-----------------------------------------------------------------+\n|  3 | 1-3   | How Many Years Behind Is the United States?                     |\n+----+-------+-----------------------------------------------------------------+\n|  4 | 4-1   | Health Care Decommodification                                   |\n+----+-------+-----------------------------------------------------------------+\n|  5 | 4-2   | Case Study: Trauma Care in the United States                    |\n+----+-------+-----------------------------------------------------------------+\n|  6 | 4-3   | Quality of Care: Survey Findings from Commonwealth Fund Surveys |\n+----+-------+-----------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "46 percent of women in 1981 chose to raise their child compared to 60 percent in 1989.\n\n",
        "evidence": "The claim from the claim section is that in 1981, 46 percent of women chose to raise their child compared to 60 percent in 1989. Furthermore, of those who did not raise their child, 60% chose to adopt, a higher number than in 1981.",
        "table": "+----+----------------------+---------------+---------------+\n|    | Unnamed: 0           | 1981          | 1989          |\n+====+======================+===============+===============+\n|  0 | Chose abortion       | 33,577 (49%)  | 29,246 (38%)  |\n+----+----------------------+---------------+---------------+\n|  1 | Chose to raise child | 31,657 (46%)  | 46,234 (60%)  |\n+----+----------------------+---------------+---------------+\n|  2 | Chose adoption       | 3,521 (5%)    | 1,730 (2%)    |\n+----+----------------------+---------------+---------------+\n|  3 | Total                | 68,755 (100%) | 77,210 (100%) |\n+----+----------------------+---------------+---------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Metastatic breast cancer and early breast cancer share the same standard treatment options.",
        "evidence": "They show that patients with metastatic breast cancer and early-stage breast cancer share many of the same standard treatment options. The most common treatment option for patients with metastatic breast cancer is radiation therapy. However, the treatment options for patients with early/localized/operable breast cancer are not as many as they are for patients with other cancers.",
        "table": "+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|    | Stage (TNM Definitions)                                                                                              | Standard Treatment Options                                                                                           |\n+====+======================================================================================================================+======================================================================================================================+\n|  0 | Early/localized/operable breast cancer                                                                               | Surgery with or without radiation therapy                                                                            |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  1 | Early/localized/operable breast cancer                                                                               | Adjuvant therapy—chemotherapy, endocrine therapy, HER2-directed therapy                                              |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  2 | Locoregional recurrent breast cancer                                                                                 | Surgery                                                                                                              |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  3 | Locoregional recurrent breast cancer                                                                                 | Radiation therapy and chemotherapy                                                                                   |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  4 | Metastatic breast cancer                                                                                             | Hormone therapy and/or chemotherapy                                                                                  |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+\n|  5 | T = primary tumor; N = regional lymph node; M = distant metastasis; HER2 = human epidermal growth factor receptor 2. | T = primary tumor; N = regional lymph node; M = distant metastasis; HER2 = human epidermal growth factor receptor 2. |\n+----+----------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Fossil fuels require cheaper capital compared to wind power",
        "evidence": "From this table, we see that renewable energy generally requires cheaper capital compared to coal, natural gas and wind power. In particular, we see that the cost element of renewable energy is 30.4 compared to 11.4 for coal, and 42.7 compared to 6.6 for oil.",
        "table": "+----+----------------+--------------+----------------+----------------+----------------+\n|    | Cost Element   | Technology   | Technology.1   | Technology.2   | Technology.3   |\n+====+================+==============+================+================+================+\n|  0 | Cost Element   | Coal         | Natural Gas    | Wind           | Nuclear        |\n+----+----------------+--------------+----------------+----------------+----------------+\n|  1 | Capital        | 30.4         | 11.4           | 40.7           | 42.7           |\n+----+----------------+--------------+----------------+----------------+----------------+\n|  2 | O&M            | 4.7          | 1.4            | 8.3            | 7.8            |\n+----+----------------+--------------+----------------+----------------+----------------+\n|  3 | Fuel           | 14.5         | 36.9           | 0.0            | 6.6            |\n+----+----------------+--------------+----------------+----------------+----------------+\n|  4 | Totala         | 53.1         | 52.5           | 55.8           | 59.3           |\n+----+----------------+--------------+----------------+----------------+----------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Biden has a total of +1 against Trump in the states of Arizona and Florida.",
        "evidence": "The claim template generalizes to support or oppose Trump in the above fashion. In particular, it shows that Trump has a “President Trump” score of +1 against Biaden in the states of Arizona and Florida, and +4 against Trump in the state of North Carolina.",
        "table": "+----+--------------------------+----------+------------+----------+\n|    | Trumpvs.                 | Biden    | Sanders    | Warren   |\n+====+==========================+==========+============+==========+\n|  0 | Mich.Michigan (n=501)    | Biden +1 | Sanders +3 | Trump +4 |\n+----+--------------------------+----------+------------+----------+\n|  1 | Penn.Pennsylvania (661)  | Biden +1 | Trump +1   | Trump +2 |\n+----+--------------------------+----------+------------+----------+\n|  2 | Wisc.Wisconsin (651)     | Biden +2 | Even       | Trump +2 |\n+----+--------------------------+----------+------------+----------+\n|  3 | Fla.Florida (650)        | Biden +2 | Trump +2   | Trump +4 |\n+----+--------------------------+----------+------------+----------+\n|  4 | Ariz.Arizona (652)       | Biden +2 | Trump +4   | Even     |\n+----+--------------------------+----------+------------+----------+\n|  5 | N.C.North Carolina (651) | Trump +2 | Trump +4   | Trump +4 |\n+----+--------------------------+----------+------------+----------+",
        "label": "REFUTES"
    },
    {
        "claim": "The University of Louisville is title of book ",
        "evidence": "The claim made by the university of louisville is rather strong. It states that the author of the novel, Dwayne D. Cox and William J. Morison, is a Professor of English literature at the University of Louisville.",
        "table": "+----+-----------------+---------------------------------------+\n|    | Title           | The University of Louisville          |\n+====+=================+=======================================+\n|  0 | Author          | Dwayne D. Cox, William J. Morison     |\n+----+-----------------+---------------------------------------+\n|  1 | Publisher       | University Press of Kentucky          |\n+----+-----------------+---------------------------------------+\n|  2 | ISBN            | 0813127270, 9780813127279             |\n+----+-----------------+---------------------------------------+\n|  3 | Subjects        | Education › Higher Education / Higher |\n+----+-----------------+---------------------------------------+\n|  5 | Export Citation | BiBTeX EndNote RefMan                 |\n+----+-----------------+---------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Planned Parenthood and the Clergy Consultation Service on Abortion 19671973 is discussed earlier than Building Public Acceptance 19351957.",
        "evidence": "The claim that Planned Parenthood and the clergy consultation service on Abortion 19671973 is discussed earlier than building public acceptance 19351957 is supported by the data.",
        "table": "+----+-----------------------------------------------------------------------------+-----+\n|    | Introduction                                                                |   1 |\n+====+=============================================================================+=====+\n|  1 | The Concept of Sacred Work                                                  |   5 |\n+----+-----------------------------------------------------------------------------+-----+\n|  3 | Margaret Sanger Recruits the Clergy                                         |  27 |\n+----+-----------------------------------------------------------------------------+-----+\n|  5 | Building Public Acceptance 19351957                                         |  47 |\n+----+-----------------------------------------------------------------------------+-----+\n|  7 | The 1958 Battle over the New York City Hospitals                            |  72 |\n+----+-----------------------------------------------------------------------------+-----+\n|  9 | Sacred Work in Baltimore 19611965                                           |  88 |\n+----+-----------------------------------------------------------------------------+-----+\n| 11 | Victories in the Sixties                                                    | 104 |\n+----+-----------------------------------------------------------------------------+-----+\n| 13 | Planned Parenthood and the Clergy Consultation Service on Abortion 19671973 | 121 |\n+----+-----------------------------------------------------------------------------+-----+",
        "label": "REFUTES"
    },
    {
        "claim": "Dec 12, 1985 was debate about gun violence ",
        "evidence": "In this section, we present the experiments and results on the Gun violence dataset to demonstrate the effectiveness of our approach. On December 12, 1985, the Gun Violence database was the dominant topic in the news. The Gun Violence database contains 5, more than 2,000 articles on topics such as terrorism, mental health, and drug addiction. It is here that we first observe that the gun violence topic was a major topic in the news. Over 12,000 articles were annotated by community members.",
        "table": "",
        "label": "SUPPORTS"
    },
    {
        "claim": "increased adoption family and relationships ",
        "evidence": "The claim makes use of information about adoptive family and relationships. We use the idea proposed by \\citeauthorrichardmintzer:2015: Long \\shortciterichardmintzer:2015: Long dataset for this experiment. Each document is a collection of triples describing a real-world adoption scenario. The text of the “excerpt” is the first sentence of the document, and each triple is the text of the paragraph that follows. We removed the punctuation, and the HTML file was removed. The introduction, introduction, and conclusion of each document are the same. The main conclusion from this experiment is that it is essential to adopt, foster, and foster a family together.",
        "table": "+----+-----------------+---------------------------------------------------------------------------------------------+\n|    | Title           | Yes, You Can Adopt!: A Comprehensive Guide to Adoption                                      |\n+====+=================+=============================================================================================+\n|  0 | Author          | Richard Mintzer                                                                             |\n+----+-----------------+---------------------------------------------------------------------------------------------+\n|  1 | Publisher       | Carroll & Graf, 2003                                                                        |\n+----+-----------------+---------------------------------------------------------------------------------------------+\n|  2 | ISBN            | 0786710357, 9780786710355                                                                   |\n+----+-----------------+---------------------------------------------------------------------------------------------+\n|  3 | Length          | 338 pages                                                                                   |\n+----+-----------------+---------------------------------------------------------------------------------------------+\n|  4 | Subjects        | Family & Relationships › Adoption & Fostering Family & Relationships / Adoption & Fostering |\n+----+-----------------+---------------------------------------------------------------------------------------------+\n|  6 | Export Citation | BiBTeX EndNote RefMan                                                                       |\n+----+-----------------+---------------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "United Kingdom has the highest number of PCT ABOVENORMAL as of +67%",
        "evidence": "The claim made by the United Kingdom has a higher percentage of abovenormal than other countries. As of +67%, the United Kingdom has 53300 excessdeaths, which is more than Spain's 60% and Belgium's 50%. The amount of deaths in the two countries increase from 5300 in Belgium to over 53300 in the United Kingdom.",
        "table": "+----+----------------+-------------------+----------------+-------------------+\n|    | COUNTRY        | PCT ABOVENORMAL   | EXCESSDEATHS   | TIME PERIOD       |\n+====+================+===================+================+===================+\n|  0 | United Kingdom | +67%              | 53300          | Mar. 14 - May 1   |\n+----+----------------+-------------------+----------------+-------------------+\n|  1 | Spain          | +60%              | 31500          | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  2 | Belgium        | +50%              | 5300           | Mar. 16 - Apr. 19 |\n+----+----------------+-------------------+----------------+-------------------+\n|  3 | Netherlands    | +50%              | 8700           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n|  4 | Italy          | +49%              | 24600          | March             |\n+----+----------------+-------------------+----------------+-------------------+\n|  5 | France         | +44%              | 28500          | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n|  6 | Sweden         | +27%              | 3300           | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  7 | Switzerland    | +24%              | 2000           | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  8 | Portugal       | +15%              | 1300           | Mar. 16 - Apr. 12 |\n+----+----------------+-------------------+----------------+-------------------+\n|  9 | Austria        | +11%              | 1000           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n| 10 | Germany        | +6%               | 4100           | Mar. 16 - Apr. 12 |\n+----+----------------+-------------------+----------------+-------------------+\n| 11 | Denmark        | +5%               | 300            | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n| 12 | Norway         | +0%               | <100           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n| 13 | Finland        | +0%               | <100           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "J&J joins development of blood test that can spot 1 cancer cell in a billion healthy ones\n\n",
        "evidence": "The table shows that the proposed method can spot cancer cell in a billion healthy people’s blood only after training on a small number of diseases and infections. The number of infections that can be detected by the method is reduced from 46 to 1.9 million for the most common disease group (Tuberculosis) and from 19 million to 1.0 million for malaria. There are also zero positive tags for a number of other groups.",
        "table": "+----+---------------------------------+--------------------------+\n|    | Disorder                        | Number of Participants   |\n+====+=================================+==========================+\n|  0 | Cancer                          | 45                       |\n+----+---------------------------------+--------------------------+\n|  1 | HIV                             | 46                       |\n+----+---------------------------------+--------------------------+\n|  2 | Tuberculosis                    | 8                        |\n+----+---------------------------------+--------------------------+\n|  3 | Sickle cell disease             | 19                       |\n+----+---------------------------------+--------------------------+\n|  4 | Acute kidney failure            | 1                        |\n+----+---------------------------------+--------------------------+\n|  5 | Heart failure                   | 4                        |\n+----+---------------------------------+--------------------------+\n|  6 | Malaria                         | 1                        |\n+----+---------------------------------+--------------------------+\n|  7 | Anemia                          | 3                        |\n+----+---------------------------------+--------------------------+\n|  8 | Immune thrombocytopenic purpura | 1                        |\n+----+---------------------------------+--------------------------+\n|  9 | No major disease                | 25                       |\n+----+---------------------------------+--------------------------+\n| 10 | Dataset                         | Average Blood Hgb ()     |\n+----+---------------------------------+--------------------------+\n| 11 | Training dataset ()             | 12.65 ()                 |\n+----+---------------------------------+--------------------------+\n| 12 | Validation dataset ()           | 11.06 ()                 |\n+----+---------------------------------+--------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "in prolonging life, heart stents were found to be non effective",
        "evidence": "In order to investigate the claim that a heart stent increases the prolonging life of patients, we ran a set of experiments where we replaced the heart stents with other stents. We also found that these heart stents were not effective in prolonging life.",
        "table": "",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The book \"Amnesty International, the Human Rights Story\" is 128 pages long.",
        "evidence": "The claim text is 128 pages long and was produced by Jonathan Power, the author of the Amnesty International, the human rights story. It is illustrated by illustrated features and was published in 1981 by Mcgraw-Hill. The original English text was digitized and provided by the University of Michigan’s Computation and Information Retrieval Program. However, it is missing its English title. To retrieve the title, we need the English title of the original manuscript. We found it in the International Corpus of Political Science and Technology (ICTP) At last, we have the English title of the original manuscript. It is written by Jonathan Power and it is illustrated by illustrated features. It is available at http://www.nist.gov/citeauthor/corr/abs-1809-10683.html.",
        "table": "+----+-----------------+---------------------------------------------------------+\n|    | Title           | Amnesty International, the Human Rights Story           |\n+====+=================+=========================================================+\n|  0 | Author          | Jonathan Power                                          |\n+----+-----------------+---------------------------------------------------------+\n|  1 | Edition         | illustrated                                             |\n+----+-----------------+---------------------------------------------------------+\n|  2 | Publisher       | McGraw-Hill, 1981                                       |\n+----+-----------------+---------------------------------------------------------+\n|  3 | Original from   | the University of Michigan                              |\n+----+-----------------+---------------------------------------------------------+\n|  4 | Digitized       | 1 Jun 2011                                              |\n+----+-----------------+---------------------------------------------------------+\n|  5 | ISBN            | 0070505977, 9780070505971                               |\n+----+-----------------+---------------------------------------------------------+\n|  6 | Length          | 128 pages                                               |\n+----+-----------------+---------------------------------------------------------+\n|  7 | Subjects        | Political Science › General Political Science / General |\n+----+-----------------+---------------------------------------------------------+\n|  9 | Export Citation | BiBTeX EndNote RefMan                                   |\n+----+-----------------+---------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Change in the OASDI 75-Year Actuarial Balance Since the 2019 Report, Based on Intermediate Assumptions in the methods and programmatic data is 02 ,  02 ,  00,",
        "evidence": "The actuarial balance, shown in the 2019 report, is far from perfect. In fact, there is a large loss of -3.21 in the actuarial balance compared to thebalance in the 2020 report. It is also interesting to note that prior to the change in actuarial balance, all methods and programmatic data had similar trends in their predictions. Forward error reductions ranged from 0.03 to 0.05 in value for methods and 0.1 for programmatic data. The largest change in the actuarial balance since the 2019 report happened due to the change in: (i) demographic data and assumptions; (ii) economic data and assumptions; (iii) disability data and assumptions; and (iv) actuarial balance due to the availability of new data.",
        "table": "+----+-------------------------------------------------+--------+--------+---------+\n|    | Item                                            |   OASI |     DI |   OASDI |\n+====+=================================================+========+========+=========+\n|  0 | Actuarial balance shown in the 2019 Report      |  -2.67 |  -0.12 |   -2.78 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  1 | Changes in actuarial balance due to changes in: | nan    | nan    |  nan    |\n+----+-------------------------------------------------+--------+--------+---------+\n|  2 | Valuation period                                |  -0.05 |  -0.01 |   -0.05 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  3 | Demographic data and assumptions                |  -0.12 |   0    |   -0.13 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  4 | Economic data and assumptions                   |  -0.16 |  -0.02 |   -0.18 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  5 | Disability data and assumptions                 |  -0.01 |   0.06 |    0.05 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  6 | Methods and programmatic data                   |  -0.02 |   0.02 |    0    |\n+----+-------------------------------------------------+--------+--------+---------+\n|  7 | Total change in actuarial balance               |  -0.47 |   0.05 |   -0.43 |\n+----+-------------------------------------------------+--------+--------+---------+\n|  8 | Actuarial balance shown in the 2020 Report      |  -3.14 |  -0.07 |   -3.21 |\n+----+-------------------------------------------------+--------+--------+---------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "A diagnosis of diabetes occurs when a person's A1C percentage is lower than normal.",
        "evidence": "The claim template shows that a diagnosis of diabetes occurs when: (i) a person's A1c percentage is lower than normal than normal, (ii) they have Diabetes and (iii) the blood glucose tolerance test (GTT) score is 200 or higher than normal. We consider these results as supporting the claim template. Additionally, we believe the higher the blood glucose tolerance score is, the stronger the diagnosis is, and then the lower the A1c percentage is.",
        "table": "+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|    | Diagnosis   | A1C (percent)   | Fasting plasma glucose (FPG)a   | Oral glucose tolerance test (OGTT)ab   | Random plasma glucose test (RPG)a   |\n+====+=============+=================+=================================+========================================+=====================================+\n|  0 | Normal      | below 5.7       | 99 or below                     | 139 or below                           | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  1 | Prediabetes | 5.7 to 6.4      | 100 to 125                      | 140 to 199                             | nan                                 |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+\n|  2 | Diabetes    | 6.5 or above    | 126 or above                    | 200 or above                           | 200 or above                        |\n+----+-------------+-----------------+---------------------------------+----------------------------------------+-------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The fiscal year 2017 proposed Total school funding TPP Replacement is the highest amount in the last 8 years.",
        "evidence": "The table shows that the amount of school funding tpp replacement increased in the last 8 years. The highest amount was proposed in the year of 2016 by Kasich, which increased the school funding tpp replacement from $8.0 to $8.2.",
        "table": "+----+--------------------+------------+----------------------------------------+\n|    | Year               | Governor   | Total school funding TPP Replacement   |\n+====+====================+============+========================================+\n|  0 | FY 2010            | Strickland | $7.9                                   |\n+----+--------------------+------------+----------------------------------------+\n|  1 | FY 2011            | Strickland | $7.9                                   |\n+----+--------------------+------------+----------------------------------------+\n|  2 | FY 2012            | Kasich     | $7.3                                   |\n+----+--------------------+------------+----------------------------------------+\n|  3 | FY 2013            | Kasich     | $7.1                                   |\n+----+--------------------+------------+----------------------------------------+\n|  4 | FY 2014            | Kasich     | $7.4                                   |\n+----+--------------------+------------+----------------------------------------+\n|  5 | FY 2015            | Kasich     | $7.8                                   |\n+----+--------------------+------------+----------------------------------------+\n|  6 | FY 2016 (proposed) | Kasich     | $8.0                                   |\n+----+--------------------+------------+----------------------------------------+\n|  7 | FY 2017 (proposed) | Kasich     | $8.2                                   |\n+----+--------------------+------------+----------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The Canadian flag was found to be more important in 1997 than in 2007.",
        "evidence": "The claim that the Canadian flag was found to be more important in 1997 than in 2007 is supported by the differences in the number of articles that were found to be important in 1997, 2000, and 2007. For instance, in 1997, the National Health Care System was ranked highest, followed by the Charter of Rights and Freedoms, then the Canadian flag, and taken separately in 2000 and 2007. In comparison, the National National Anthem, the National Ballet of Canada, and the Canadian literature and music were found to be the most important in 1997, 2000, and 2007, respectively.",
        "table": "+----+--------------------------------+--------+--------+--------+--------+\n|    | Option                         | 1997   |   2000 |   2003 |   2007 |\n+====+================================+========+========+========+========+\n|  0 | Health care system             | 89     |     80 |     78 |     83 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  1 | Charter of Rights and Freedoms | 72     |     76 |     71 |     72 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  2 | Canadian flag                  | 70     |     73 |     68 |     69 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  3 | National parks                 | 71     |     73 |     62 |     63 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  4 | National anthem                | 67     |     65 |     60 |     62 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  5 | Historic sites                 | 65     |     67 |     53 |     58 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  6 | RCMP                           | 60     |     60 |     57 |     52 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  7 | Multiculturalism               | 37     |     54 |     47 |     50 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  8 | Canadian literature and music  | 49     |     58 |     46 |     46 |\n+----+--------------------------------+--------+--------+--------+--------+\n|  9 | Bilingualism                   | 37     |     45 |     38 |     40 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 10 | CBC                            | 39     |     37 |     37 |     39 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 11 | Hockey                         | 30     |     35 |     40 |     37 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 12 | National capital Ottawa        | â    |     43 |     36 |     33 |\n+----+--------------------------------+--------+--------+--------+--------+\n| 13 | The Queen                      | 14     |     16 |     16 |     16 |\n+----+--------------------------------+--------+--------+--------+--------+",
        "label": "REFUTES"
    },
    {
        "claim": "Uganda clears three experimental Ebola treatments, watches for spread.",
        "evidence": "The claim that using three experimental Ebola treatments, i.e. “Understanding EBM”, “Ebola” and “Combatting EBM” was the most effective in detecting the disease was not effective. This is not surprising, since these are concepts that are well-suited for detecting the disease. It is also interesting to note that some themes were not effective in identifying the disease, such as “There is no evidence of Ebola in our training set”, “The Situation in Uganda has no Ebola watchers”, and “The Situation in Uganda has no Ebola watchers”.",
        "table": "+----+----------------------------------+-----------------+---------------+\n|    | Theme                            |   No. of tweets | % of tweets   |\n+====+==================================+=================+===============+\n|  0 | Understanding Ebola              |             205 | 35.65         |\n+----+----------------------------------+-----------------+---------------+\n|  1 | Etiology of Ebola                |             148 | 25.74         |\n+----+----------------------------------+-----------------+---------------+\n|  2 | Spread and Scope                 |              57 | 9.91          |\n+----+----------------------------------+-----------------+---------------+\n|  3 | Combatting Ebola                 |             247 | 42.96         |\n+----+----------------------------------+-----------------+---------------+\n|  4 | Policy                           |             106 | 18.43         |\n+----+----------------------------------+-----------------+---------------+\n|  5 | Environment                      |              92 | 16.00         |\n+----+----------------------------------+-----------------+---------------+\n|  6 | Individual Behavior              |              49 | 8.52          |\n+----+----------------------------------+-----------------+---------------+\n|  7 | Managing Information about Ebola |             123 | 21.39         |\n+----+----------------------------------+-----------------+---------------+\n|  8 | Fear/Anxiety                     |              60 | 10.43         |\n+----+----------------------------------+-----------------+---------------+\n|  9 | CDC                              |              48 | 8.35          |\n+----+----------------------------------+-----------------+---------------+\n| 10 | Misinformation                   |              15 | 2.61          |\n+----+----------------------------------+-----------------+---------------+\n| 11 | Total                            |             575 | Â             |\n+----+----------------------------------+-----------------+---------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Region 1 saw an elevated out-patient ILI during this current week.",
        "evidence": "The HHS Surveillance Region of Region 1 saw an elevated out-patient ICD during this current week. During this week, there was an an elevated number of jurisdictions reporting both regional and widespread activity. The region also had the highest number of pediatric deaths, with 142 compared to the 142 of the nation.",
        "table": "+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|    | HHS Surveillance Regions*   | Data for current week   | Data for current week.1   | Data for current week.2                                             | Data cumulative for the season since August 30, 2009 (Week 35)   | Data cumulative for the season since August 30, 2009 (Week 35).1   | Data cumulative for the season since August 30, 2009 (Week 35).2   | Data cumulative for the season since August 30, 2009 (Week 35).3   | Data cumulative for the season since August 30, 2009 (Week 35).4   | Data cumulative for the season since August 30, 2009 (Week 35).5   | Data cumulative for the season since August 30, 2009 (Week 35).6   |\n+====+=============================+=========================+===========================+=====================================================================+==================================================================+====================================================================+====================================================================+====================================================================+====================================================================+====================================================================+====================================================================+\n|  0 | HHS Surveillance Regions*   | Out-patient ILIâ       | % positive for fluâ¡     | Number of jurisdictions reporting regional or widespread activityÂ§ | A (H1)                                                           | A (H3)                                                             | 2009 A (H1N1)                                                      | A (unable to sub-type)Â¥                                           | A(Subtyping not performed)                                         | B                                                                  | Pediatric Deaths                                                   |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  1 | Nation                      | Elevated                | 28.8 %                    | 51 of 54                                                            | 20                                                               | 36                                                                 | 46920                                                              | 371                                                                | 16847                                                              | 142                                                                | 138                                                                |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  2 | Region 1                    | Elevated                | 38.0 %                    | 6 of 6                                                              | 5                                                                | 2                                                                  | 2327                                                               | 8                                                                  | 338                                                                | 9                                                                  | 0                                                                  |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  3 | Region 2                    | Elevated                | 29.4 %                    | 3 of 4                                                              | 1                                                                | 5                                                                  | 623                                                                | 0                                                                  | 766                                                                | 3                                                                  | 4                                                                  |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  4 | Region 3                    | Elevated                | 51.8 %                    | 5 of 6                                                              | 2                                                                | 6                                                                  | 9042                                                               | 20                                                                 | 1232                                                               | 13                                                                 | 9                                                                  |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  5 | Region 4                    | Elevated                | 21.5 %                    | 8 of 8                                                              | 0                                                                | 3                                                                  | 4080                                                               | 82                                                                 | 3658                                                               | 24                                                                 | 28                                                                 |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  6 | Region 5                    | Elevated                | 41.9 %                    | 6 of 6                                                              | 4                                                                | 12                                                                 | 7140                                                               | 77                                                                 | 1166                                                               | 10                                                                 | 14                                                                 |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  7 | Region 6                    | Elevated                | 13.3 %                    | 5 of 5                                                              | 0                                                                | 3                                                                  | 2181                                                               | 4                                                                  | 4237                                                               | 26                                                                 | 48                                                                 |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  8 | Region 7                    | Elevated                | 28.8 %                    | 4 of 4                                                              | 4                                                                | 1                                                                  | 3049                                                               | 145                                                                | 885                                                                | 3                                                                  | 2                                                                  |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n|  9 | Region 8                    | Elevated                | 29.5 %                    | 6 of 6                                                              | 2                                                                | 0                                                                  | 8640                                                               | 0                                                                  | 3528                                                               | 46                                                                 | 11                                                                 |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n| 10 | Region 9                    | Elevated                | 21.6 %                    | 4 of 5                                                              | 0                                                                | 3                                                                  | 6011                                                               | 25                                                                 | 865                                                                | 4                                                                  | 14                                                                 |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+\n| 11 | Region 10                   | Elevated                | 41.7 %                    | 4 of 4                                                              | 2                                                                | 1                                                                  | 3827                                                               | 10                                                                 | 172                                                                | 4                                                                  | 8                                                                  |\n+----+-----------------------------+-------------------------+---------------------------+---------------------------------------------------------------------+------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "One parent with heart attack 50 years of age of CI was 1.67(1,551.81)",
        "evidence": "The claim template extracted from the claim template shows that both parents with heart attack are significantly better than the one parent with heart attack and both parents with heart attack <50 years of age. One parent has heart attack and one parent has heart attack, and they are both significantly better than the one parent (1.08 times larger than the other) Therefore, we assume that both parents with heart attack are significantly better than the one parent with heart attack.",
        "table": "+----+---------------------------------------------------+---------------------+\n|    | Unnamed: 0                                        | OR (95% CI)         |\n+====+===================================================+=====================+\n|  0 | No family history                                 | 1.00                |\n+----+---------------------------------------------------+---------------------+\n|  1 | One parent with heart attack â¥50 y of age       | 1.67 (1.55â1.81)  |\n+----+---------------------------------------------------+---------------------+\n|  2 | One parent with heart attack <50 y of age         | 2.36 (1.89â2.95)  |\n+----+---------------------------------------------------+---------------------+\n|  3 | Both parents with heart attack â¥50 y of age     | 2.90 (2.30â3.66)  |\n+----+---------------------------------------------------+---------------------+\n|  4 | Both parents with heart attack, one <50 y of age  | 3.26 (1.72â6.18)  |\n+----+---------------------------------------------------+---------------------+\n|  5 | Both parents with heart attack, both <50 y of age | 6.56 (1.39â30.95) |\n+----+---------------------------------------------------+---------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The people affected by TB causes more Harm to the people with HIV infection rather than the people who are using Alcohol.",
        "evidence": "The table shows that HIV infection appears to be a more likely risk factor for active Tb compared to both Alcohol use and smoking. This is consistent with the fact that even without using alcohol, the people who suffer from HIV infection are more likely to suffer from active Tb.",
        "table": "+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|    | Unnamed: 0                   | Unnamed: 1                                   | Unnamed: 2                                                            | Unnamed: 3                                |\n+====+==============================+==============================================+=======================================================================+===========================================+\n|  0 | Risk factor (reference)      | Relative risk for active TB disease (range)a | Weighted prevalence, total population, 22âTB high burden countriesb | Population attributable fraction (range)c |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  2 | HIV infection                | 8.3 (6.1â10.8)                             | 1.1%                                                                  | 7.3% (5.2â6.9)                          |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  3 | Malnutrition                 | 4.0 (2.0â6.0)                              | 17.2%                                                                 | 34.1% (14.7â46.3)                       |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  4 | Diabetes                     | 3.0 (1.5â7.8)                              | 3.4%                                                                  | 6.3% (1.6â18.6)                         |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  5 | Alcohol useâ>â40âg/day | 2.9 (1.9â4.6)                              | 7.9%                                                                  | 13.1% (6.7â22.2)                        |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  6 | Active smoking               | 2.6 (1.6â4.3)                              | 18.2%                                                                 | 22.7% (9.9â37.4)                        |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+\n|  7 | Indoor pollution             | 1.5 (1.2â3.2)                              | 71.1%                                                                 | 26.2% (12.4â61.0)                       |\n+----+------------------------------+----------------------------------------------+-----------------------------------------------------------------------+-------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The almond tree that it native from central Asia has yellow flowers",
        "evidence": "The claim made by the table indicates that the almond tree that it native from Central Asia has yellow flowers.",
        "table": "+----+-----------------+--------------------------+\n|    | Common Name     | Almond tree              |\n+====+=================+==========================+\n|  0 | Scientific Name | Prunus amygdalus         |\n+----+-----------------+--------------------------+\n|  1 | Plant Type      | Hardy annual             |\n+----+-----------------+--------------------------+\n|  2 | Mature Size     | 13-33 ft tall            |\n+----+-----------------+--------------------------+\n|  3 | Sun Exposure    | Full sun                 |\n+----+-----------------+--------------------------+\n|  4 | Soil Type       | Average and well-drained |\n+----+-----------------+--------------------------+\n|  5 | Soil pH         | 5.5 to 6.0               |\n+----+-----------------+--------------------------+\n|  6 | Bloom Time      | Early Spring             |\n+----+-----------------+--------------------------+\n|  7 | Flower Color    | white to pale pink       |\n+----+-----------------+--------------------------+\n|  8 | Hardiness Zones | 5 to 9                   |\n+----+-----------------+--------------------------+\n|  9 | Native Area     | Central Asia             |\n+----+-----------------+--------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "The Guggenheim Museum planned to host a Chinese art exhibition that included three installations condemned as cruel to animals.",
        "evidence": "The Guggenheim Museum planned to host a Chinese art exhibition that included three installations condemned as cruel to animals. The text of the claim was collected from the online publication “The History of China Understanding China”, “Kenneth Pletcher”, and “Isbirch”. The exhibition’s title does not contain information about the condemnation of the three installations. Instead, the text is dedicated to the subjects, i.e. “The Guggenheim Museum planned to host a Chinese art exhibition that included three installations condemned as cruel to animals.” Throughout the exhibition, the text of the claim was collected from online publication “Isbirch” and “Kenneth Pletcher”.",
        "table": "+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|    | Title           | The History of China Understanding China                                                                |\n+====+=================+=========================================================================================================+\n|  0 | Author          | Britannica Educational Publishing                                                                       |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  1 | Editor          | Kenneth Pletcher                                                                                        |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  2 | Publisher       | Britannica Educational Publishing, 2010                                                                 |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  3 | ISBN            | 161530181X, 9781615301812                                                                               |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  4 | Length          | 362 pages                                                                                               |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  5 | Subjects        | History › Asia › China History / Asia / China History / World Juvenile Nonfiction / Reference / General |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                                                                   |\n+----+-----------------+---------------------------------------------------------------------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Confectionary products has Contamination range 0.3945.9 (mg/kg) with 200 possible products.",
        "evidence": "From the table information, we can see that there are 200 possible products in the Contamination Range 0.3 to 0.9. These products include various types of confectionary products. They include powdered infant formula, liquid milk and yogurt, powdered milk products, frozen dairy products, snack foods, frozen processed foods, and protein powders and liquid eggs.",
        "table": "+----+-----------------------------------+-------------------------------+----------------------------+\n|    | Product category                  | Contamination range (mg/kg)   |   No. of positive products |\n+====+===================================+===============================+============================+\n|  0 | Powdered infant formula           | 0.1â2,563                   |                         22 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  1 | Liquid milk and yogurt            | 0.6â648                     |                         52 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  2 | Powdered milk products            | < 1â6,196                   |                         56 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  3 | Frozen dairy products             | 4.4â60.8                    |                          6 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  4 | Confectionary products            | 0.3â945.9                   |                        200 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  5 | Snack foods                       | 0.5â54                      |                         17 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  6 | Frozen processed foods            | 0.5â41                      |                         20 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  7 | Ammonium bicarbonate              | 33.4â508                    |                          4 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  8 | Nondairy creamer                  | 1.5â6,694                   |                          2 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n|  9 | Protein powder                    | 3.8â8.3                     |                          2 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n| 10 | Dried egg powders and liquid eggs | 0.1â5                       |                          8 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n| 11 | Whole eggs                        | 2.9â4.7                     |                          4 |\n+----+-----------------------------------+-------------------------------+----------------------------+\n| 12 | Animal feed                       | 3.3â21,000                  |                          7 |\n+----+-----------------------------------+-------------------------------+----------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Symptomatic attack rate, community on scale 1 is 10 percent",
        "evidence": "We used the data from the MIMIC-III complaint dataset to construct some basic measures of symptmissibility and clinical severity. For measures of transmissibility, we only use the five dimensions (2, 3, 4, 5, 7) of the MIMIC-III scale. The measures of transmissibility and clinical severity are consistent with the standard MIMIC-III scale. Out of the 1,000 observations, we discarded the ones with less than 10% symptomatic attack rate in the community, school, and workplace. For clinical severity, we only use the following dimensions (1, 3, 4, 5, 7) of the MIMIC-III scale: 1, 2, 3, 4, 5, 7. (11%–15% of the patients in the community, 6%–10% in the school, 22%–25% in the workplace, and 6%–10% in the household).",
        "table": "+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|    | Measures of transmissibility and clinical severity              | Scale                            | Scale.1                          | Scale.2                          | Scale.3                          | Scale.4                          | Scale.5                          | Scale.6                          |\n+====+=================================================================+==================================+==================================+==================================+==================================+==================================+==================================+==================================+\n|  0 | Measures of transmissibility and clinical severity              | 1                                | 2                                | 3                                | 4                                | 5                                | 6                                | 7                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  1 | Transmissibility (scale of 1–5)                                 | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  | Transmissibility (scale of 1–5)  |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  2 | Symptomatic attack rate, community                              | ≤10%                             | 11%–15%                          | 16%–20%                          | 21%–24%                          | ≥25%                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  3 | Symptomatic attack rate, school                                 | ≤20%                             | 21%–25%                          | 26%–30%                          | 31%–35%                          | ≥36%                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  4 | Symptomatic attack rate, workplace                              | ≤10%                             | 11%–15%                          | 16%–20%                          | 21%–24%                          | ≥25%                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  5 | Household secondary attack rate, symptomatic                    | ≤5%                              | 6%–10%                           | 11%–15%                          | 16%–20%                          | ≥21%                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  6 | R0: basic reproductive number                                   | ≤1.1                             | 1.2–1.3                          | 1.4–1.5                          | 1.6–1.7                          | ≥1.8                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  7 | Peak percentage of outpatient visits for influenza-like illness | 1%–3%                            | 4%–6%                            | 7%–9%                            | 10%–12%                          | ≥13%                             | —                                | —                                |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  8 | Clinical severity (scale of 1–7)                                | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) | Clinical severity (scale of 1–7) |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n|  9 | Case-fatality ratio                                             | <0.02%                           | 0.02%–0.05%                      | 0.05%–0.1%                       | 0.1%–0.25%                       | 0.25%–0.5%                       | 0.5%–1%                          | >1%                              |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n| 10 | Case-hospitalization ratio                                      | <0.5%                            | 0.5%–0.8%                        | 0.8%–1.5%                        | 1.5%–3%                          | 3%–5%                            | 5%–7%                            | >7%                              |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+\n| 11 | Deaths-hospitalizations ratio                                   | ≤3%                              | 4%–6%                            | 7%–9%                            | 10%–12%                          | 13%–15%                          | 16%–18%                          | >18%                             |\n+----+-----------------------------------------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+----------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Insight: FDA warned PIP on breast implant safety in 2000.",
        "evidence": "In this section we provide some additional insight into the work of the FDA, as well as some additional details that were mentioned in the main paper. In 2000, the FDA published a “Pipeline” summary of a set of safety studies on breast implants. The conclusions summarized by the FDA were “that silicone breast implants generally are not harmful”, “that they do not increase recall”, and “that performing mammograms and other breast imaging in women with implants is generally” good. However, they did not provide any clear guidelines or “best practice” in regards to the placement of the devices.",
        "table": "+----+--------------------------------------------------------------------+----------------+\n|    | Table of Contents                                                  | skim chapter   |\n+====+====================================================================+================+\n|  0 | Front Matter                                                       | i-iv           |\n+----+--------------------------------------------------------------------+----------------+\n|  1 | Information for Women About the Safety of Silicone Breast Implants | 1-19           |\n+----+--------------------------------------------------------------------+----------------+\n|  2 | Conclusions                                                        | 20-20          |\n+----+--------------------------------------------------------------------+----------------+\n|  3 | Mammograms and Other Breast Imaging in Women with Implants         | 21-23          |\n+----+--------------------------------------------------------------------+----------------+\n|  4 | Recommendations                                                    | 24-25          |\n+----+--------------------------------------------------------------------+----------------+\n|  5 | A History of Implants                                              | 26-30          |\n+----+--------------------------------------------------------------------+----------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The current price of natural gas oil is five times greater than the price of WTI crude oil.",
        "evidence": "The claim made by GMT is that the price of natural gas oil is five times greater than the price of WTI crude oil. In the news at this time, natural gas prices are hovering around $3.36 dollars per US gallon. This is a three times higher than the price of petroleum oil.",
        "table": "+----+---------------------------+---------------------------+---------------------------+---------------------------+\n|    | Energy Prices             | Energy Prices.1           | Energy Prices.2           | Unnamed: 3                |\n+====+===========================+===========================+===========================+===========================+\n|  0 | INDEX                     | PRICE                     | %                         | TIME(GMT)                 |\n+----+---------------------------+---------------------------+---------------------------+---------------------------+\n|  1 | WTI Crude                 | $73.88                    | +1.41                     | 2:42 PM                   |\n+----+---------------------------+---------------------------+---------------------------+---------------------------+\n|  2 | Brent Crude               | $75.76                    | +1.27                     | 2:40 PM                   |\n+----+---------------------------+---------------------------+---------------------------+---------------------------+\n|  3 | Natural Gas               | $3.36                     | +3.07                     | 2:42 PM                   |\n+----+---------------------------+---------------------------+---------------------------+---------------------------+\n|  4 | 23 June 2021 02:52 PM GMT | 23 June 2021 02:52 PM GMT | 23 June 2021 02:52 PM GMT | 23 June 2021 02:52 PM GMT |\n+----+---------------------------+---------------------------+---------------------------+---------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Japan health ministry projects 400,000 deaths without virus containment measures: media.",
        "evidence": "The claim makes use of information from the Japanese Health Ministry, which projects 400,000 deaths without any measures. We will refer to this figure as R0. It shows that there is little underlying population immunity (≥20%) available in the population, with the exception of attack rate of school and community. And when we look at the clinical severity, we see that influenza-like illness has a low overall symptom score of 1–1.7 and only a few are of extreme severity. While the number of deaths from influenza-like illness in Japan is very rare, the upper bound for the case-fatality ratio and the upper bound for the deaths-hospitalization ratio are also relatively low. That is, less than 10% people need ICU visits for influenza-like illness and more than 30% people need to go to the ER for the same.",
        "table": "+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|    | Measures of transmissibility and clinical severity                         | Scale                                           | Scale.1                                      |\n+====+============================================================================+=================================================+==============================================+\n|  0 | Measures of transmissibility and clinical severity                         | Low to moderate                                 | Moderate to high                             |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  1 | Transmissibility                                                           | Transmissibility                                | Transmissibility                             |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  2 | Secondary attack rate, household                                           | ≤20%                                            | >20%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  3 | Attack rate, school or university                                          | ≤30%                                            | >30%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  4 | Attack rate, workplace or community                                        | ≤20%                                            | >20%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  5 | R0: basic reproductive number                                              | 1–1.7                                           | ≥1.8                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  6 | Underlying population immunity                                             | Some underlying population immunity             | Little to no underlying population immunity  |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  7 | Emergency department or other outpatient visits for influenza-like illness | <10%                                            | ≥10%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  8 | Virologic characterization                                                 | Genetic markers for transmissibility absent     | Genetic markers for transmissibility present |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n|  9 | Animal models, transmission studies                                        | Less efficient or similar to seasonal influenza | More efficient than seasonal influenza       |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 10 | Clinical severity                                                          | Clinical severity                               | Clinical severity                            |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 11 | Upper bound of case-fatality ratio                                         | <1%                                             | ≥1%                                          |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 12 | Upper bound of case-hospitalization ratio                                  | <10%                                            | ≥10%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 13 | Deaths-hospitalizations ratio                                              | <10%                                            | ≥10%                                         |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 14 | Virologic characterization                                                 | Genetic markers for virulence absent            | Genetic markers for virulence present        |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+\n| 15 | Animal models, evaluation of morbidity and mortality                       | Less virulent or similar to seasonal influenza  | More virulent than seasonal influenza        |\n+----+----------------------------------------------------------------------------+-------------------------------------------------+----------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Dryer sheets permeated with fabric softener contain at least seven dangerous toxic chemicals.",
        "evidence": "The claim alleges that dryer sheets permeated with detergent containing organic esters of phosphoric acid contain at least seven dangerous toxic chemicals. The number of toxic chemicals in the materials is listed in the table: phosphoric acid, verite, proffitt, mccarty, papalos, chiddix, and dickey.",
        "table": "+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|    |   3957661 | Fabric softening laundry detergent containing organic esters of phosphoric acid   | 1976-05-18   | Verite         | 252/8.9    |\n+====+===========+===================================================================================+==============+================+============+\n|  0 |   3622378 | FIBERS WITH ANIONIC-CATIONIC FINISH                                               | 1971-11-23   | Proffitt       | 81/156     |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  1 |   3591405 | nan                                                                               | 1971-07-06   | McCarty        | 252/8.6    |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  2 |   3346670 | Method for the preparation of phosphate esters                                    | 1967-10-10   | Papalos        | 252/DIG.17 |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  3 |   3033889 | Phosphate esters of branched chain alcohols                                       | 1962-05-08   | Chiddix et al. | 252/8.6    |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+\n|  4 |   2286794 | Yarn conditioning process and composition therefor                                | 1942-06-16   | Dickey et al.  | 252/8.8R   |\n+----+-----------+-----------------------------------------------------------------------------------+--------------+----------------+------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Developing alternate explanations of schizophrenia symptoms",
        "evidence": "We also develop alternate explanations of schizophrenia symptoms in the scope of the task of developing a therapeutic alliance. We do this by developing a therapeutic alliance based on the patient’s perspective. In setting out a problem list based on the patient’s, we are setting out a problem list based on the patientâs perspective. We then develop a therapeutic alliance based on the patientâs perspective. Further, we consider developing alternate explanations of schizophrenia symptoms when the patientâs symptoms are normalizing and a perspective of psychosis as a continuum is available. Keeping the patient baseline in mind, we are able to develop a therapeutic alliance based on the patientâs perspective.",
        "table": "+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | â¢   | Developing a therapeutic alliance based on the patientâs perspective                                                                                      | Developing a therapeutic alliance based on the patientâs perspective.1                                                                                    | Developing a therapeutic alliance based on the patientâs perspective.2                                                                                    | Developing a therapeutic alliance based on the patientâs perspective.3                                                                                    | Developing a therapeutic alliance based on the patientâs perspective.4                                                                                    |\n+====+=======+=============================================================================================================================================================+=============================================================================================================================================================+=============================================================================================================================================================+=============================================================================================================================================================+=============================================================================================================================================================+\n|  0 | â¢   | Setting out a problem list based on the patientâs priorities                                                                                              | Setting out a problem list based on the patientâs priorities                                                                                              | Setting out a problem list based on the patientâs priorities                                                                                              | Setting out a problem list based on the patientâs priorities                                                                                              | Setting out a problem list based on the patientâs priorities                                                                                              |\n+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | â¢   | Normalizing and a perspective of psychosis as a continuum                                                                                                   | Normalizing and a perspective of psychosis as a continuum                                                                                                   | Normalizing and a perspective of psychosis as a continuum                                                                                                   | Normalizing and a perspective of psychosis as a continuum                                                                                                   | Normalizing and a perspective of psychosis as a continuum                                                                                                   |\n+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | â¢   | Developing alternate explanations of schizophrenia symptoms                                                                                                 | Developing alternate explanations of schizophrenia symptoms                                                                                                 | Developing alternate explanations of schizophrenia symptoms                                                                                                 | Developing alternate explanations of schizophrenia symptoms                                                                                                 | Developing alternate explanations of schizophrenia symptoms                                                                                                 |\n+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | â¢   | Reducing the impact of disruptive or distressing symptoms that may be drivers of some or all of the issues established in the problem list                  | Reducing the impact of disruptive or distressing symptoms that may be drivers of some or all of the issues established in the problem list                  | Reducing the impact of disruptive or distressing symptoms that may be drivers of some or all of the issues established in the problem list                  | Reducing the impact of disruptive or distressing symptoms that may be drivers of some or all of the issues established in the problem list                  | Reducing the impact of disruptive or distressing symptoms that may be drivers of some or all of the issues established in the problem list                  |\n+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | â¢   | Summarizing the course of the CBTp, along with a review of therapy progress and a review of relapse prevention strategies prior to the last therapy session | Summarizing the course of the CBTp, along with a review of therapy progress and a review of relapse prevention strategies prior to the last therapy session | Summarizing the course of the CBTp, along with a review of therapy progress and a review of relapse prevention strategies prior to the last therapy session | Summarizing the course of the CBTp, along with a review of therapy progress and a review of relapse prevention strategies prior to the last therapy session | Summarizing the course of the CBTp, along with a review of therapy progress and a review of relapse prevention strategies prior to the last therapy session |\n+----+-------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The number of people in Atlanta dying from HIV and AIDS declined 59 percent between 2004 and 2012.",
        "evidence": "The claim that race is a reason for the higher number of deaths in Atlanta can be supported by the data shown in this table. Between 2004 and 2012, the number of African-Americans dying from HIV and aids went down by 29. However, the number of Hispanics affected by the diagnosis also went down by 29.",
        "table": "+----+----------------------------------------+-----------------------+\n|    | Race or Ethnicity                      |   Number of Diagnoses |\n+====+========================================+=======================+\n|  0 | American Indian/Alaska Native          |                   186 |\n+----+----------------------------------------+-----------------------+\n|  1 | Asian                                  |                   875 |\n+----+----------------------------------------+-----------------------+\n|  2 | Black/African American                 |                 16002 |\n+----+----------------------------------------+-----------------------+\n|  3 | Hispanic/Latinob                       |                 10246 |\n+----+----------------------------------------+-----------------------+\n|  4 | Native Hawaiian/Other Pacific Islander |                    68 |\n+----+----------------------------------------+-----------------------+\n|  5 | White                                  |                  9560 |\n+----+----------------------------------------+-----------------------+\n|  6 | Multiple Races                         |                   944 |\n+----+----------------------------------------+-----------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "SYSTOLIC reading of 120-129 is in the elevated blood category ",
        "evidence": "We see that a blood pressure of 120-129 is in the elevated blood category and normal blood pressure of less than 80 is in the lower blood pressure category.",
        "table": "+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|    | BLOOD PRESSURE CATEGORY                               | SYSTOLIC mm Hg (upper number)   | and/or   | DIASTOLIC mm Hg (lower number)   |\n+====+=======================================================+=================================+==========+==================================+\n|  0 | NORMAL                                                | LESS THAN 120                   | and      | LESS THAN 80                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  1 | ELEVATED                                              | 120 – 129                       | and      | LESS THAN 80                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  2 | HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1            | 130 – 139                       | or       | 80 – 89                          |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  3 | HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2            | 140 OR HIGHER                   | or       | 90 OR HIGHER                     |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+\n|  4 | HYPERTENSIVE CRISIS (consult your doctor immediately) | HIGHER THAN 180                 | and/or   | HIGHER THAN 120                  |\n+----+-------------------------------------------------------+---------------------------------+----------+----------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The report was written by internal auditor of the Los Angeles Police Department.",
        "evidence": "The claim that the report was written by an internal auditor of the Los Angeles police department is supported or partially supported by the data shown in the table.",
        "table": "+----+-----------------+-----------------------------------------------------------------------------------+\n|    | Title           | Report of the Independent Commission on the Los Angeles Police Department         |\n+====+=================+===================================================================================+\n|  0 | Author          | Independent Commission on the Los Angeles Police Department (Los Angeles, Calif.) |\n+----+-----------------+-----------------------------------------------------------------------------------+\n|  1 | Edition         | reprint                                                                           |\n+----+-----------------+-----------------------------------------------------------------------------------+\n|  2 | Publisher       | Diane Publishing Company, 1998                                                    |\n+----+-----------------+-----------------------------------------------------------------------------------+\n|  3 | Length          | 228 pages                                                                         |\n+----+-----------------+-----------------------------------------------------------------------------------+\n|  5 | Export Citation | BiBTeX EndNote RefMan                                                             |\n+----+-----------------+-----------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Meetings set to discuss higher cancer rates in 4 NY regions.",
        "evidence": "In order to investigate this claim, we designed a meeting set to discuss the impact of data collection for cancer data in the New York Region. The total number of meetings was set to have about 3000 participants. We randomly selected 1,000 cancer rate development reports from the Onetoone meetings and the results of these meetings were used as the input to our analysis.",
        "table": "+----+-------------------------------+-----+\n|    | Onetoone meetings             |   1 |\n+====+===============================+=====+\n|  1 | Giving and receiving feedback |  31 |\n+----+-------------------------------+-----+\n|  3 | Group meetings                |  51 |\n+----+-------------------------------+-----+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The number for Home Patient Center Angioplasty is 101",
        "evidence": "The claim text is shown in Table. The number for home patient center Angioplasty is 101.",
        "table": "",
        "label": "SUPPORTS"
    },
    {
        "claim": "Candida albicans can cause both Superficial Fungal Infections and Systemic Fungal Infections.",
        "evidence": "According to the table, candida albicans can cause superficial fungal infections. In most cases, these infections appear as ‘normal’ skin and glandular infarction. However, some dermatitis cases can be caused by candida albicans and streptomycosis. In at least one of the studies, we have found that candida albicans can cause systemic fungal infections. The cell structure of candida albicans is similar to that of other small glandular infarction (e.g., trichophyton) and there is only one main difference is that the surface forms are not pleric (e.g., instead ofwings or scales) and the entire cell structure is not elongated (e.g., instead of muscles or intestines). Instead, candida albicans can cause small, thin-walled, ovoid cells in the cell membranes and sinuses. This makes them more vulnerable to infection. On the other hand, candidiasis can be caused by systemic fungal infections. We think that this is due to the cell structures of candida albicans are very similar to other small glandular infarction. For example, although they do not have the cell structures of galaxy (like scales or scales), they can have many surface forms such as small, thin-walled, orvoid cells. And although they do not have the cell structures of galaxy, they can have many surface forms such as small, thin-walled, orvoid cells.",
        "table": "+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|    | Superficial Fungal Infections         | Superficial Fungal Infections.1           | Superficial Fungal Infections.2                                | Superficial Fungal Infections.3                                                                  |\n+====+=======================================+===========================================+================================================================+==================================================================================================+\n|  0 | Disease                               | Causative Organisms                       | Structures Infected                                            | Microscopic Appearance                                                                           |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  1 | Epidermophytosis (e.g., dhobie itch)  | Epidermophyton, (e.g., floccosum)         | Inguinal, axillary, and interdigital folds; hairs not affected | Long, wavy, branched, and segmented hyphae and spindle-shaped cells in stratum corneum           |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  2 | Favus (tinea favosa)                  | Trichophyton schoenleinii                 | Epidermis around a hair; all parts of body; nails              | Vertical hyphae and spores in epidermis; sinuous branching mycelium and chains in hairs          |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  3 | Ringworm (tinea, otomycosis)          | Microsporum (e.g., audouinii)             | Horny layer of epidermis and hairs, chiefly of scalp           | Fine septate mycelium inside hairs and scales; spores in rows and mosaic plaques on hair surface |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  4 | nan                                   | Trichophyton (e.g., tonsurans)            | Hairs of scalp, beard, and other parts; nails                  | Mycelium of chained cubical elements and threads in and on hairs; often pigmented                |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  5 | Thrush and other forms of candidiasis | Candida albicans                          | Tongue, mouth, throat, vagina, and skin                        | Yeastlike budding cells and oval thick-walled bodies in lesion                                   |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  6 | Systemic Fungal Infections            | Systemic Fungal Infections                | Systemic Fungal Infections                                     | Systemic Fungal Infections                                                                       |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  7 | Aspergillosis                         | Aspergillus fumigatus                     | Lungs                                                          | Y-shaped branching of septate hyphae                                                             |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  8 | Blastomycosis                         | Blastomyces brasiliensis, B. dermatitidis | Skin and lungs                                                 | Yeastlike cells demonstrated in lesion                                                           |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n|  9 | Candidiasis                           | Candida albicans                          | Esophagus, lungs, peritoneum, mucous membranes                 | Small, thin-walled, ovoid cells                                                                  |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n| 10 | Coccidioidomycosis                    | Coccidioides immitis                      | Respiratory tract                                              | Nonbudding spores containing many endospores, in sputum                                          |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n| 11 | Cryptococcosis                        | Cryptococcus neoformans                   | Meninges, lungs, bone, skin                                    | Yeastlike fungus having gelatinous capsule; demonstrated in spinal fluid                         |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+\n| 12 | Histoplasmosis                        | Histoplasma capsulatum                    | Lungs                                                          | Oval, budding, uninucleated cells                                                                |\n+----+---------------------------------------+-------------------------------------------+----------------------------------------------------------------+--------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "There are 56,000,000 Annual Deaths Per Year",
        "evidence": "The claim made by the claim authors is that there are 56,000,000 annual deaths in our population. If the number of deaths in our population is calculated from all the people over the years, the number of annual deaths is approximately 56000000. Therefore, the claim verifies the claim.",
        "table": "+----+-----------------+-------------------+\n|    | Annual Deaths   |   Annual Deaths.1 |\n+====+=================+===================+\n|  0 | Per Year        |       5.6e+07     |\n+----+-----------------+-------------------+\n|  1 | Per Month       |       4.67945e+06 |\n+----+-----------------+-------------------+\n|  2 | Per Day         |  153425           |\n+----+-----------------+-------------------+\n|  3 | Per Hour        |    6392.7         |\n+----+-----------------+-------------------+\n|  4 | Per Minute      |     106.6         |\n+----+-----------------+-------------------+\n|  5 | Per Second      |       1.8         |\n+----+-----------------+-------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Cases of Haemophilus influenzae decreased between 1981 and 1986. ",
        "evidence": "The claim that Haemophilus Influenzae decreases between 1981 and 1986 refers to the reduction in the number of cases of Haemophilus Influenza from 48% for the 1978-1981 time period to 45% for the 1995-2002 time period and to 6.7% for the 1998-2007 time period. This decreases represents a relative improvement of 3.7%.",
        "table": "+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|    | Bacteria                                                                                         | 1978-1981                                                                                        | 1986                                                                                             | 1995                                                                                             | 1998-2007   |\n+====+==================================================================================================+==================================================================================================+==================================================================================================+==================================================================================================+=============+\n|  0 | Haemophilus influenzae                                                                           | 48%                                                                                              | 45%                                                                                              | 7%                                                                                               | 6.7%        |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|  1 | Listeria monocytogenes                                                                           | 2%                                                                                               | 3%                                                                                               | 8%                                                                                               | 3.4%        |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|  2 | Neisseria meningitidis                                                                           | 20%                                                                                              | 14%                                                                                              | 25%                                                                                              | 13.9%       |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|  3 | Streptococcus agalactiae (group B streptococcus)                                                 | 3%                                                                                               | 6%                                                                                               | 12%                                                                                              | 18.1%       |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|  4 | Streptococcus pneumoniae                                                                         | 13%                                                                                              | 18%                                                                                              | 47%                                                                                              | 58%         |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+\n|  5 | *Nosocomial meningitis is not included; these data include only the 5 major meningeal pathogens. | *Nosocomial meningitis is not included; these data include only the 5 major meningeal pathogens. | *Nosocomial meningitis is not included; these data include only the 5 major meningeal pathogens. | *Nosocomial meningitis is not included; these data include only the 5 major meningeal pathogens. | nan         |\n+----+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------------------+-------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Nixons the one is ranked 57. ",
        "evidence": "The claim writer is asked to rank a sequence of sentences based on the information in the prologue. The higher the score is, the higher the probability that the rewritten sentence is the same as the original. Each sentence is rated independently. The final ranking of a sentence is obtained by taking the average of the scores in all of the sentences, and then averaged over all of the sentences.",
        "table": "+----+------------------------------+-----+\n|    | PROLOGUE                     |   3 |\n+====+==============================+=====+\n|  1 | 1 TWENTY BROAD STREET        |  21 |\n+----+------------------------------+-----+\n|  3 | 2 DEAR NELSON                |  28 |\n+----+------------------------------+-----+\n|  5 | 3 TURNING POINT              |  34 |\n+----+------------------------------+-----+\n|  7 | 4 WASHIN DIRTY DISHES        |  42 |\n+----+------------------------------+-----+\n|  9 | 5 THE MAN WHO                |  52 |\n+----+------------------------------+-----+\n| 11 | NIXONS THE ONE               |  57 |\n+----+------------------------------+-----+\n| 13 | 1 THE MAN AT THE WILSON DESK |  97 |\n+----+------------------------------+-----+",
        "label": "SUPPORTS"
    },
    {
        "claim": "LSD is commonly ingested by either snorting or injecting it.",
        "evidence": "Based on the information provided in the table, it is evident that lsd is commonly ingested by either snorting or injecting it. Although the exact number of times this method has been used is unknown, the similarity is unmistakable as it appears to be significantly more common than the other methods. Additionally, it should be noted that, in all the cases where it was used as a baseline, the performance measured by the DMT metric was the same.",
        "table": "+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|    | Mode                                                                     | DMT   | LSD   | Peyote   | Psilocybin   | DXM   | Ketamine   | PCP   | Salvia   |\n+====+==========================================================================+=======+=======+==========+==============+=======+============+=======+==========+\n|  0 | Swallowing as tablets or pills                                           | Â     | X     | Â        | Â            | X     | X          | X     | Â        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  1 | Swallowing as liquid                                                     | Â     | X     | X        | Â            | X     | X          | Â     | Â        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  2 | Consuming raw or dried                                                   | Â     | Â     | X        | X            | Â     | Â          | Â     | X        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  3 | Brewing into tea                                                         | X     | Â     | X        | X            | Â     | Â          | Â     | X        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  4 | Snorting                                                                 | Â     | Â     | Â        | Â            | Â     | X          | X     | Â        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  5 | Injecting                                                                | Â     | Â     | Â        | Â            | Â     | Â          | X     | Â        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  6 | Inhaling, vaporizing, or smoking                                         | X     | Â     | Â        | Â            | Â     | Â          | X     | X        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+\n|  7 | Absorbing through the lining of the mouth using drug-soaked paper pieces | Â     | X     | Â        | Â            | Â     | Â          | Â     | Â        |\n+----+--------------------------------------------------------------------------+-------+-------+----------+--------------+-------+------------+-------+----------+",
        "label": "REFUTES"
    },
    {
        "claim": "Pregnant women with BMI less than 18.5, its recommended then gain 31-50 pounds ",
        "evidence": "The claim here is that if a pregnancy result is associated with a BMI greater than or equal to 30.0, then the user should gain 31-50 pounds. This is based on the fact that, if the pregnancy risk is associated with a BMI greater than or equal to 30.0, then the user should also gain the same amount of pounds. We find that most women who gain less than 50 pounds during pregnancy are not obese. It’s also likely that they were not high BMI earlier.",
        "table": "+----+-----------------------------------------+--------------------+\n|    | If before pregnancy, you were…          | You should gain…   |\n+====+=========================================+====================+\n|  0 | Underweight BMI less than 18.5          | 50-62 pounds*      |\n+----+-----------------------------------------+--------------------+\n|  1 | Normal Weight BMI 18.5-24.9             | 37-54 pounds       |\n+----+-----------------------------------------+--------------------+\n|  2 | Overweight BMI 25.0-29.9                | 31-50 pounds       |\n+----+-----------------------------------------+--------------------+\n|  3 | Obese BMI greater than or equal to 30.0 | 25-42 pounds       |\n+----+-----------------------------------------+--------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "OGTT according to american association diabetes is considered normal if <140 ",
        "evidence": "According to the American Diabetes Association, there is a significantly lower estimation of the OGtt test’s error compared to other measurements. The largest error is seen in the HbA1c class, where the error is 5.7% compared to 5.7% in the glucose test. Although this error may represent errors in the optimization of the algorithm, it is not the primary reason for the error. Instead, it may result from a problem in the optimization of the algorithm. Because of this, the optimization algorithm needs to be adjusted according to the unique algorithm for each class.",
        "table": "+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+\n|    | Test                                                                                                                               | Normal                                                                                                                             | Impaired Glucose Regulation                                                                                                        | Diabetes                                                                                                                           |\n+====+====================================================================================================================================+====================================================================================================================================+====================================================================================================================================+====================================================================================================================================+\n|  0 | FPG (mg/dL [mmol/L])                                                                                                               | <100 (< 5.6)                                                                                                                       | 100â125 (5.6â6.9)                                                                                                              | â¥126 (â¥7.0)                                                                                                                    |\n+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | OGTT (mg/dL [mmol/L])                                                                                                              | < 140 (<7.8)                                                                                                                       | 140â199 (7.8â11.0)                                                                                                             | â¥200 (â¥ 11.1)                                                                                                                  |\n+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | HbA1C (%)                                                                                                                          | < 5.7                                                                                                                              | 5.7â6.4                                                                                                                          | â¥ 6.5                                                                                                                            |\n+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | * See also American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 43 (Supplement 1): S1âS212, 2020. | * See also American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 43 (Supplement 1): S1âS212, 2020. | * See also American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 43 (Supplement 1): S1âS212, 2020. | * See also American Diabetes Association: Standards of Medical Care in Diabetes. Diabetes Care 43 (Supplement 1): S1âS212, 2020. |\n+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | FPG = fasting plasma glucose; HbA1C = glycosylated hemoglobin; OGTT = oral glucose tolerance test, 2-hour glucose level.           | FPG = fasting plasma glucose; HbA1C = glycosylated hemoglobin; OGTT = oral glucose tolerance test, 2-hour glucose level.           | FPG = fasting plasma glucose; HbA1C = glycosylated hemoglobin; OGTT = oral glucose tolerance test, 2-hour glucose level.           | FPG = fasting plasma glucose; HbA1C = glycosylated hemoglobin; OGTT = oral glucose tolerance test, 2-hour glucose level.           |\n+----+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Foreign Policy is a domestic issue ",
        "evidence": "According to the table, the claim that foreign policy is a domestic issue is true. This is consistent with the information from the claim section. For example, the most expensive foreign policy issue is the gun control one, followed by the energy and oil issues. The remaining major domestic issues are the drug reform, the war in Iraq, the health care, and the immigration issues.",
        "table": "+----+------------------------+-------------------+-------------------+---------------------+\n|    | International Issues   | Domestic Issues   | Economic Issues   | Social Issues       |\n+====+========================+===================+===================+=====================+\n|  0 | Foreign Policy         | Gun Control       | Budget & Economy  | Education           |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  1 | Homeland Security      | Crime             | Government Reform | Civil Rights        |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  2 | War & Peace            | Drugs             | Tax Reform        | Abortion            |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  3 | Free Trade             | Health Care       | Social Security   | Families & Children |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  4 | Immigration            | Technology        | Corporations      | Welfare & Poverty   |\n+----+------------------------+-------------------+-------------------+---------------------+\n|  5 | Energy & Oil           | Environment       | Jobs              | Principles & Values |\n+----+------------------------+-------------------+-------------------+---------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Methotrexate Sodiumis is taken orally.",
        "evidence": "The claim of methotrexate sodiumis is available in several routes. It is taken orally in tablets through the film-coated lines. There are 2.5 mg, 7.5 mg, and 10 mg per ml for tablets, 5 mg, and 15 mg per ml for tablets, and for injection, there are 1 g, 10 mg, and 25 mg per ml for tablets, 5 mg, and 15 mg per ml for injections. The table shows that the safest dosing form is still tablets.",
        "table": "+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|    | Routes     | Dosage Forms         | Strengths                       | Brand Names                            | Manufacturer   |\n+====+============+======================+=================================+========================================+================+\n|  0 | Oral       | Tablets              | 2.5 mg (of methotrexate)*       | Methotrexate Sodium Tablets (scored)   | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  1 | nan        | nan                  | nan                             | Rheumatrex Dose Pack (scored)          | Dava           |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  2 | nan        | Tablets, film-coated | 5 mg (of methotrexate)          | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  3 | nan        | nan                  | 7.5 mg (of methotrexate)        | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  4 | nan        | nan                  | 10 mg (of methotrexate)         | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  5 | nan        | nan                  | 15 mg (of methotrexate)         | Trexall (scored)                       | Duramed        |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  6 | Parenteral | For injection        | 1 g (of methotrexate)*          | Methotrexate Sodium for Injection      | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  7 | nan        | Injection            | 10 mg (of methotrexate) per mL* | Methotrexate Sodium Injection Isotonic | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+\n|  8 | nan        | nan                  | 25 mg (of methotrexate) per mL* | Methotrexate Sodium Injection Isotonic | nan            |\n+----+------------+----------------------+---------------------------------+----------------------------------------+----------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Measles for 2007 Quebec was double of those found in British Columbia in 2010.",
        "evidence": "The claim made by the claim authors is true. In 2007, there were 94 cases of measles in Quebec and it was carried out by a D4 classifier. In 2010, British Columbia had 82 cases of measles and it was carried out by a D8 classifier that used ClimaMART. There were two unique D8 strains circulating during this outbreak: one was from British Columbia and the other was from Ontario. We use ClimaMART as a baseline because it showed that the differences between the clusters of annotations for 2007 and 2010 were not statistically significant.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Province                                                                                                                                                                                                                                                                                                                                                                                | Year                                                                                                                                                                                                                                                                                                                                                                                    | Number of  cases                                                                                                                                                                                                                                                                                                                                                                        | Duration  (weeks)                                                                                                                                                                                                                                                                                                                                                                       | Strain                                                                                                                                                                                                                                                                                                                                                                                  |\n+====+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+=========================================================================================================================================================================================================================================================================================================================================================================================+\n|  0 | Quebec                                                                                                                                                                                                                                                                                                                                                                                  | 2007                                                                                                                                                                                                                                                                                                                                                                                    | 94                                                                                                                                                                                                                                                                                                                                                                                      | 24                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Ontario                                                                                                                                                                                                                                                                                                                                                                                 | 2008                                                                                                                                                                                                                                                                                                                                                                                    | 53                                                                                                                                                                                                                                                                                                                                                                                      | 11                                                                                                                                                                                                                                                                                                                                                                                      | D8                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | British Columbia                                                                                                                                                                                                                                                                                                                                                                        | 2010                                                                                                                                                                                                                                                                                                                                                                                    | 82                                                                                                                                                                                                                                                                                                                                                                                      | 7                                                                                                                                                                                                                                                                                                                                                                                       | D8table 1 Footnote 2 and H1                                                                                                                                                                                                                                                                                                                                                             |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Quebectable 1 Footnote 3                                                                                                                                                                                                                                                                                                                                                                | 2011                                                                                                                                                                                                                                                                                                                                                                                    | 20                                                                                                                                                                                                                                                                                                                                                                                      | 11                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Quebectable 1 Footnote 4                                                                                                                                                                                                                                                                                                                                                                | 2011                                                                                                                                                                                                                                                                                                                                                                                    | 678                                                                                                                                                                                                                                                                                                                                                                                     | 33                                                                                                                                                                                                                                                                                                                                                                                      | D4                                                                                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer | Table 1 Footnote 2There were two unique D8 strains circulating during this outbreak. Return to table 1 footnote 2 referrer Table 1 Footnote 3Outbreak commenced February 2011. Return to table 1 footnote 3 referrer Table 1 Footnote 4Outbreak commenced April 2011. This total includes one outbreak-associated case reported in New Brunswick. Return to table 1 footnote 4 referrer |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Antigen detection can distinguished 2009 H1N1 influenza from other influenza A viruses",
        "evidence": "The results show that our method can distinguished 2009 H1N1 influenza from other influenza A viruses on a few different tests. The detection of influenza virus in contrast to other influenza A viruses was 96% in case of RDIt-4 and 77% in case of Direct and Indirect Immunofluorescence assays (dfa and iFAA). This compared to a relative improvement of only 11% for RDIt-4 and 18% for the Direct and Indirect Immunofluorescence assays. Although the results are not as good as RDIt-4, they show that our method can distinguish H1N1 influenza from other influenza A viruses.",
        "table": "+----+--------------------------------------------------------------+-------------------+----------------+-----------------------------------------------+----------------------------------------+---------------------------------------------------------------------+\n|    | Influenza Diagnostic Tests                                   | Method            | Availability   | Typical  Processing Time2                     | Sensitivity3 for 2009 H1N1 influenza   | Distinguishes 2009 H1N1 influenza from other influenza A viruses?   |\n+====+==============================================================+===================+================+===============================================+========================================+=====================================================================+\n|  0 | Rapid influenza diagnostic tests (RIDT)4                     | Antigen detection | Wide           | 0.5 hour                                      | 10 â 70%                             | No                                                                  |\n+----+--------------------------------------------------------------+-------------------+----------------+-----------------------------------------------+----------------------------------------+---------------------------------------------------------------------+\n|  1 | Direct and indirect immunofluorescence assays (DFA and IFA)5 | Antigen detection | Wide           | 2 â 4 hours                                 | 47â93%                               | No                                                                  |\n+----+--------------------------------------------------------------+-------------------+----------------+-----------------------------------------------+----------------------------------------+---------------------------------------------------------------------+\n|  2 | Viral isolation in tissue cell culture                       | Virus isolation   | Limited        | 2 -10 days                                    | -                                      | Yes 6                                                               |\n+----+--------------------------------------------------------------+-------------------+----------------+-----------------------------------------------+----------------------------------------+---------------------------------------------------------------------+\n|  3 | Nucleic acid amplification tests (including rRT-PCR) 7       | RNA detection     | Limited8       | Â 48 â 96 hours [6-8 hours to perform test] | 86 â 100%                            | Yes                                                                 |\n+----+--------------------------------------------------------------+-------------------+----------------+-----------------------------------------------+----------------------------------------+---------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Fewer people rode the metro on the day of the Trump inaugural than both Obama inaugurals. ",
        "evidence": "The claim made by the claim authors is that on the day of the Trump inaugural, less people rode the metro than the other two inaugurals. In fact, the number of people who rode the metro on the day of the Trump Inauguration was 193000, which is still 193000 lower than the number of people who rode in the same way on the day of the Obama Inaugural.",
        "table": "+----+----------------------------------+-------------------------------+-----------------------------------+\n|    | Day                              |   Metro ridership (whole day) |   Metro ridership (as of 11 a.m.) |\n+====+==================================+===============================+===================================+\n|  0 | Jan. 20, 2017 (Trump inaugural)  |                        570557 |                            193000 |\n+----+----------------------------------+-------------------------------+-----------------------------------+\n|  1 | Jan. 21, 2013* (Obama inaugural) |                        782000 |                            317000 |\n+----+----------------------------------+-------------------------------+-----------------------------------+\n|  2 | Jan. 20, 2009 (Obama inaugural)  |                       1100000 |                            513000 |\n+----+----------------------------------+-------------------------------+-----------------------------------+\n|  3 | Jan. 20, 2005 (Bush inaugural)   |                        583803 |                            197000 |\n+----+----------------------------------+-------------------------------+-----------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "the federal poverty level for household is greater than $50000",
        "evidence": "The claim from the table shows that: (1) There are four persons in our household who have incomes greater than $50000. (2) For those who have higher than $50000, the threshold for 100% FPL is $28,910, the threshold for 138% FPL is $41,865, and the threshold for 200% FPL is $79,925. (3) For those who have higher than $10,000, the threshold for 100% FPL is $55,324, the threshold for 200% FPL is $60,135 and the threshold for 400% FPL is $160,360.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Persons in Household                                                                                                                                                                                      | 2014 Federal Poverty Level threshold 100% FPL                                                                                                                                                             | Medicaid eligibility* threshold 138% FPL                                                                                                                                                                  | CSR* & Premium Cap eligibility threshold 150% FPL                                                                                                                                                         | CSR eligibility threshold 250% FPL                                                                                                                                                                        | PTC* eligibility threshold 400% FPL                                                                                                                                                                       |\n+====+===========================================================================================================================================================================================================+===========================================================================================================================================================================================================+===========================================================================================================================================================================================================+===========================================================================================================================================================================================================+===========================================================================================================================================================================================================+===========================================================================================================================================================================================================+\n|  0 | 1                                                                                                                                                                                                         | $11,670                                                                                                                                                                                                   | $16,105                                                                                                                                                                                                   | $17,505                                                                                                                                                                                                   | $29,175                                                                                                                                                                                                   | $46,680                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | 2                                                                                                                                                                                                         | $15,730                                                                                                                                                                                                   | $21,707                                                                                                                                                                                                   | $23,595                                                                                                                                                                                                   | $39,325                                                                                                                                                                                                   | $62,920                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | 3                                                                                                                                                                                                         | $19,790                                                                                                                                                                                                   | $27,310                                                                                                                                                                                                   | $29,685                                                                                                                                                                                                   | $49,475                                                                                                                                                                                                   | $79,160                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | 4                                                                                                                                                                                                         | $23,850                                                                                                                                                                                                   | $32,913                                                                                                                                                                                                   | $35,775                                                                                                                                                                                                   | $59,625                                                                                                                                                                                                   | $95,400                                                                                                                                                                                                   |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | 5                                                                                                                                                                                                         | $27,910                                                                                                                                                                                                   | $38,516                                                                                                                                                                                                   | $41,865                                                                                                                                                                                                   | $69,775                                                                                                                                                                                                   | $111,640                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | 6                                                                                                                                                                                                         | $31,970                                                                                                                                                                                                   | $44,119                                                                                                                                                                                                   | $47,955                                                                                                                                                                                                   | $79,925                                                                                                                                                                                                   | $127,880                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | 7                                                                                                                                                                                                         | $36,030                                                                                                                                                                                                   | $49,721                                                                                                                                                                                                   | $54,045                                                                                                                                                                                                   | $90,075                                                                                                                                                                                                   | $144,120                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | 8                                                                                                                                                                                                         | $40,090                                                                                                                                                                                                   | $55,324                                                                                                                                                                                                   | $60,135                                                                                                                                                                                                   | $100,225                                                                                                                                                                                                  | $160,360                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits | *Medicaid eligibility is different in states that did not expand Medicaid. Federal Poverty Guidelines are different in Hawaii and Alaska. *CSR Cost Sharing Reduction subsidy *PTC or Premium Tax Credits |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Benlysta Injection, powder, for solution of dosage as 400 mg.",
        "evidence": "The claim is that at the time of injection, Benlysta injection, powder, for solution of dosage as 400 mg/5 ml was the active ingredient in a pipeline and therefore, it is not possible to freeze the solution and therefore, it cannot be used in our products. This is another statement that does not apply to our products.",
        "table": "+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|    | Name     | Dosage                                       | Strength      | Route        | Labeller                            | Marketing Start   | Marketing End   | Region   |\n+====+==========+==============================================+===============+==============+=====================================+===================+=================+==========+\n|  0 | Benlysta | Solution                                     | 200 mg / 1 mL | Subcutaneous | Glaxosmithkline Inc                 | 2018-05-14        | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  1 | Benlysta | Solution                                     | 200 mg/1mL    | Subcutaneous | GlaxoSmithKline LLC                 | 2017-07-20        | Not applicable  | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  2 | Benlysta | Injection, powder, lyophilized, for solution | 120 mg/1.5mL  | Intravenous  | GlaxoSmithKline Manufacturing SpA   | 2011-03-10        | 2018-03-12      | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  3 | Benlysta | Powder, for solution                         | 120 mg / vial | Intravenous  | Glaxosmithkline Inc                 | 2011-08-24        | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  4 | Benlysta | Injection, solution                          | 200 mg        | Subcutaneous | Glaxo Smith Kline (Ireland) Limited | 2020-12-16        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  5 | Benlysta | Injection, powder, for solution              | 400 mg        | Intravenous  | Glaxo Smith Kline (Ireland) Limited | 2016-09-08        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  6 | Benlysta | Injection, powder, lyophilized, for solution | 120 mg/1.5mL  | Intravenous  | GlaxoSmithKline LLC                 | 2011-03-10        | Not applicable  | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  7 | Benlysta | Solution                                     | 200 mg / 1 mL | Subcutaneous | Glaxosmithkline Inc                 | Not applicable    | Not applicable  | Canada   |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  8 | Benlysta | Injection, solution                          | 200 mg        | Subcutaneous | Glaxo Smith Kline (Ireland) Limited | 2020-12-16        | Not applicable  | EU       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+\n|  9 | Benlysta | Injection, powder, lyophilized, for solution | 400 mg/5mL    | Intravenous  | GlaxoSmithKline Manufacturing SpA   | 2011-03-10        | 2018-03-12      | US       |\n+----+----------+----------------------------------------------+---------------+--------------+-------------------------------------+-------------------+-----------------+----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The budget funds 13% of educational services.",
        "evidence": "The claim of higher education quality is only supported by the federal government, which provides education services for 22% of the total budget. The lowest percentage of education services is provided by the local government, which only provides education and hospitals. This shows that local government has the least direct access to education, and that the level of education provided by the state government is greater than that of the private ones.",
        "table": "+----+-----------------------------------------------------+-------+\n|    | Federal government                                  |   22% |\n+====+=====================================================+=======+\n|  0 | Educational services; state, local, and private     |    13 |\n+----+-----------------------------------------------------+-------+\n|  1 | Professional, scientific, and technical services    |    11 |\n+----+-----------------------------------------------------+-------+\n|  2 | State government, excluding education and hospitals |    11 |\n+----+-----------------------------------------------------+-------+\n|  3 | Local government, excluding education and hospitals |    11 |\n+----+-----------------------------------------------------+-------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "France drafts law to extend IVF to lesbians, single women.",
        "evidence": "The aim of the experiments in this section is to analyse the behavior of IVF in a population where the state-of-the-art are already well-known. The idea is to compare the performance of IVF in a population where the state-of-the-art are already well-known. This dataset provides a comparison of the performance of IVF in a population where one half of the population is a lesbian and the other half of the population is male. We observe that in 19.9% of the cases do we have insufficient data to train a reliable IVF model. On the other hand, we do not have a very large amount of samples in the population. Therefore, we evaluate on a sample size of 1,000 where we can compare both the quality of the eggs and the sperm. We use this in the following experiments to show the behavior of IVF in a population where one half of the people are a lesbian and the other half of the people are a male.",
        "table": "+----+------------------------------+---------+\n|    | Own eggs and sperm           | 15.4%   |\n+====+==============================+=========+\n|  0 | Own eggs and donor sperm     | 19.9%   |\n+----+------------------------------+---------+\n|  1 | Own sperm and donated eggs   | 21.9%   |\n+----+------------------------------+---------+\n|  2 | Donated eggs and donor sperm | 22.2%   |\n+----+------------------------------+---------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "THIN Prevalence (95% CI) for Dementia (65+) is higher than that for Parkinsonism (all ages).",
        "evidence": "The claim text shows that at all ages, individuals with hereditary hypertension have significantly higher thin prevalence than their peers in the general population. Specifically, the prevalence of hypertension is increased from 13.4% in England to 13.8% in the UK, which is more than twice as high as that for Parkinsonism. The table also shows that the English prevalence for all the conditions is significantly higher than that for each condition.",
        "table": "+----+-----------------------------+----------------------------+-------------------------------------+\n|    | Condition (ages included)   | THIN Prevalence (95% CI)   | England Prevalence (QOF) (95% CI)   |\n+====+=============================+============================+=====================================+\n|  0 | Dementia (65+)              | 4.1 (4.0 to 4.1)           | 4.3 (4.3 to 4.3)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  1 | Asthma (all ages)           | 9.3 (9.3 to 9.3)           | 5.9 (5.9 to 5.9)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  2 | CHD (all ages)              | 3.1 (3.1 to 3.2)           | 3.2 (3.2 to 3.2)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  3 | COPD (all ages)             | 1.9 (1.9 to 1.9)           | 1.9 (1.9 to 1.9)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  4 | Depression (18+)            | 11.3 (11.2 to 11.3)        | 8.3 (8.3 to 8.3)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  5 | Diabetes (17+)              | 6.3 (6.3 to 6.4)           | 6.6 (6.5 to 6.)                     |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  6 | Epilepsy (18+)              | 1.3 (1.2 to 1.3)           | 0.8 (0.8 to 0.8)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  7 | Hypertension (all ages)     | 13.4 (13.4 to 13.5)        | 13.8 (13.8 to 13.8)                 |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  8 | Parkinsonism (all ages)     | 2.0 (1.9 to 2.0)           | -                                   |\n+----+-----------------------------+----------------------------+-------------------------------------+\n|  9 | SMI (all ages)              | 0.8 (0.8 to 0.8)           | 0.9 (0.9 to 0.9)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+\n| 10 | Stroke/TIA (all ages)       | 1.8 (1.8 to 1.8)           | 1.7 (1.7 to 1.7)                    |\n+----+-----------------------------+----------------------------+-------------------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "men of age 26 are given nod to HPV shots   by vaccine pannel",
        "evidence": "This claim is supported or partially based on the information provided by the human evaluation. The goal of the human evaluation was to observe whether or not people are sensitive to the proposed method. It can be observed that about 40% of the patients who are given the antigen by the vaccine are not sensitive to the antigen. This result is in line with the results of the manual evaluation.",
        "table": "+----+---------------------------------------------------------+------------------------------------------+\n|    | Disease                                                 | HPV 9-valent                             |\n+====+=========================================================+==========================================+\n|  0 | Anal cancer                                             | HPV types 16, 18, 31, 33, 45, 52, and 58 |\n+----+---------------------------------------------------------+------------------------------------------+\n|  1 | Genital warts (condyloma acuminata)                     | HPV types 6 and 11                       |\n+----+---------------------------------------------------------+------------------------------------------+\n|  2 | Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 | HPV types 16, 18, 31, 33, 45, 52, and 58 |\n+----+---------------------------------------------------------+------------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "New coronavirus cases in Italy fall to 25-day low, deaths rise by 604.",
        "evidence": "This claim is based on the claim that coronavirus cases in Italy fall to a 25-day low in 2017 compared to the previous year, while the number of deaths also remains stable at 24600.",
        "table": "+----+----------------+-------------------+----------------+-------------------+\n|    | COUNTRY        | PCT ABOVENORMAL   | EXCESSDEATHS   | TIME PERIOD       |\n+====+================+===================+================+===================+\n|  0 | United Kingdom | +67%              | 53300          | Mar. 14 - May 1   |\n+----+----------------+-------------------+----------------+-------------------+\n|  1 | Spain          | +60%              | 31500          | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  2 | Belgium        | +50%              | 5300           | Mar. 16 - Apr. 19 |\n+----+----------------+-------------------+----------------+-------------------+\n|  3 | Netherlands    | +50%              | 8700           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n|  4 | Italy          | +49%              | 24600          | March             |\n+----+----------------+-------------------+----------------+-------------------+\n|  5 | France         | +44%              | 28500          | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n|  6 | Sweden         | +27%              | 3300           | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  7 | Switzerland    | +24%              | 2000           | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n|  8 | Portugal       | +15%              | 1300           | Mar. 16 - Apr. 12 |\n+----+----------------+-------------------+----------------+-------------------+\n|  9 | Austria        | +11%              | 1000           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n| 10 | Germany        | +6%               | 4100           | Mar. 16 - Apr. 12 |\n+----+----------------+-------------------+----------------+-------------------+\n| 11 | Denmark        | +5%               | 300            | Mar. 16 - May 3   |\n+----+----------------+-------------------+----------------+-------------------+\n| 12 | Norway         | +0%               | <100           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+\n| 13 | Finland        | +0%               | <100           | Mar. 16 - Apr. 26 |\n+----+----------------+-------------------+----------------+-------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "The number of suicide planes in January is more than double the amount in October.",
        "evidence": "From this table, we can see that in October, the number of suicide planes increasing from 456 to 282. This number is more than double the amount in October, the number of suicide planes stopped at 96. The total number of non-suicide airplane usage in January is also much higher than the other two months, with 456 in October and 211 in November. While the number of suicide planes taking place in January is very high, the number of non-suicide airplane takes into account a very small number of them.",
        "table": "+----+--------------------+--------+--------+--------+--------+----------+\n|    | Unnamed: 0         |   Oct. |   Nov. |   Dec. |   Jan. |   Totals |\n+====+====================+========+========+========+========+==========+\n|  0 | Total planes       |    510 |    282 |    320 |    332 |     1444 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  1 | Suicide planes     |     54 |     79 |    109 |    110 |      352 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  2 | Non-suicide planes |    456 |    203 |    211 |    222 |     1092 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  3 | Suicide kills      |     36 |     51 |     76 |     68 |      231 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  4 | Non-suicide kills  |     95 |     16 |     23 |     22 |      156 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  5 | Suicide hits       |     18 |     28 |     33 |     42 |      121 |\n+----+--------------------+--------+--------+--------+--------+----------+\n|  6 | Non-suicide hits   |     10 |      1 |      3 |      9 |       23 |\n+----+--------------------+--------+--------+--------+--------+----------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "DD Machiavellianism for Expression has the same value as DD Narcissism.",
        "evidence": "From the table we can see that DD Machiavellianism for expression has the same value as DD N narcissism. This is very important, since the higher level values, the more narcissistic the disorder tends to be.",
        "table": "+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|    | Subscale              | DD Machiavellianism   | DD Narcissism   | DD Psychopathy   | SOI-R Behavior   | SOI-R Attitudes   | SOI-R Desire   |\n+====+=======================+=======================+=================+==================+==================+===================+================+\n|  0 | Stress Reduction      | .276**                | .320**          | .371***          | .114             | .039              | .252**         |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  1 | Pleasure              | â.102               | .048            | â.088          | â.108          | .154              | .168           |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  2 | Physical Desirability | â.207*              | â.050         | â.203*         | â.092          | â.103           | .115           |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  3 | Experience Seeking    | .069                  | .146            | â.122          | â.125          | â.153           | .063           |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  4 | Resources             | .408***               | .153            | .393***          | .239*            | .025              | .314**         |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  5 | Reproduction          | .154                  | .191            | .260**           | â.158          | â.204*          | .048           |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  6 | Social Status         | .467***               | .360***         | .389***          | .194*            | .025              | .406***        |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  7 | Revenge               | .368***               | .199*           | .320**           | .267**           | â.006           | .410***        |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  8 | Practical             | .216*                 | .196*           | .292**           | .001             | .059              | .232*          |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n|  9 | Love & Commitment     | â.124               | .065            | â.112          | â.161          | â.121           | â.016        |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n| 10 | Expression            | .234*                 | .234*           | .289**           | .032             | .003              | .170           |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n| 11 | Self-Esteem Boost     | .338***               | .332**          | .192             | .237*            | .076              | .359***        |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n| 12 | Duty/Pressure         | .287**                | .119            | .322**           | .286**           | â.001           | .208*          |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+\n| 13 | Mate Guarding         | .333**                | .347***         | .308**           | .183             | â.077           | .271**         |\n+----+-----------------------+-----------------------+-----------------+------------------+------------------+-------------------+----------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "State: 8 cases of severe lung disease from vaping, e-cigs.",
        "evidence": "We identified 8 cases of severe lung disease from vaping, e-cigarettes. These 8 individuals had the most common diagnoses among all the patients in our sample. They all suffered from COPD ( chronic obstructive pulmonary disease), E-cig (electronic cigarette) and FENO (fantal exhaled nitric oxide) diseases.",
        "table": "+----+--------+---------------------------------------+\n|    | CVD:   | Cardiovascular disease                |\n+====+========+=======================================+\n|  0 | COPD:  | Chronic obstructive pulmonary disease |\n+----+--------+---------------------------------------+\n|  1 | E-cig: | Electronic cigarette                  |\n+----+--------+---------------------------------------+\n|  2 | FeNO:  | Fractional exhaled nitric oxide       |\n+----+--------+---------------------------------------+\n|  3 | NCDs:  | Noncommunicable diseases              |\n+----+--------+---------------------------------------+\n|  4 | SSA:   | Sub-Saharan Africa                    |\n+----+--------+---------------------------------------+\n|  5 | WHO:   | World Health Organization.            |\n+----+--------+---------------------------------------+",
        "label": "NOT ENOUGH INFO"
    },
    {
        "claim": "Methicillin is the traditional antimicrobial therapy for Gonorrhea.",
        "evidence": "The antimicrobial therapy of Neisseria gonorrhoeae is Penicillin, along with anti-tetracycline. The current estimated community prevalence of resistance is 20% for gonorrhea and 40% for tuberculosis. However, there are multiple outbreaks reported for this drug.",
        "table": "+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|    | Type of infection                         | Causative agent(s)                                                      | Traditional antimicrobial therapy                                      | Current estimated community prevalence of resistance                        |\n+====+===========================================+=========================================================================+========================================================================+=============================================================================+\n|  0 | Respiratory tract, conjunctivitis, otitis | Streptococcus penumoniae, Haemophilus influenzae, Moraxella catarrhalis | Penicillin                                                             | 20%â60%, â¼20%, â¼95%                                                   |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  1 | âStrepâ throat, impetigo              | Streptococcus pyogenes                                                  | Penicillin, Erythromycin                                               | 45%, 10%â30%                                                              |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  2 | Tuberculosis                              | Mycobacterium tuberculosis                                              | Isoniazid, rifampin                                                    | 0.7% (for both drugs combined)                                              |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  3 | Gonorrhea                                 | Neisseria gonorrhoeae                                                   | Penicillin, Tetracycline                                               | 20%â90% 0%â46%                                                          |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  4 | Skin and soft tissue, sepsis, pneumonia   | Staphylococcus aureus                                                   | Methicillin                                                            | 0.84%, but multiple outbreaks reported                                      |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  5 | Gastrointestinal, diarrhea                | Salmonella enteritidis, choleraesuis                                    | Non-typhi species should not be treated with antibiotics               | Depends on subtype: multi-drug resistant strains, 1%â25%                  |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  6 | Â                                         | Shigella spp.                                                           | Ampicillin, Trimethoprim- sulfamethoxazole                             | 78%, 46%                                                                    |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  7 | Enteric fever                             | Salmonella typhi                                                        | Fluoroquinolones, Third-generation cephalosporins                      | 25%â40% resistant to one or more agents, 17%â20% resistant to >5 agents |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+\n|  8 | Cholera                                   | Vibrio cholerae                                                         | Supportive treatment, usually Tetracycline, Ampicillin, Co-trimoxazole | Resistance to at least one agent now >90%                                   |\n+----+-------------------------------------------+-------------------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Statistics on legionnaire's shows that hospital exposure had the highest combined number of cases in 2014 & 2015.",
        "evidence": "This claim makes use of the following information from the claim section: * * This table shows that Hospital ExposureA had the highest combined number of cases in 2014 & 2015. This was because: (i) it had 19 (49) hospital exposures in total; and (ii) it had 27 (57) hospital exposures in total; and (iii) the number of out-of-patient cases was relatively low at 3 (60) and 1 (25) for 2014+2015.",
        "table": "+----+---------------------------------+--------------------+----------------------+----------------------+\n|    | Exposure type                   | No. of cases (%)   | No. of cases (%).1   | No. of cases (%).2   |\n+====+=================================+====================+======================+======================+\n|  0 | Exposure type                   | 2014 + 2015 ()     | 2014 ()              | 2015 ()              |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  1 | Residence served by Flint water | 29 (34)            | 20 (51)              | 9 (19)               |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  2 | Hospital Exposurea              | 46 (53)            | 19 (49)              | 27 (57)              |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  3 | Hospital Aa                     | 42 (49)            | 17 (44)              | 25 (53)              |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  4 | âInpatientb                   | 37 (88)            | 14 (82)              | 23 (92)              |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  5 | âOutpatientb                  | 3 (7)              | 1 (6)                | 2 (8)                |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  6 | âVisitorb                     | 5 (12)             | 2 (12)               | 3 (12)               |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  7 | Hospital Ba                     | 5 (6)              | 4 (10)               | 1 (2)                |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  8 | âInpatient                    | 3 (60)             | 3 (75)               | 0 (0)                |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n|  9 | âOutpatient                   | 0 (0)              | 0 (0)                | 0 (0)                |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n| 10 | âVisitor                      | 2 (40)             | 1 (25)               | 1 (100)              |\n+----+---------------------------------+--------------------+----------------------+----------------------+\n| 11 | Hospital C                      | 0 (0)              | 0 (0)                | 0 (0)                |\n+----+---------------------------------+--------------------+----------------------+----------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "Information for Women About the Safety of Silicone Breast Implants is found in chapter 1-19",
        "evidence": "The claim that silicone breast implants do not decrease the safety of mammograms and other breast imaging is supported by the results of a scale-up study conducted by the authors of this manuscript. In particular, the results of the study are summarized in “The complete safety of silicone breast implants”, which provides information for women about the safety of silicone breast implants in 19 different chapters.",
        "table": "+----+--------------------------------------------------------------------+----------------+\n|    | Table of Contents                                                  | skim chapter   |\n+====+====================================================================+================+\n|  0 | Front Matter                                                       | i-iv           |\n+----+--------------------------------------------------------------------+----------------+\n|  1 | Information for Women About the Safety of Silicone Breast Implants | 1-19           |\n+----+--------------------------------------------------------------------+----------------+\n|  2 | Conclusions                                                        | 20-20          |\n+----+--------------------------------------------------------------------+----------------+\n|  3 | Mammograms and Other Breast Imaging in Women with Implants         | 21-23          |\n+----+--------------------------------------------------------------------+----------------+\n|  4 | Recommendations                                                    | 24-25          |\n+----+--------------------------------------------------------------------+----------------+\n|  5 | A History of Implants                                              | 26-30          |\n+----+--------------------------------------------------------------------+----------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "More Democrats were represented in the table as of June 2021, than were Republicans in the same time frame.",
        "evidence": "The claim made by the NRAN coalition is that there were 41 more Democratic Party members in the table as of June 2021 compared to the republicans who were represented in the same time frame. This suggests that the Democratic Party is more represented in the table than the Republicans.",
        "table": "+----+---------+------------------+-------------------+\n|    | Party   | Party.1          |   As of June 2021 |\n+====+=========+==================+===================+\n|  0 | nan     | Democratic Party |                41 |\n+----+---------+------------------+-------------------+\n|  1 | nan     | Republican Party |                18 |\n+----+---------+------------------+-------------------+\n|  2 | nan     | Vacancies        |                 0 |\n+----+---------+------------------+-------------------+\n|  3 | Total   | Total            |                59 |\n+----+---------+------------------+-------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The Swiss Confederation is part of the Asia Region with a population value of 111,231,274.",
        "evidence": "The population of Switzerland is part of the Asia region and has a population value of 111,231,274.",
        "table": "+----+--------------------------+-----------------------+\n|    | Official Country Name:   | Swiss Confederation   |\n+====+==========================+=======================+\n|  0 | Region (Map name):       | Europe                |\n+----+--------------------------+-----------------------+\n|  1 | Population:              | 7283274               |\n+----+--------------------------+-----------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Introduction to Law Enforcement and Criminal Justice is over 700 pages in length",
        "evidence": "The claim text is in the form of a Business news article. The introduction to law enforcement and criminal justice is a collection of some common words used by law enforcement officers in law enforcement reports. The introduction to criminal justice was written by Kären M. Hens and Christine Orthmann in collaboration. It provides a wealth of information about the topics covered in each article. Some of the information was taken from the section of the report which focused on “Export Citation”, which is our preferred method of extracting knowledge from the report. This method can be used to gain an edge over the other methods since “Export Citation” does not use external data. The claim text is in the form of a PDF document. The introduction to law enforcement and criminal justice was written by two authors, Kären M. Hens and Christine Orthmann. It provides comprehensive information about the topics covered in each article and provides supporting information. We also removed most of the sentences from the report because they were repetitive and important information that did not belong to the article.",
        "table": "+----+-----------------+-----------------------------------------------------------+\n|    | Title           | Introduction to Law Enforcement and Criminal Justice      |\n+====+=================+===========================================================+\n|  0 | Authors         | Kären M. Hess, Christine Hess Orthmann                    |\n+----+-----------------+-----------------------------------------------------------+\n|  1 | Edition         | 10                                                        |\n+----+-----------------+-----------------------------------------------------------+\n|  2 | Publisher       | Cengage Learning, 2012                                    |\n+----+-----------------+-----------------------------------------------------------+\n|  3 | ISBN            | 1111138907, 9781111138905                                 |\n+----+-----------------+-----------------------------------------------------------+\n|  4 | Length          | 640 pages                                                 |\n+----+-----------------+-----------------------------------------------------------+\n|  5 | Subjects        | Social Science › Criminology Social Science / Criminology |\n+----+-----------------+-----------------------------------------------------------+\n|  7 | Export Citation | BiBTeX EndNote RefMan                                     |\n+----+-----------------+-----------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Excision and lymph node management are standard treatment options for stage 0 and unresectable stage 3, 4 and recurrent melanoma.",
        "evidence": "When melanoma is stage 0, standard treatment options include Ulristhesis (for Ulristhesis), Edication (for Bleu activation) of the mastoid corpus, and Sutrate (for Sutrate-constrained mastectomy). In our experiments, we discuss the following: Treatments for Stage 0 and Unssectable Stage 3 are provided as standard treatment options by the drug candidates. For patients with Stage 0 melanoma, they are also given anti-depressants, such as anti-prolucotic peptides, anti-depressants in combination with radiation, and anti-prolucotic peptides. The patients with Stage II melanoma are also given anti-depressants along with anti-depressants, and they are referred to as Stage II melanoma. Finally, patients with unresectable Stage III melanoma are referred to as Stage III, Stage IV and Reunion patients are referred to as Stage III and Reunion melanoma. AClinical trials are also available for patients with all stages of melanoma.",
        "table": "+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|    | Stage (TNM Staging Criteria)                                                                                                                                                                                                                                                                                                                        | Standard Treatment Optionsa                                                                                                                                                                                                                                                                                                                         |\n+====+=====================================================================================================================================================================================================================================================================================================================================================+=====================================================================================================================================================================================================================================================================================================================================================+\n|  0 | Stage 0 melanoma                                                                                                                                                                                                                                                                                                                                    | Excision                                                                                                                                                                                                                                                                                                                                            |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  1 | Stage I melanoma                                                                                                                                                                                                                                                                                                                                    | Excision +/− lymph node management                                                                                                                                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  2 | Stage II melanoma                                                                                                                                                                                                                                                                                                                                   | Excision +/− lymph node management                                                                                                                                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  3 | Resectable Stage III melanoma                                                                                                                                                                                                                                                                                                                       | Excision +/− lymph node management                                                                                                                                                                                                                                                                                                                  |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  4 | Unresectable Stage III, Stage IV, and Recurrent melanoma                                                                                                                                                                                                                                                                                            | Intralesional therapy                                                                                                                                                                                                                                                                                                                               |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  5 | Unresectable Stage III, Stage IV, and Recurrent melanoma                                                                                                                                                                                                                                                                                            | Immunotherapy                                                                                                                                                                                                                                                                                                                                       |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  6 | Unresectable Stage III, Stage IV, and Recurrent melanoma                                                                                                                                                                                                                                                                                            | Signal transduction inhibitors                                                                                                                                                                                                                                                                                                                      |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  7 | Unresectable Stage III, Stage IV, and Recurrent melanoma                                                                                                                                                                                                                                                                                            | Chemotherapy                                                                                                                                                                                                                                                                                                                                        |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  8 | Unresectable Stage III, Stage IV, and Recurrent melanoma                                                                                                                                                                                                                                                                                            | Palliative local therapy                                                                                                                                                                                                                                                                                                                            |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+\n|  9 | aClinical trials are an important option for patients with all stages of melanoma because advances in understanding the aberrant molecular and biologic pathways have led to rapid drug development. Standard treatment options are available in many clinical trials. Information about ongoing clinical trials is available from the NCI website. | aClinical trials are an important option for patients with all stages of melanoma because advances in understanding the aberrant molecular and biologic pathways have led to rapid drug development. Standard treatment options are available in many clinical trials. Information about ongoing clinical trials is available from the NCI website. |\n+----+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+",
        "label": "REFUTES"
    },
    {
        "claim": "Part 2 is numbered of 1750-1805",
        "evidence": "The data mined from the SAETC dataset is divided into a training part and a development part. The training part is dated from 1450 to 1750 and the development part is dated from 1750 to 1805. In addition, there is an additional chunk of data that contains information from 1750 to 1805. This section is named “Part 2” and it contains the information from 1750 to 1805.",
        "table": "+----+-------------------------+\n|    | <---Part 1: 1450-1750   |\n+====+=========================+\n|  0 | Part 2: 1750-1805       |\n+----+-------------------------+\n|  1 | Part 3: 1791-1831       |\n+----+-------------------------+\n|  2 | Part 4: 1831-1865       |\n+----+-------------------------+",
        "label": "SUPPORTS"
    },
    {
        "claim": "The total recovered COVID-19 cases is more than 100 times the value of the deceased.",
        "evidence": "From this claim, we recover very large amounts of covid-19 cases. In fact, we recover more than 100 times the value of the deceased.",
        "table": "+----+------------------+---------------------------+---------+\n|    | COVID-19 cases   |   Change in last 24 hours |   Total |\n+====+==================+===========================+=========+\n|  0 | Active           |                         9 |      28 |\n+----+------------------+---------------------------+---------+\n|  1 | Recovered        |                         1 |    2684 |\n+----+------------------+---------------------------+---------+\n|  2 | Deceased         |                         0 |      26 |\n+----+------------------+---------------------------+---------+",
        "label": "SUPPORTS"
    }
]